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CHAPTER ONE 
A BRIEF HISTORY OF THE DEVELOPMENT OF MEDICAL RESEARCH  
Introduction 
 The rapid development of medical research over the past 150 years has resulted in 
scientific innovations with greater capabilities of addressing catastrophic and population-
based health events, treating acute health needs, developing new drugs, and utilizing cutting-
edge technology to improve medical care. Describing the details of these advances in 
medicine would require several dissertations; therefore, this chapter modestly aims to 
provide a brief sketch of the way medical research develops over the past century and a half. 
I will focus on the ways in which medical research contributes to bettering the health of 
individuals and populations and the effect of these innovations on society at large. However, 
this dissertation is not simply about the development of medical research, but also about 
how the trajectory of these developments has led to a socio-economic and global imbalance 
with respect to the beneficiaries of medical research.  
 In order to understand the unequal distribution of the developments within medical 
research, a first step requires understanding what constitutes medical research, as well as the 
implications for individuals and for communities. Medical research in the late nineteenth 
century, begins by taking-up local concerns. However, larger political and economic contexts 
shape local health concerns. While the Second Chapter takes up the ethical norms aiming to 
protect research subjects, this First Chapter describes the various contexts in which medical
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research develops.  
 This chapter begins with a brief description of what constitutes medical research. 
The remaining three sections describe the progress made in medical research beginning from 
the mid-nineteenth century, by turning to exemplary case studies to describe the variety of 
research being conducted and the contextual problems to which it responds. The first of 
these periods focuses on the research from the cholera epidemic of 1850s London and the 
acute and population-based health responses. The work of John Snow, Robert Koch, and 
the international hygiene movements exemplify the research of this period. The practices of 
the hygiene movements within this period mark an important development in research 
translation and the dissemination of new knowledge. Dissemination of knowledge plays an 
essential role in the second period I consider in this chapter—research during the pre and 
post-World War era.  
 Research during and after the World Wars centers on the health of particular classes 
or groups of people, chief among them workers and soldiers. Yellow fever research, 
emerging surgical techniques, and eugenic research all play key roles in advancing scientific 
knowledge in the hope of developing a stronger and “more fit” society. While this second 
period is characterized by a focus on particular groups of people, the examples in the third 
period demonstrate an interest on broader global health concerns that target disease 
eradication and new ways of improving the lives of those suffering from chronic and 
infectious disease.  
 In this final section, the eradication of smallpox, the necessity of medicating 
hypertension, and the possibilities of research in synthetic biology demonstrate the potential 
of research that targets the treatment or prevention of particular diseases. The focus on 
smallpox, and its eradication, represents a targeted approach to research that allows for more 
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intentional focus on populations who disproportionately bear the burden of particular 
diseases.  The importance of concentrating on diseases that affect the global poor, as 
smallpox did, is a practice that I will emphasize throughout my argument. However, as the 
cost of research rises, so too has the importance of earning an economic return on 
investments in research—explored most fully in Chapter Four. While economics now plays 
an important role in deciding which medical research options to pursue, judging from the 
definitions of medical research from international research institutes, the emphasis placed on 
financial gain as an explicit goal of the practice of medical research varies.  
What is Medical Research? 
 Henry Sigerist, a medical historian from Switzerland, describes medicine as a practice 
motivated by bettering the health of individuals. He describes medicine’s task “under the 
following four headings: 1. Promotion of health; 2. Prevention of illness; 3. Restoration of 
health; and 4. Rehabilitation.”1 Following Sigerist, medicine concerns itself about positive 
health outcomes. Medical research, then, participates in this mission by combining the focus 
on disease prevention and restoration of health with scientific investigation. Thus, one of the 
many motivations in the development of a medical research, as related to the goals of 
medicine, requires a genuine interest in improving the lives and health of people.  
International Definitions of Medical Research 
 Highlighting different international definitions of medical research contributes to a 
broader understanding of what constitutes medical research, and, additionally, the diversity 
in motivations for its pursuit. France’s Institut national de la santé et la recherche médicale (Inserm) 
articulates its mission as the only public institute in France focusing “entirely on human 
                                                
1  Robert J. Levine, “The Nature, Scope, and Justification of Clinical Research: What is Research? Who is 
Subject?” in The Oxford Textbook for Research Ethics, ed. Ezekiel J. Emanuel, et al. (New York: Oxford University 
Press, 2008), 211. 
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health.”2  Its definition emphasizes the humanistic element present in medical research and 
also highlights the public and private partnerships necessary in making research possible. 
University hospitals and research centers serve as two of Inserm’s primary collaborators.3  In 
the U.K., the Medical Research Council (MRC) more broadly states their intention to 
support research in order to “produce skilled researchers, advance and disseminate 
knowledge and technology to improve the quality of life and economic competitiveness of 
the U.K.; and promote dialogue with the public about medical research.”4 Here the MRC’s 
definition begins to point to the role medical research can play economically in promoting 
research. The U.S.’s National Institute of Health (NIH) takes a slightly different tone by 
describing it as “fundamental knowledge about the nature and behavior of living systems and 
the application of that knowledge to enhance health, lengthen life, and reduce illness and 
disability.”5 The NIH emphasizes the importance of increasing and disseminating the 
discoveries of medical research in the hope of enabling longer and healthier lives. Offering a 
different perspective, and at the least a non-western perspective, is that of the Indian Council 
of Medical Research (ICMR). The ICMR describes the types of projects that fall within the 
purview of medical research as:   
control and management of communicable diseases, fertility control, maternal and 
child health, control of nutritional disorders, developing alternative strategies for 
health care delivery, containment within safety limits of environmental and 
occupational health problems; research on major non-communicable diseases like 
cancer, cardiovascular diseases, blindness, diabetes and other metabolic and 
                                                
2  Institut national de la santé et de la recherche médicale, “The Institute Mission,” Institut national de la santé et de 
la recherche médicale, http://english.inserm.fr/what-s-inserm/the-institute-missions (accessed October 23, 2014). 
 
3  Institut national de la santé et de la recherche médicale, “The Institute Mission.” 
 
4  Medical Research Council, “Our Mission,” Medical Research Council - United Kingdom, 
http://www.mrc.ac.uk/About/Missionstatement/index.htm (accessed October 23, 2014). 
 
5  National Institute of Health, “Mission,” National Institute of Health, 
http://www.nih.gov/about/mission.htm (accessed October 23, 2014). 
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hematological disorders; mental health research and drug research (including 
traditional remedies). All these efforts are undertaken with a view to reduce the total 
burden of disease and to promote health and well-being of the population.6 
 
The ICMR does not include economic interests or pursuit of new knowledge in its mission 
statement, and instead lists specific types of research concerning the importance of the 
population’s overall health. The wide-ranging mission statements from leading international 
medical research organizations give strong indications, not only as to the type of initiatives 
that constitute medical research, but also the intellectual, economic, and health-based 
commitment of the various research institutes.  
 While high-income countries focus on economics and technological innovation as a 
component of medical research, India’s ICMR, a low-middle income country, does not 
mention either of these aspects, focusing instead on research that impacts population health. 
Population health is not only concerned with outcomes, but also with the underlying 
factors—environmental, social, political, economic, etc.—that contribute to the health 
challenges of particular communities and how they can be overcome.7 The ICMR values 
medical research pertaining to the health of individuals within the context of the health of 
the community as a whole. Any allusion to community or public health, which is a 
constitutive dynamic of improving or maintaining health, remains absent from the 
descriptions from Inserm, NIH, or the MRC. The inattention to the health concerns of 
community in framing the goals of medical research creates a tension that contributes to 
health disparities and disparate medical research priorities between lower and higher income 
countries,  a topic I address in Chapter Four and Five. For the purposes of this chapter, 
                                                
6  Indian Council of Medical Research, “About ICMR,” Indian Council of Medical Research, 
http://icmr.nic.in/About_Us/About_ICMR.html (accessed October 23, 2014). 
 
7  Joshua M. Sharfstein,“The Strange Journey of Population Health,” Milbank Quarterly 92, no. 4 (2014): 640. 
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however, it is important to note who has established the priorities for research historically 
and overseen its progress, as well as who stands to benefit from the basic science, clinical, 
and epidemiologic research being conducted.  
Basic, Epidemiologic, and Clinical Research 
 Basic science research is driven by a desire to discover and/or to understand some 
biological phenomena. The NIH describes basic science research broadly as an area that 
leads to a deeper understanding of the “biological rules of life.”8 While basic research 
provides the building blocks, clinical research sets out to apply the fruits of basic research in 
an effort to understand more fully their efficacy in the clinical setting.  
 Clinical research is broken down into three sub-categories: epidemiologic-based, 
patient-oriented, or outcome/delivery-based.9 In some instances clinical research can be 
difficult to distinguish from good clinical practice, which can operate as a research-like 
process.10 However, arriving at the best approach to patient care transcends the latest 
                                                
8  Toby E. Huff, Intellectual Curiosity and the Scientific Revolution: A Global Perspective (Cambridge: New York: 
Cambridge University Press, 2011), 171-208; National Institute of General Medical Sciences, “Curiosity Creates 
Cures: The Value and Impact of Basic Research,” National Institute of Health, 
http://www.nigms.nih.gov/Education/factsheet_CuriosityCreatesCures.htm (accessed October 26, 2014). 
 
9  While epidemiological research is a form of medical research in its own right, it also functions as a sub-
category of clinical research. An example of this type of study might be a clinical trial that sets to study the 
effects of a particular drug on a certain group of people in a particular area.  
 
10  Robert J. Levine, Ethics and Regulation of Clinical Research (New Haven, Conn: Yale University Press, 1988); 
Ruth R. Faden et al., “An Ethics Framework for a Learning Health Care System: A Departure from Traditional 
Research Ethics and Clinical Ethics,” Hastings Center Report 43, no. s1 (2013): s16. An example of this can be 
seen when a patient is being treated for pain management or when treating a psychological disorder. In both 
instances, the concern of the physician is to try a variety of treatments aimed at curing or managing symptoms. 
The treatment is therapeutic in nature, specifically focusing on the care of the patient’s health, but could also be 
considered a form of research because it is not immediately clear what the best course of treatment for the 
patient is. Those responsible for the care of the patient inevitably enter into a process of trial and error in an 
effort to discover the possible treatment.  Many of the ethical issues in research stem from clinical trials, 
particularly ensuring that patient’s understand they are participating in an experiment and may not receive any 
therapeutic benefit from their participation. Questions of research ethics will be taken up in more detail in the 
next chapter.  
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scientific advances in order to consider how these advances affect or fail to affect change in 
the health of the population—a practice often left to epidemiologic research.  
 Epidemiologic research works within the discipline of epidemiology to apply 
knowledge related to a population’s health and the spread of disease by drawing on both 
basic science and clinical research, with the goal of improving the health of particular 
persons or groups of people. Leon Gordis defines epidemiology as the “study of how 
disease is distributed in populations and of the factors that influence or determine this 
distribution.”11 Epidemiologic-based medical research, then, begins with a focus on the 
particular health-related needs of the community and considers other factors that contribute 
to this particular distribution of health.12 Epidemiologic-based medical research proves 
important when identifying health challenges faced by particular communities. Both 
epidemiologic and basic science research prove crucial in the first phase of research 
development that discovered the relationship between bacteria and hygiene and its effects on 
particular communities during the cholera epidemics of the latter half of the Nineteenth 
Century.  
Bacteria and Hygiene 
 The developments in medical research from 1850 to the early parts of the twentieth 
century focus largely on controlling widespread and population-based health problems. At 
that time, one of the more rampant health problems stemmed from frequent cholera 
epidemics. Cholera is a bacterial disease that spreads by drinking water or eating food that 
has been contaminated by fecal matter. While the transmission of the disease is now 
                                                
11  Leon Gordis, Epidemiology (Philadelphia: W.B. Saunders, 2000), 3. 
 
12  Gordis defines five objectives for epidemiology: 1) identify etiology cause of disease, and risk factors; 2) 
determine extent of disease in a given community; 3) study natural history and prognosis of disease; 4) evaluate 
existing and new preventative and therapeutic measures; 5) provide foundation for developing public policy 
and regulatory decisions related to environmental problems. See Gordis, Epidemiology, 4.  
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commonly understood, it remained a mystery until late into the nineteenth century. At that 
time, it was thought to have spread through air that smelled, i.e. “bad air.”  
 The epidemiologic research of John Snow and the basic science efforts of Robert 
Koch, some 20 years after Snow’s epidemiologic research, contradicted the miasma (“bad-
air”) theory. Koch’s scientific proof of Snow’s epidemiologic-based hypothesis leads to the 
mobilization of global campaigns to promote hygiene and prevent the spread of disease. 
These hygiene campaigns, largely funded by the U.S.-based Rockefeller Foundation, serve as 
catalysts for an array of international efforts to improve hygiene practices. What proves 
distinctive about the development of medical research in this period is the importance placed 
on public health strategies by various stakeholders within the research community, including 
public and private investors.  
John Snow 
 English physician John Snow’s anesthesia research provided him necessary 
physiologic data that offered an alternative to the miasma theory. 13  The miasma theory 
posited that cholera was spread through the inhalation of noxious fumes. If this were valid, 
Snow concluded the same physiologic process that took place in aestheticizing a patient 
would hold true for the inhalation of cholera. 14 It was his anesthesia research, focused on 
understanding the physiological interaction between the respiratory and circulatory systems, 
                                                
13  Steven Johnson, The Ghost Map: The Story of London's Most Terrifying Epidemic and how it Changed Science, Cities, 
and the Modern World, (New York: Riverhead Books, 2006). London’s population in 1853 was near three million 
people, with most people living in close proximity to one another. Johnson’s book offers an insightful look at 
the story around John Snow and the city of London during the epidemic’s outbreak.  
 
14  Michael Ramsay, “John Snow, MD: Anesthetist to the Queen of England and Pioneer Epidemiologist,” 
Baylor University Medical Center Proceedings 19, no. 1 (2006): 24. Snow’s understanding of the beginnings of his 
investigations took place, unbeknownst to him, as a medical student. During his time as a student, he and 
others participated in the examination of patients after death, a process which made many students became 
sick. He then set up a series of experiments in which he traced the cause of his colleagues’ nausea to the 
inhalation of the arsenic vapors from the embalmed bodies. Not only was arsenic a common source for 
embalming, it was also used in candles in order for them to burn longer and brighter. Snow’s research also 
paved the way for a halt in the sale of candles that used arsenic.   
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that played a crucial role in his ability to offer an alternative theory.15 Armed with the 
knowledge that the breathing in of oxygen led to its circulation throughout the body, Snow 
hypothesized that he would find a high percentage of cholera deaths within the same 
household. When this proved not to be the case, he took up a more diligent study of the 
weekly notifications of deaths in London to determine if a common location or pattern 
existed between the various deaths.  
 Snow’s physiologic understanding of the airborne transmission of disease, combined 
with the Weekly Return’s reports of births and deaths in London, provided him with the 
necessary information to theorize how cholera spread. The Weekly Returns, published by 
London’s primary demographer, William Farr, proved essential to Snow’s project. If cholera 
spread because of an airborne disease, then those living in the same neighborhood and the 
same home were significantly more likely to have contracted the disease. 16 After reviewing 
the Weekly Returns, Snow traveled door-to-door to investigate the households of those who 
suspected to have died of cholera in an effort to determine if anyone still living was 
symptomatic. Though he could not definitively prove that other family members did not 
have the disease, his respiratory and circulatory background led him to believe that if the 
miasma theory were true they should display symptoms of cholera. Given the absence of 
these factors, Snow believed the disease was not airborne.   
 Snow’s research during the cholera epidemic functioned as epidemiologic research 
through its focus on the health of a particular population and studying the factors that 
contributed to the disproportionate distribution of cholera in certain areas. The uneven 
                                                
15  Ramsay, “John Snow, MD,” 24.  
 
16  D.E. Lilienfeld, “Celebration: William Farr (1807–1883)—an Appreciation on the 200th Anniversary of His 
Birth,” International Journal of Epidemiology 36, no. 5 (October 01, 2007): 985; John M. Eyler, Victorian Social 
Medicine: The Ideas and Methods of William Farr (Baltimore: Johns Hopkins University Press, 1979). 
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distribution of cholera led him to focus his research on various companies that provided 
water to some 300,000 persons. Snow’s study included: 
people of both sexes, of every age and occupation, and of every rank and station, from 
gentlefolks down to the very poor, were divided into two groups without their choice, 
and in most cases, without their knowledge; one group being supplied with water 
containing sewage of London, and, amongst it, whatever might have come from the 
cholera patients, the other group having water quite free from impurity.17  
 
His study represented a wide segment of the population and focused tested a very specific 
outcome related to water consumption. Snow’s had to test the water supply from two 
companies: Southwark and Vauxhall Company and the Lambeth Company. In one of the 
sub-districts that drew Snow’s attention, 44 deaths had occurred due to cholera. Of those 44 
deaths, 38 had their water supplied by Southwark and Vauxhall, four from Lambeth, and 
two from personal pumps.18 Yet, the most compelling aspect of his study came from the 
research undertaken near his own home. Snow began canvassing his own neighborhood, and 
discovered the most frequently used water source was the Broad Street pump. The pump did 
emit noxious fumes, contributing to the miasma theory, but the source of the fumes came 
from London’s raw sewage leaking into the city’s water supply underneath the pump and the 
source of contagion.19 Though Snow had discovered the contamination source, he could not 
corroborate it as the culprit of the epidemic due to the infant stage of bacteriological studies. 
The slow acceptance of his conclusions signaled the necessity of complementary research to 
affect health outcomes. The research of Robert Koch proved to be the missing link in 
understanding the spread of cholera. 
                                                
17  John Snow and Stanton Friedberg M.D., On the Mode of Communication of Cholera, (London: John Churchill, 
1855), 75. 
 
18  Ramsay, “John Snow, MD,” 76-77; Johnson, The Ghost Map, 81-109. 
 
19  Johnson, 178-179. 
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Robert Koch 
 Robert Koch’s discovery of the cholera causing bacteria validated both Snow’s 
research outcomes and Louis Pasteur’s “germ theory.” Pasteur’s germ theory evolved 
through his work in the 1860s that demonstrated certain diseases developed from 
microscopic bacteria that infect the body. Koch built on the groundwork laid by Pasteur by 
devising a scientific process capable of isolating, reproducing, and establishing particular 
bacteria as the root cause of certain diseases, cholera being one of them. In an address at the 
1890 International Medical Conference in Berlin, Koch described the method for 
determining the pathology for a bacteriological disease.   
If, however, it can be proved: First that the parasite is met with in each individual 
case of the particular disease and under the conditions which correspond to the 
pathological changes and the clinical course of the disease; secondly that in no other 
disease is it found as an accidental non-pathogenic guest; and thirdly, that if 
completely isolated from the body and cultivated in pure cultures with sufficient 
frequency it can reproduce the disease—then it can no longer be considered an 
accidental accompaniment to the disease, but in that case no other relation between 
the parasite and the disease can be admitted than that the parasite is the cause of the 
disease.20 
 
The talk at Berlin proved essential in describing to the scientific community the 
fundamentals of bacteriology, and in particular how it applied to cholera. The cholera 
bacteria consistently manifested itself when isolated and cultivated in an uncontaminated 
host. By proving that certain bacteria existed as the root cause of the disease, Koch’s 
presentation became a high point the conference, and led to his appointment on the German 
Cholera Commission.21  
                                                
20  Robert Koch, “An Address on Bacteriological Research,” The British Medical Journal 2, no. 1546 (1890): 381. 
 
21  Koch’s presentation was able to articulate how to reproduce bacterial cultures of several micro-organisms 
including: anthrax, which commonly resulted in the death of farm animals in Germany, and tuberculosis in 
1882. Koch attempted, but ultimately failed, at developing a vaccine for tuberculosis, tuberculin, which 
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 Koch’s role allowed him to continue his research and work with those in both 
Europe and Northern Africa to prevent the further transmission of bacterial disease. In his 
capacity as a member of the German Cholera Commission, Koch discovered that the 
bacteria developed from a foodborne infection. This discovery, ultimately led Koch’s to 
translate his findings from the scientific discovery to the implementation of public health 
practices that proved crucial for the success of international hygiene commissions.  
 The scientific research of Koch paved the way for further developments of the 
international hygiene movement. By the mid 1860s, the International Sanitary Conference 
(ISC) had built on the work of Koch and Snow and concentrated its efforts on cholera as the 
disease that Europe needed to prevent from returning.22 In an effort to stop its spread, a 
more coordinated international effort centered on effective communication of the necessary 
preventive measures needed to take hold. The purpose of the ISC was to serve as a type of 
clearinghouse for communicating and developing strategies aimed at disease prevention.23 
Among the practices implemented were quarantining of those who had contracted 
communicable diseases and simple education about disease transmission. The ISC, however, 
was not the only organization that would take this as its mission. 
International Hygiene Movements 
 The ISC was the first in a number of international organizations aimed at 
establishing and implementing hygiene standards and practices. As a direct result of the ISC, 
the International Sanitary Bureau (ISB) was established in 1902 to implement the strategies 
                                                                                                                                            
somewhat tainted his legacy as a researcher, see Christoph Gradmann, “Robert Koch and the Pressures of 
Scientific Research: Tuberculosis and Tuberculin.” Medical History 45, no. 1 (2001). 
 
22  Alison Bashford, “Global Biopolitics and the History of World Health,” History of the Human Sciences 19, no. 1 
(2006): 67. 
 
23  Jeremy R. Youde, Biopolitical Surveillance and Public Health in International Politics, (New York: Palgrave 
Macmillan, 2010), 151. 
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of the ISC in the Americas. In 1907, L’Office International d’Hygiene Publique was established to 
focus on regional European concerns facing the shipyards of European ports. The shipyards 
represented potential sources for importing or exporting cholera and/or other epidemic-
causing diseases.24 As the growth of the shipping and trade industry continued throughout 
the early part of the twentieth century, so too did the development of hygiene commissions. 
In addition to the multiple hygiene commissions already established, in 1923, the League of 
Nations Health Organization (LNHO) added to the growing list of organizations charged 
with preventing the spread of disease. These various international sanitary commissions 
assumed the tasks of studying epidemic diseases, revising and administering preventive 
guidelines, and preparing international conferences at which important epidemiologic and 
public health information could be exchanged.25 By implementing new preventive strategies 
and communicating best practices, these institutions became laboratories for studying public 
health and hygiene, but, like most research endeavors, funding proved essential.  
 The institutionalization of the sanitary and hygiene movement ushered in an era of 
public institutes of health that required significant financial and intellectual investments in 
order to perform the research necessary to prevent the spread of disease. The New York-
based Rockefeller Health Commission (RHC) provided funding for research investigating 
the cause of disease and its prevention. The Rockefeller Foundation made substantial 
contributions to implement the protocols developed by the sanitation movement by 
establishing its own health commission in 1913. In its 1914 annual report, the Rockefeller 
Foundation reflected on its commitment to “the advancement of public health through 
                                                
24  Akira Iriye, Global Community the Role of International Organizations in the Making of the Contemporary World, 
Berkley: University of California Press, 2002; Youde, Biopolitical Surveillance and Public Health in International 
Politics, 152-153. 
 
25  Bashford, Global Biopolitics and the History of World Health, 71. 
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medical research and education, including the demonstration of known methods of treating 
and preventing disease, afforded the surest prospect of such usefulness.”26 The RHC, unlike 
the other hygiene commissions, supported medical research that could lead to new 
information aimed at prevention or treatment. In the foundation’s efforts to demonstrate 
their successful methods, the RHC centered its U.S. efforts on hookworm disease. 
The Rockefeller Health Commission and Hookworm 
 At the turn of the century, the southern U.S. states were a particularly agrarian 
society, and given the nature of the work in the fields, those living in the south had a higher 
risk of contracting the disease.27  While cholera contaminated water, the hookworm bacteria 
contaminated the soil.28 Hookworm caused “vast suffering, partial arrest of physical, mental 
and normal growth, great loss of life, and noticeable decrease in economic efficiency over 
vast regions…”29 The U.S.-based program had been able to treat some 500,000 persons by 
establishing agencies focused on promoting “public sanitation and the spread of the 
knowledge of scientist medicine.”30 These efforts included a focus on personal hygiene, but 
also testing the possibilities of “scientist medicine” to gauge dosing amount and frequency. 
A.G. Fort reported at the 1914 meeting of the American Public Health Association on 
collaborative clinical research between the state of Georgia and the RHC that demonstrated 
the effectiveness of particular drugs over others, which resulted in differing mortality rates 
                                                
26  The Rockefeller Foundation, “The Rockefeller Foundation Annual Report 1913-14,” 
http://www.rockefellerfoundation.org/uploads/files/812e6b1a-4785-4d58-b2e3-77eb3f5a2b0d-1913-1914.pdf 
(accessed October 17, 2014). 
 
27  Hookworm is a disease that has not been eradicated and remains a problem in 2/3rds of the world.  
 
28  World Health Organization, “Soil-Transmitted Helminth Infections,” World Health Organization,  
http://www.who.int/mediacentre/factsheets/fs366/en/ (accessed January 21, 2014). 
 
29  The Rockefeller Foundation, The Rockefeller Foundation Annual Report 1913-14, 450. 
 
30  Ibid. 
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amongst those who were compliant versus non-compliant with recommended treatments.31 
The RHC wanted to take the collaborative works on hookworm, however, beyond the 
southern U.S. states and beyond hookworm.  
 In their 1913-14 annual report, the RHC described their efforts to combat the spread 
of disease through a variety of “military-sanitary campaigns” in collaboration with the U.S. 
government. These campaigns extended beyond the U.S. and included work with Britain’s 
territories, British Honduras (Belize), Federated Malay States (Malaysia), Fiji, and Australia.32 
By 1922, the Rockefeller Foundation was a key contributor to the League of Nations and 
was essentially the sole funder of the Epidemiological Intelligence Service of the League of 
Nations. In other words, without the Rockefeller Foundation, health-based research in both 
the U.S. and abroad would have been quite limited. Furthermore, the targeted and disease-
focused approach of the Rockefeller Foundation played an essential role in influencing the 
practice medical research. The RHC’s international and targeted approach to research shifted 
from the general sanitary and hygiene practices of the international commissions concerned 
with public health.  They now took a disease-based approach to medical research that 
targeted the treatment of individuals, once treatments regimens were verified through clinical 
trials.  
 From the middle of the nineteenth century through the 1920s, medical research 
developed significantly in three impactful ways: understanding of disease, the importance of 
public health/hygiene practices, and the necessity of investment in clinical research. John 
Snow and Robert Koch distinguished themselves as examples of how diseases came to be 
understood and how the spread of disease could be controlled. Building on the work of 
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Snow and Koch, public health measures proved important as a key development to prevent 
the spread of disease and to improve health outcomes. This was one of the key tasks of the 
hygiene commissions that served as clearinghouses for best preventive practices. These 
practices placed a priority on the needs of the community above those of individuals. 
Examples of this can be seen in the practice of quarantine in which one individual was 
isolated in order to prevent others from contracting the disease. Yet, prevention does not 
always happen, and, therefore, it proved necessary to develop methods for targeted 
treatments. Within this initial phase, tension began to develop between disease prevention, 
promoted by the public health and hygiene commissions, and disease control, focused on 
research for developing curative treatments. The Rockefeller Foundation found itself as one 
of the key players in emphasizing research both for prevention and treatment of particular 
diseases.  
 The RHC’s hookworm strategy demonstrated the confluence of the contributions of 
epidemiologic and basic science to developing targeted clinical trials aimed at controlling the 
spread of disease by treating it and ultimately eliminating it. Their targeted approach to 
research and generous financial investments, set the stage for how the Rockefeller 
Foundation would shaped development of research during the second phase of research 
described in this chapter. This second phase of research was influenced heavily by the two 
World Wars, which provided the catalyst for countless developments in medical research 
aimed at responding to the acute injuries of soldiers and the importance of health in the 
rebuilding of society during the aftermath of war.   
Disease, Wars, and the Pursuit of Perfection 
 The two World Wars provided the catalyst for many technological and scientific 
innovations that advanced medical research by focusing on the health of individuals and 
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their ability to contribute to the rebuilding of a post-war society. With countless economic 
and human resources being poured into the Wars and the expansion of international trade 
through the Panama Canal, there was heightened concern about preventing the potential 
global spread of a disease. The first example of research in this period highlights a disease-
based approached focusing on disease prevention through vaccine development. Resaerch 
on disease prevention research addressed directly the concern about transporting the 
contagious yellow fever disease through trade routes, while also allowing for the vaccination 
of soldiers fighting abroad. Yet, diseases were not the only threat soldiers faced, the nature 
of combat had changed to the degree that wounds sustained in battle had never before been 
seen.  
The second example described below details the improvements in surgical 
innovations for those suffering facial wounds in battle. Utilizing a surgical team comprised 
of dentists, surgeons, nurses, and artists to treat persons was an experiment in and of itself, 
but also proved significant for enabling soldiers to return from war and function in society 
after the war. Being able to contribute to society was crucial following the World Wars. The 
importance placed on working in society, and limiting the roles of those who were not 
judged to be adequately contributing, was of central importance in the global efforts in 
eugenics research.  
The final example from this section focuses on the international development of 
eugenics programs that reached a crescendo with the Nazi eugenics experiments. While the 
Nazi eugenic experiments were the most ethically egregious in their practice, centers for 
eugenics were widespread. Eugenics research, in many ways, reduced the measure of 
prevention and promotion of health to a genetic level, compared to vaccines that had the 
potential to benefit all. Moreover, the differences in eugenics and vaccine research highlight 
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tensions in priorities of research that had the potential to benefit a select few versus the 
majority. The tensions between health benefit for a few or the many, seem to be fueled 
during this period of war and economic expansion as the world became increasingly 
interconnected. The beginnings of this interdependence can be seen in the Rockefeller-
sponsored yellow fever research.  
Yellow Fever  
 William Gorgas served as the U.S. Surgeon General in 1914, leading the first of three 
Rockefeller-funded yellow fever research teams throughout South America. The first 
commission ran from 1914 until 1916, but was halted by the shifting of U.S. resources after 
their entrance into World War I in 1917. While the war caused the delay in research, it was 
the presence of increased trade routes via the Panama Canal that served as a significant 
source of concern for Gorgas. Gorgas, and others, feared that the frequent merchant travel 
would add to the prospect of disease spread to the U.S. and beyond. “Yellow fever could be 
carried directly to South Africa and India, and through the Panama Canal, to Hawaii, the 
Philippines, Australia, and China.” 33 Given the increased risk of the spread of disease, the 
importance of developing a treatment, or at the least an etiological understanding of the 
disease, became the focus of the work of the next commission in 1918. The second 
commission made significant strides toward understanding yellow fever and paved the way 
for vaccine development. 
 Hideyo Noguchi played a key role in the work of the RHC’s second yellow fever 
commission in Ecuador. Noguchi believed the cause of yellow fever originated from a 
                                                
33 John Farley, To Cast Out Disease a History of the International Health Division of the Rockefeller Foundation (1913-
1951), (New York, NY: Oxford University Press, 2004), 89. 
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bacterium similar to jaundice.34 Noguchi reproduced the suspected bacterium by taking 
blood from those who had died from yellow fever and experimenting with potential cures. 
By the fall of 1918 he was confident he had discovered a vaccination. 35  
 That fall, Noguchi and his team vaccinated 325 military members and their families, 
for a total of 427 non-immune individuals. Of those vaccinated, only five developed yellow 
fever, compared with 386 reported cases in the unvaccinated population. Out of the 386 
cases, 217 victims died.36 Given the success of these initial trials, inoculation efforts were 
made to expand beyond Ecuador and into Brazil, Mexico, and Peru. After this expansion, 
over 20,000 individuals were vaccinated in the region.37 Though widespread research efforts 
had begun in Central and South America, the West African arm of the RHC began to 
discover results that differed from those of Noguchi.  
 By the mid 1920’s the West African RHC group had begun to conduct corollary 
experimentation following-up on Noguchi’s findings. Their research with monkeys, 
mosquitos, and human victims of yellow fever resulted in strikingly different results. In one 
such experiment the team drew blood from a human victim and injected it into a host 
monkey. Upon showing symptoms, a swath of mosquitos fed upon the monkey. “By 
December, the Asisbi strain of ‘virus’ had been passed by mosquitoes through 26 monkeys, 
                                                
34  Center for Disease Control and Prevention, “Yellow Fever,” Center for Disease Control and 
Prevention, http://www.cdc.gov/yellowfever/ (accessed January 15, 2015). Jaundice causes yellow 
discoloration of the skin that is frequently linked to liver disease, particularly in forms of hepatitis or gastro-
intestinal cancers. The initial symptoms of yellow fever include: sudden onset of fever, chills, severe headache, 
back pain, general body aches, nausea, and vomiting, fatigue, and weakness. 
 
35  Farley, To Cast Out Disease a History of the International Health Division of the Rockefeller Foundation (1913-1951), 
93.  
 
36  Hideyo Noguchi, “Contribution to the Etiology of Yellow Fever,” Journal of the American Medical Association 
72, no. 3 (1919), 187. 
 
37 Here some real ethical questions emerge, particularly with respect to informed consent, i.e. did the research 
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all but two of which developed a high fever and died.”38 This led the West African research 
team to conclude that Noguchi mistook jaundice for yellow fever. Upon hearing these 
results, a disbelieving Noguchi came to work with the West African research team in 1928. 
After several weeks of experimentation he concluded that he had made a serious error and 
had not developed an effective vaccine for yellow fever. This insight proved crucial to the 
continued work of the yellow fever commission in its third phase, a phase marked by an 
increased sense of urgency with the looming possibility of biological warfare during World 
War II.  
 Fred Soper served as the regional director during the third commission of the RHC’s 
International Health Division in South America. With the disproven results of Noguchi’s 
experiments, a greater urgency existed to study the disease more closely. While this included 
focusing on vaccine development, it also meant taking measures to control the disease. 
During this third phase, Soper and his researchers began the practice of taking liver cultures 
from victims to develop vaccines. The preferred method of study was through viscerotomy, 
a procedure through which the pieces of liver would be resected from the victims in order to 
be cultured and studied. The procedure was performed on persons who died from yellow 
fever, or from an unknown fever where yellow fever had not previously been reported. In 
order to have access to the deceased, Soper’s group received government authorization to 
“prevent burial of anyone dying of a fever until a ‘viscerotomia’ had been performed.”39 
Greater access to cadavers allowed for some 14,000 examinations that resulted in the 
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discovery of yellow fever in seven states and 25 rural municipalities in which the disease had 
never before been reported or suspected.40  
 The systematic way in which information was gathered and stored gave Soper’s 
commission a wealth of epidemiologic data with respect to where people lived, what they 
did, and how they might have become infected with the disease. Included in these findings 
was the recognition of a higher prevalence of disease in rural locales, as opposed to 
urban/port areas, a different outcome than previously expected. The increased etiological 
and epidemiological knowledge of the disease garnered during this phase of research proved 
important for implementing the next stage of research that included vaccine development.  
 The ability to produce a successful vaccine was fraught with challenges that 
culminated in two mass vaccination campaigns, one targeting Brazilians and the other U.S. 
and U.K. military personnel. The development of a vaccine proved difficult because of the 
research team’s inability to standardize a method for replicating the virus. Once they could 
replicate the virus, they began testing the vaccine on mice. However, rather than developing 
immunity, mice frequently became sick or died.41 It was not until a third round of 
experiments, in 1933, that a vaccine was produced. The successful development took place 
once the virus, “passed through brain-less tissue cultures, became less and less virulent, until 
after 114 passages none of the monkeys inoculated with the virus showed any signs of the 
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disease.”42 Once the vaccine was deemed safe for mice and monkeys, a massive campaign 
began in 1937. During this campaign, 59,532 workers in the coffee plantations of Minas 
Gerasi, Brazil were vaccinated.43 The success of this vaccination efforts, led to the 1940 
recommendation that all military personnel be vaccinated with the newly tested vaccine. 
Between 1940-42, over six million doses of the vaccine were distributed to the U.K. and U.S. 
armed forces. 
 The research on yellow fever points to a confluence of factors that made it an 
important field of research, the most influential being new trade possibilities because of the 
Panama Canal and the threats during two World Wars. Though this research was not 
without its setbacks, particularly those of Noguchi and the death of several military 
personnel during the inoculations campaigns, the three yellow fever commissions 
demonstrated the importance of translating research from basic science and epidemiology 
research to vaccine development and “clinical trials.”44 While these were not official clinical 
trials, at least in the way one thinks of trials today, it is worth noting that earlier versions of 
the vaccine were repeatedly tested on those workers who played prominently in trade 
practices running through the Panama Canal, while others who had no business associations 
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were left untreated. Over 60,000 Brazilians were vaccinated in the initial rollout of the 
vaccine. It was only after those vaccines proved successful that over six million service men 
from the U.K. and U.S. were then vaccinated.45 
By the end of the yellow fever vaccination developments, research on disease and 
injuries affecting soldiers during the war had to take utmost priority. The addition of 
prophylactic health measures, such as vaccinations, proved crucial in preventing many non-
war related deaths. However, these preventive and public health measures were not the only 
life saving innovations during World War II. Individually-focused research proved crucial for 
treating injuries suffered in the midst of battle was also needed, given the advances in 
weapons technology. These surgical techniques for reconstructive surgeries resulted in truly 
experimental medical care. 
Maxillofacial Reconstruction 
 The surgical procedures undertaken to repair and reconstruct facial and head injuries 
during both World Wars took an experimental approach to the practice of surgery. The 
experimental nature of these surgeries began with the development of new surgical 
techniques to the diversity of persons who comprised the surgical teams. At the time of the 
First World War (1914-1918), much of the medical community remained unprepared for the 
injuries soldiers would face. 46 The trench warfare presented debilitating and grotesque 
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wounds that, when not resulting in death, led to extreme pain, disfigurement, and the need 
for immediate medical attention. The medical care received, however, was primitive and in a 
constant state of development. The field hospital, in many ways, was transformed into a 
clinical laboratory in which new surgical, anesthetic, and dental approaches were explored. 
Though particular types of cosmetic surgery existed already, few techniques demonstrated 
the capacity for confronting the sheer volume of never before seen injuries. 47  
 It seemed impossible to evaluate, let alone to operate on all of those who needed 
surgery. However, the large volume of patients allowed for a pool of patients on which to 
learn and develop new innovative surgical techniques. In the 1916 Battle of Somme, a 
surgical team headed by Australian Harold Gillies saw 2,000 patients in a single day.48 Gillies 
served as one of the pioneers in skin grafting. Skin grafting made reconstruction possible 
through by utilizing a “tube pedicle enable[ing] surgeons to transfer skin in stages from one 
location another while maintaining the blood supply, which helped ensure that grafts would 
                                                                                                                                            
for over 40 years, in which the innovations of rifles and modern artillery was not of use. British surgeons found 
themselves in better position following their involvement in the Second Boer War, fought over land rights in 
South Africa from 1899-1902. Despite this preparation the introduction of trench warfare and the proximity of 
violent attacks provided a unique challenge.  
 
47 Charles Conrad Miller, The Correction of Featural Imperfections, (Los Angeles, CA: University of California 
Medical School, 1908). Miller’s work focused on what today would be considered cosmetic surgery, but this 
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benefit from surgical intervention. His list included: the head, folds, bags, and wrinkles about the eyes, face 
lifting, palpebral fissures, “double chin,” wrinkles of face and neck, softening of nasolabial lines, forming 
dimples, various nasal reconstructive surgeries, external era, the notorious “unduly large mouth.” Miller’s work 
in correcting imperfections signaled one of the earliest instantiations of cosmetic surgery. His efforts, more 
importantly, laid conceptual groundwork from which further innovative procedures could develop, giving at 
least a starting point for helping some of the patients that these surgical teams saw. 
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take.”49  This procedure allowed for better cosmetic results and improved health outcomes 
in these life and death situations.  
 Those with the most severe injuries received as urgent care of as possible from the 
surgical team on-site. Some of the soldiers suffered multiple bullet wounds to the face and 
eyes, while for others the bullets passed completely through their head. While these surgical 
teams included experts from highly respected universities, Yale, Harvard, Colombia, they all 
remained relatively inexperienced in tending to these types of wounds. The inexperience and 
diversity of the teams, coupled with the challenges presented by war-wounds, resulted in the 
development of different approaches to treat the same problem.  
 For certain neurological wounds, the Germans opted to leave parts of the brain 
exposed in order to allow for free drainage in an effort to prevent infection. Conversely, the 
British favored swift operations focused on removing foreign bodies and quickly closing the 
scalp.50 In 1917, American neurosurgeon Harvey Cushing utilized an electromagnetic 
procedure to extract iron shell fragments and “devised a simple method of debridement by 
suction and he urged water-tight two-layer scalp closure. Most importantly, he maintained 
meticulous records and surgical audits, finishing with a case mortality of 28.8%, which was 
then a marked improvement.”51 Cushing later published his findings, laying the groundwork 
for other surgeons working in the field to learn how to treat head wounds beyond the 
battlefields. Credit for successful treatments was the result of the interdisciplinary nature of 
the surgical teams. 
                                                
49  Elizabeth Haiken, Venus Envy: A History of Cosmetic Surgery (Baltimore: Johns Hopkins University Press, 
1997), 31. 
 
50  Simpson, “World War I: The Genesis of Craniomaxillofacial Surgery?,” 74. 
 
51  Ibid., 75.  
26 
 
 
 The successful approaches to treating the wounds seen during World War I 
incorporated an interdisciplinary approach comprised of nurses, doctors, surgeons, 
anesthesiologists, dentists, and perhaps the most unique addition to the team came from the 
use of artists in facial reconstruction. Artists created masks initially to give a rendering of 
what the patient’s face should look like following surgery, but also for a patient to wear 
whose surgery was unable to be completed to the team’s or patient’s satisfaction.52 
Furthermore, the interdisciplinary nature of the team, at its most basic level, resulted in fresh 
ways of thinking through the complex problems that presented in their operating rooms and 
led to significant surgical advances.  
 The increased level of education and the experimental approach to surgical 
treatments led to significant advances in patient care. One commentator told the New York 
Times, “that medicine and surgery had advanced half a century in four years.”53 While this 
statement may tend towards hyperbole, the advances were nevertheless dramatic. 
Interdisciplinary teams brought together professionals who had never worked or trained 
together to care for patients. The patients they treated would have died in ordinary 
circumstances, but were saved through the use of procedures that had never been attempted. 
Teams utilizing the different techniques and publishing the results, as Cushing did, allowed 
for education to spread beyond the battlefield and into hospitals and medical schools 
throughout the world.  
The techniques developed not only applied to battle wounds, but also would be 
applied to a variety of reconstructive surgeries brought on by disease and non-war related 
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injuries. Positively, one can say that an interdisciplinary approach to research that targeted 
patients with critical needs resulted in rapid advances in the field and cultivated new 
approaches to reconstructive surgery, even leading to the development of the field of 
cosmetic surgery. Negatively, however, one might see this type of surgery lending itself to 
the objectification of the body when done outside of an emergent medical need. Yet, non-
emergent procedures were becoming more frequent throughout the 1930s as beauty and the 
striving towards perfection was increasingly becoming a priority. The arguments for 
perfection, however, extended beyond the operating room and into eugenic research centers 
focused on enhancing particular individuals, while at the same time limiting the participation 
several other individuals and social groups deemed less desirable, in the hope of building a 
stronger society.  
Eugenics 
 Discussions of eugenic-based research typically center on Nazi scientists during 
World War II, but the groundwork for this type of research was well established globally 
prior to the war. Eugenics research focused on experiments aimed at genetically enhancing 
and improving upon certain genetic traits, and the elimination of others, in the hope of 
developing a more advanced society. In a certain sense, the approach was very individualistic 
and seemingly beneficial to society. The goal was to find and enhance particular individual 
characteristics that made for healthier, stronger, and more independent individuals. This 
meant eliminating negative characteristics such as physical disabilities and proclivity for 
disease. Yet, while eugenics focused on individual procedures, the intended aim was the 
good of society. Sterilizations and even the killing of racially ethnic, and/or religious “sub-
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groups” were just some of the control methods considered by eugenicists that relied on the 
contributions of science. 54   
From the perspective of eugenics, science served as a tool to maximize the potential 
of human beings for the betterment of society.  Science focused on improving the quality of 
human beings responsible for continuing society’s progress in a variety of forums. 
Ultimately, it “would allow man to conquer space, conquer time, overcome ‘the dark and evil 
elements in his own soul,’ and ultimately refashion ‘his own body and those of other living 
beings.’”55 For eugenicists, science was about human progress and improvement. The 
prevalence of this vision made eugenics appealing globally, especially in the economic 
depression following World War I. It was thought that by maximizing human potential, 
hope would emerge from that the stark economic reality, health challenges, and disabilities 
that people faced.  
  At the turn of the twentieth century, Sir Francis Galton’s research built on the 
earlier genetic research of Gregor Mendel to fulfill what he understood to be the duty and 
responsibility of a scientist to engage in research aimed at improving the human species as a 
whole.56 Galton saw eugenics as a process of “supplanting inefficient human stock by better 
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strains, and to consider whether it might not be our duty to do so by such efforts as may be 
reasonable, thus exerting ourselves further over the ends of evolution more rapidly and with 
less distress than if events were left to their own course.”57 For Galton, science was not 
about observing nature, but rather taking control of nature. His scientific focus resulted in a 
research fellowship in National Eugenics at the University College of London. In 1904, 
Galton and his team of researchers engaged in work that sought to understand differences in 
human beings based on race. Galton’s emphasis on race was not unique and fell in line with 
much of the work of other eugenic researchers, influencing one of the U.S.’s leading 
eugenicists: Charles Davenport. 
In 1910, Charles Davenport followed Galton’s lead by starting the Eugenics Record 
Office in Long Island, New York. This office focused on establishing “research via house-
to-house surveys and by studying records from prisons, almshouses, and institutions for the 
mentally deficient, deaf, blind, and insane…the Office supported scholarship students to 
study human heredity and collect data, primarily on the subjects of ‘feeblemindedness’…”58 
To this end, Davenport’s research concentrated primarily on research subjects who would 
have been mostly physically or mentally disabled and were considered unable to contribute 
to society. Davenport’s work can best be characterized as negative eugenics because his 
efforts centered on methods of eliminating particular characteristics from certain persons. In 
the U.S., his research extended beyond the Eugenic Record Office and resulted in state-
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enforced sterilization practices based on any number of “disabilities,” including race. By 
1934, sterilization laws were on the books in 27 U.S. states for “feebleminded” persons.59 
These race-related protocols were made possible by the research of Galton in Britain and 
Davenport in the U.S. The efforts of Galton and Davenport were furthered by the work of 
the Kaiser Wilhelm Institute during the rise of German nationalism.  
 The Kaiser Wilhelm Institute operated as one of a number of research institutions 
that pursued eugenics research for the advancement of society as a whole. By 1922, 
Germany joined Great Britain, Switzerland, Sweden, and the United States in establishing its 
own research center for eugenics.60 Germany, in many ways, built on already established 
eugenics programs, but was divided as to the type of research that ought to be pursued, 
positive or negative. A “positive” approach would focus primarily on the promotion of 
improvements that could be offered by pairing genetically desired characteristics together. 
While initially taking this path, the rise of German nationalism gave way to a negative focus 
of genetics research that emphasized the elimination of undesirable characteristics, similar to 
the U.S. approach, through sterilization. This type of negative research was exemplified in 
the work of Otmar Freiherr von Verscheur.  
 Von Verscheur became the director of the Kaiser Institute in 1942, and played a key 
role in establishing the research priorities in the concentration camps.61 He was a noted 
“racial hygienist” who, in his primer on race hygiene, took six pages to detail the “racial 
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genetic differences between Jews and Germans and the various forms of separation which 
were, at the time, imposed on Jews and [Roma].”62 It is the relationship between race and 
genetics that becomes the driving force, not only of his research, but also that of much of 
the research conducted in Nazi Germany. Moreover, Von Verscheur’s previous work on 
genetics and twins proved important to the work of the notorious “camp doctor” at 
Auschwitz, Josef Mengele.63  
Mengele’s research agenda in Auschwitz centered on race and infectious disease, 
which included experiments that required the killing of and subsequent dissection of Roma 
twins. He attempted to decipher genetic differences among “Jews, [Roma], and others who 
proved resistant to various infectious disease in particular to tuberculosis and typhoid.”64 
Many of Mengele’s experiments focused on infectious disease, genetics, and resistance to 
specific diseases including tuberculosis and typhus. Mengele’s hypothesis was that genetics, 
inclusive of race, proved indicative of those likely to contract and/or disseminate disease. 
While his research did not prove this to be true, it did not disprove the theory either. In fact, 
his research bias has been influential in the way in which research developed throughout the 
remainder of the century, which initially focused exclusively on white males, and certainly 
contributed to some of the current debates in health disparities and outcomes research.65  
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 Though eugenics research may have prompted broader ethical considerations in 
research—explored in Chapter Two—it nevertheless focused on the importance of research 
that benefited the health of society, even if only the minority within society. In fact, all of the 
research in this period tried to balance the needs of individuals with those of society. The 
scientific efforts of the Rockefeller yellow fever commissions, the emergence of plastic 
surgeons, and even eugenic researchers used medical research—at least from their 
perspective—to improve society. Vaccine development addressed the health needs of 
workers in South America in developing a vaccine that was useful with the opening of the 
Panama Canal and the onset of two World Wars. The surgical techniques, while focused on 
improving the health of individuals, the real impact was on the interdisciplinary nature of the 
surgical team and the unique procedure being performed. These efforts were so unique that 
a new medical specialty, cosmetic surgery, was born. The post World War era, however, saw 
a shift in the types of medical research projects pursued. The Wars brought a new 
perspective to the importance of controlling diseases and the global impact that research can 
have on the health of persons.  
Medical Research: More of the Same or a New Era? 
 The third phase in the development of medical research began in the late 1950’s and 
endures through the present. This phase of research begins to take into account the global 
reality of disease and the potential role of medical research to alleviate some of these 
burdens. The paradigmatic examples in this period focus on diseases that potentially affect 
everyone. Though individual expertise within the disciplines of basic science, clinical, and 
epidemiologic research constantly improved, addressing the complex challenges of global 
health required a collaborative and interdisciplinary approach to research. The epidemiologic 
emphasis on the eradication of smallpox, the first example, demonstrates the need for both 
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interdisciplinary and multi-national collaboration between basic scientists, health care 
workers, and public health experts. The process of eradication took years to achieve, but still 
provides a model for preventing the global spread of disease by focusing on the low-income 
countries where the infectious disease was endemic.  
The second and third examples, the Veteran’s Administration (VA) clinical 
hypertension studies and developments for treating malaria through synthetic biology, focus 
on the importance of institutional collaboration to treat two global threats to health. 66  The 
VA hypertension studies demonstrate the importance of clinical trials and introduce the 
“gold standard” of the double-blind placebo controlled trial. At the time of the VA study, 
there was much debate surrounding the health risks of high blood pressure, and the double-
blind placebo control trial removed researcher bias in observing the different outcomes of 
those being treated compared to those in the control group. Unfortunately, malaria research, 
the third example, is not at the clinical trial stage.  
It is, however, the hope of U.S. researcher Jay Keisling that, through synthetic 
biology, new treatments will emerge from his work. Synthetic biology is a relatively new field 
of research that has played an important role in the creation of new and previously unknown 
biological phenomena through scientific engineering. Most recently, it has been applied to 
the production of artemisinin in the hope of addressing the global health challenges 
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presented by malaria. It is the hope of Keisling and his team that their work can make 
progress towards discovering a cure for one of the great challenges in global health.  
These three examples address a range of needs in global health research, which 
provides the context for research today. Global health research focuses on health concerns 
that exist on both a local and international level. In this way, research undertaken locally has 
global ramifications. Yet, as will be described in Chapter Four, pressing global health needs 
do not always receive priority in research. These examples represent a departure from the 
type of research that tends to focus more on individual or personalized approaches to 
research. On the contrary, global health research emphasizes the importance of the health of 
the community and communities. While this emphasis is not assumed at the exclusion of 
individual health concerns, it certainly prioritizes research that will improve the health status 
of a large portion of the community both locally and globally. It is the focus on research that 
is both local and global that characterizes the multifaceted effort to eradicate smallpox.  
Smallpox 
  In 1980, the World Health Organization (WHO) officially declared the eradication 
of smallpox. The eradication process was a complex journey driven by a confluence of 
factors, the least of which was the scientific capability of eliminating the disease. Though the 
ability to inoculate against smallpox was discovered in 590 BCE in China, it took over 2,000 
years for smallpox to be eradicated.67 Smallpox represented a constant health threat that had 
historically passed indiscriminately between the rich and poor. The disease seemingly struck 
at random and was fueled by prolonged human-to-human contact during the critical period 
of contagion. As living conditions improved in most of the global north, the conditions for 
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the majority of the world in the global south remained unchanged and ripe for the spread of 
a disease such as smallpox.  The facility with which the disease was transmitted made it a 
challenge to contain.  
Smallpox was a variola virus that presented as a rash and appeared in both a major or 
minor form. Variola minor was less common and less deadly, resulting in the death of 
approximately 1% of persons that contracted the virus. In contrast, the variola major 
accounted for about 90% of all smallpox cases, of which 30% proved to be fatal.68 
Characteristics of its transmission included relatively close contact, either through the air or 
physical contact with another person, and were secondarily transmitted through clothes, 
sheets, and rags.69  Historically there were persons who proved more likely to contract the 
disease than others. Medical students, nurses, doctors, hospital staff proved more susceptible 
to the disease because of their work with the unprepared bodies, skin legions, shrouds, and 
dissection.70 The incubation for smallpox typically lasted from 7 to 17 days, and averaged 12 
to 14 days.71 Once a person had become infected there was no cure, though if they survived 
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they had lifelong immunity to smallpox. The challenging aspect of the disease was that a 
person initially became contagious with relatively mild flu-like symptoms that quickly 
escalated into a rash and raised bumps that secreted a highly contagious fluid passed easily 
from individual to individual. Thus, the most crucial aspect of the global effort to eradicate 
smallpox was the urgency of identifying the individual who was the source of the infection 
and to develop a coordinated effort at containing the disease.   
 By the latter half of the twentieth century, smallpox had been virtually eliminated 
from high-income countries, leaving the disease burden resting on low and low-middle-
income countries in Asia, Africa, and South America.72 In 1958, the World Health 
Organization (WHO) considered mounting a global campaign to eradicate smallpox at the 
behest of Viktor Zhdanov of the Soviet Union. He noted that there remained only 59 global 
states in which smallpox existed, and proposed an effort to inoculate 80% of the world’s 
population within two years. This quick turnaround, however, required the immediate 
training of health workers to respond more readily to the disease.  
Zhdanov’s insistence proved important not only for the validity of the argument he 
was making, but also for the reemergence of the Soviet Union as a member of the WHO 
assembly for the first time since 1949. Zhdanov and his country were crucial to the plan, 
because it could demonstrate an eradication plan for smallpox that mimicked important 
features of a global plan, i.e. a large land area with a varied climate and a diversity in 
population and cultures. Though the Soviet plan took longer than expected due to a 
constrained budget, an increase in financial resources—by 1966 $2 million would be given 
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annually to the cause for the next five years—facilitated more effective results.73 By 1973, 
Brazil and Indonesia both were declared free of smallpox. India, who had been home to 
over half of the world’s smallpox cases, joined the list of smallpox-free countries by 1975. 
Finally, in 1977, Ali Maow Maalin, a Somalian man who ultimately survived the disease, 
contracted the last known case of smallpox.  
 The eradication process of this disease was made possible through the collaborative 
efforts of different nations and the coordinated training of health workers, financial support, 
political good will, scientific ingenuity, and timely action on the part of on the ground 
surveyors. The targeted efforts on smallpox allowed for the translation of medical research 
beyond the laboratory and clinic to transform the health of persons. While individuals 
ultimately benefited, it was out of concern for public health that the WHO eventually 
championed the issue. The coordination through the WHO made the eradication of 
smallpox possible by facilitating international collaboration and sharing of scientific findings 
amongst the research team. The collaborative approach espoused by the researchers, which 
proved crucial to Zhdanov’s plan, remained essential for addressing future challenges in 
global health.  
Given the recent outbreaks of the Ebola, the lessons of smallpox eradication efforts 
prove relevant once again. Focus on controlling or eradicating a disease requires moving 
beyond political differences, economic concerns, and making a concerted effort to involve a 
variety of health professionals. While many national research programs have been reluctant 
to take on the health challenges that plague primarily low-income countries, Ebola heightens 
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the international challenges of infectious disease. Institutions, like the WHO and others, 
need collaborative partners to focus on eradicating and controlling the spread of infectious 
disease. These responsibilities, however, extend beyond research, to call on these institutions 
to work for social change.74 Medical research, in the case of smallpox and the present case of 
Ebola, demonstrates one way change might come about. 
Although global infectious disease remains a pertinent issue, many Western and 
high-income countries have opted, instead, to focus research efforts on discovering cures for 
chronic diseases facing individuals. The rise of research on chronic disease became a focus 
of high-income countries by the 1960s. One of the first priorities that the NIH addressed on 
a large-scale clinical trial was hypertension. While today many are aware of and treated for 
hypertension on a daily basis, it was once not thought of as a serious threat to health. The 
VA study demonstrated that it was in fact a real health concern that benefited from 
treatment.   
VA Hypertension Study 
 Though evidence of hypertension existed as far back as 2600 BCE, measuring of 
blood pressure only became a consistent medical practice within the last century.75 One of 
the earliest references—around the second or third century BCE—to high blood pressure 
came from the Chinese medical textbook, Yellow Emperor’s Classic of Internal Medicine. Early 
Chinese research identified too much salt in foods as a factor that contributed to increase 
blood pressures. Other descriptions described dangerous blood pressure as “firm, rapid, and 
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large…”76 These descriptions offered by Chinese-medicine, however, lacked the capabilities 
to prove their hypothesis. However, life insurance companies, not physician researchers, led 
the way in studying the associations between hypertension and mortality.  
 In the early 1900s, life insurance companies in the United States began to take 
concerted interest in discovering why and how their clients were dying. Their inquiries led 
them to conduct clinically relevant research into the health concerns of those with high 
blood pressure.77 The research consistently showed a higher mortality rate with those who 
had higher blood pressure. Despite the evidence, however, hypertension was dismissed 
frequently as a cause for concern in the medical community. In 1912, Sir William Osler, a 
foundational figure in medical educational, dismissed high blood pressure as a medical 
problem and advised against its treatment. He stated, “The extra pressure is a necessity-as 
purely a mechanical affair as in any great irrigation system with old encrusted mains and 
weedy channels. Get it out of your heads, if possible, that the high press is the primary 
feature, and particularly the feature to treat.” 78 While Osler saw high blood pressure as 
natural, others regarded it as a potential health risk and began treating it through surgical 
interventions. Surgery, however, was often seen as a last resort and gave way to less invasive 
pharmacological remedies. With the shift to pharmacological treatments, clinical trials were 
needed to confirm if treatment would decrease a patient’s blood pressure. 
 By the 1940s, James Shannon stood at the forefront of establishing standards for 
clinical research beginning with the development of anti-malarial drugs, which had 
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unforeseen effects on hypertension research. 79 One of the key drugs that Shannon and his 
research team used was chloroquine. However, through the research process it was noted 
that some malarial strains were resistant to chloroquine and that an alternative or 
complementary drug was needed to ensure its success. The supplement drug, pentaquine, 
came to have a significant role not only in the treatment of malaria, but also as an initial 
treatment for hypertension.  
 By the end of the decade, Shannon became the lead researcher at the National Heart 
Institute and brought a familiar colleague with him, Edward Freis. Freis had already given 
pentaquine to 17 patients with moderate to severe hypertension, and after several days of 
treatment their supine blood pressure—taken when the person is lying down, which allows 
blood to flow more easily throughout the body—fell between 10% to 40% below baseline.80 
This immediate drop lowered their risk of heart attack, stroke, and heart failure. Though 
pentaquine came with some debilitating side effects, it demonstrated an initial benefit of 
treating patients with high blood pressure, while simultaneously underscoring the need for 
more research.  
 In 1964, Edward Freis continued his research by conducting an unprecedented 
collaborative study between 17 VA hospitals, utilizing a previously untried methodological 
approach to clinical research. Given the skepticism about the need to treat high blood 
pressure at all, any study undertaken had to demonstrate, without bias, a clear benefit for 
treating patients. In order to achieve unbiased results, Freis coordinated a multi-site 
randomized double-blind placebo-controlled study. In this type of study, multiple VA 
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hospitals were used and neither the researchers nor participants knew who received 
treatment and who received the “placebo” or non-therapeutic treatment. Both groups were 
selected at random, and were not deliberately chosen by any particular criteria. This type of 
research, and on such a large scale, had never been tried before. Yet, neither the size nor 
scope of the study was as impressive as the results that forced important changes in clinical 
practice.  
 The results of the VA study demonstrated the effectiveness of a drug combination of 
thiazide diuretic, reserpine, and hydralazine at lowering blood pressure.81 In total, 523 
patients were enrolled and randomized into a treatment group and a control group. After 18 
months of treatment, the study of the placebo group had to be stopped because of the 
disparity that existed in the morbidity and mortality outcomes. Freis reported the following: 
Four of the 70 patients in the control group died as a result of cardiovascular 
complications as compared to none in the 73 treated patients…17 patients in the 
control group developed non-fatal complications, such as the malignant phase of 
hypertension, severe congestive heart failure, cerebral hemorrhage, or disabling 
cerebral thrombosis… an additional 6 control patients developed non-terminating 
events, including mild congestive heart failure, myocardial infarction, and non-
disabling strokes…over the period of follow-up the incidence of cardiovascular 
complications was 27 in the placebo group versus only one in the treated group...19 
deaths due to cardiovascular causes had occurred in the control group versus 8 in the 
treated group. The most frequent cause of death was either myocardial infarction or 
sudden cardiac arrest…11 occurred in the control group and 6 in the treated group. 
Stroke was the next most common…eight in the placebo group versus only one in 
the treated group….56 (28.9 percent) of the control group developed cardiovascular 
complications during the trial, compared to 22 (11.8 percent) of the treated group.82 
 
Freis’ observations demonstrated a clear benefit to those in the treatment group, and the 
consequences for those not being treated were so equally clear and dangerous that the trial 
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had to be stopped. The results pointed to a conclusive link between mitigating the effects of 
hypertension through treatment and positive health outcomes. The conclusiveness of the 
study led to increased funding from the NIH for developing safer and more effective drugs, 
setting in motion a series of initiatives for further improvements in the treatment of 
hypertension.  
 Over the next three decades, hypertension research continued to build on Freis’ VA 
study through clinical research aimed at controlling hypertension, reducing mortality, and 
increasing nutritional intervention. After 30 years of exclusive focus on pharmacological 
treatments, more studies began to explore the effectiveness of reducing hypertension in 
patients through a combination of therapeutic drugs with nutritional and hygienic 
intervention. More recent focus has centered on studying the combined effects of other 
diseases, such as those suffering with hypertension and diabetes.83 While much progress has 
been made in anti-hypertension research, Freis’ study distinguished itself as the first to 
address treatment options for high blood pressure by utilizing a new type of clinical research. 
Perhaps more prominently, his work demonstrated the potential of a collaborative project by 
coordinating the research and staff of 17 VA hospitals. Both the new methodological 
approach and the participation of multiple hospitals contributed to a process that tried to 
eliminate bias, which proved fundamental for a study surrounded by so much skepticism.  
 Freis’ research on hypertension, which has now become a global health challenge, 
has allowed for research to continue in low and middle-income countries.84 However, 
                                                
83  Kotchen, Historical Trends and Milestones in Hypertension Research: A Model of the Process of Translational Research., 
529-30; Henry R. Black, Clinical Trials in Hypertension (New York: Marcel Dekker, 2001). Kotchen has a helpful 
table that focuses on the highlights of global hypertension research with brief descriptions of each study. Black 
offers an edited volume that details the research being done in anti-hypertensive research in a more formal way.  
 
84 Dele Abegunde, et.al., “The Burden and Costs of Chronic Diseases in Low-Income and Middle-Income 
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chronic disease, such as hypertension, in lower income countries is often experienced along 
side infectious diseases. In these areas, infectious disease remains a more persistent health 
threat.85 One of the more prominent diseases faced in low-income countries is malaria, 
which ironically played a crucial role in the story of hypertension research. While there are 
treatment protocols in place, malaria still remains a global problem that has defied traditional 
therapeutic remedies. To this end, alternative approaches to searching for anti-malarial 
treatments and cures have been undertaken with promising discoveries surfacing through 
synthetic biology.  
Synthetic Biology 
 As breakthroughs in chemistry saw the deconstruction of molecules and geneticists 
were able to observe entire strands of DNA, synthetic biologists focused on isolating genes 
and reconfiguring molecules in order to study the effects of their interaction in a newly 
created environment.86 The breakthroughs in chemistry, genetics, and biology throughout 
the 1960-1990s provided the foundation for the development of synthetic biology in the 
early 2000s.87 Two of the key elements necessary for synthetic biology to function rely on the 
building blocks of biology and systems biology. Biology focuses on the micro level by 
studying life through its functions, structures, developmental stages, environment, species, 
etc. In contrast, systems biology operates on the macro level, organizing the vast diversity of 
                                                                                                                                            
Countries,” The Lancet, vol. 370, no. 9603 (2007), 1929-1938. 
 
85  Christopher Murray, et al,  “Global, Regional, and National Incidence and Mortality for HIV, Tuberculosis, 
and Malaria During 1990-2013: a Systematic Analysis for the Global Burden of Disease Study 2013” The Lancet, 
vol. 384 no. 9947 (2014): 1005-1070. 
 
86  Steven A. Benner, “Synthetic biology: Act natural,” Nature, vol.421, January 9, 2003. 
 
87  Ewen Cameron, James Bashor, and James Collins, “A Brief History of Synthetic Biology,” Nature Reviews 
Microbiology. vol. 12, no. 5 (2014): 381-390. 
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biological study into a “quantitative understanding of natural biological systems.”88 This 
quantitative understanding creates opportunities for deeper knowledge about the way in 
which particular biological processes function as a unit. For synthetic biology, it is important 
to have the biological understanding of how these units function and to be able to both 
break down and rebuild them.  
 The reconstruction and deconstruction of biological units requires engaging with 
principles of engineering and biotechnology in order to create phenomena that do not exist 
naturally. In terms of deconstruction, synthetic biology uses available biotechnologies to 
break down existing biological entities into distinct and unique properties that do not 
otherwise exist independently in the natural world. An example of deconstruction would be 
the unraveling biological life by breaking it down to minimal set of genes that when 
separated can be utilized in artificially creating simple and manageable structures. Likewise, 
the constructive nature of synthetic biology requires the technological capabilities to 
reconstruct the previously deconstructed biological bits.  
 Isolating a genome of one organism and, constructively, inserting that isolated 
genome into the cellular properties of a completely distinct, albeit related, organism creates a 
new entity by utilizing biotechnology and bioengineering.89 First, a new entity is created 
because the cellular properties of isolated genome A do not exist as a part of organism B. In 
this complex processes, it is the combination of biotechnology, engineering, coupled with an 
understanding of biology, and systems biology that make these developments possible. In 
this light, one can see how synthetic biology inherently functions interdisciplinarily. 
                                                
88  Luis Serrano, “Synthetic Biology: Promises and Challenges,” Molecular Systems Biology 3 (2007), 2. 
 
89 This type of technology is frequently described as nanotechnology, which is the technology necessary to 
build genetic structures. “Companies have already developed techniques with which the four nucleotides, can 
be attached to each other in any desired order.” See Rinie van Est, Huib de Vriend, and Bart Walhout, 
Constructing Life: The World of Synthetic Biology. (The Hague: Rathenau Instituut, 2007). 
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Furthermore, while its interdisciplinary nature is unique, what truly sets synthetic biology 
apart is the creation of new biological phenomenon or phenomena with the potential for a 
variety of applications as indicated by patenting trends pertinent to synthetic biology.  
 Since the early 2000’s, patents for synthetic biology developments have been on the 
rise. While more time will be spent on the function of patents in Chapter Four, for now 
suffice it to say that a steady increase in patents indicates a certain level of scientific 
innovation and prioritization of a particular type of research with the potential for generating 
an economic return on investment. The U.S. has shown the most success for patenting 
innovations related to synthetic biology. A recent survey indicated that the U.S. is 
responsible for approximately 45% of the global patents in synthetic biology from 1990-
2010.90 Synthetic biology patents with potential application in the area of medicine constitute 
a small percentage, 13.8%, of the overall percentage of patents held. Most of these patents 
are filed for by businesses, followed by universities and colleges, individuals, and research 
institutions.91 The focus of these patents for medical research centers on both treatment for 
and understanding of disease mechanisms. Currently, one of the efforts in synthetic biology 
research that holds the potential to have significant consequences for global health is the 
work being done on artemisinin, used in the creation of antimalarial drugs.92  
                                                
90  Davy van Doren, Stefan Koenigstein, and Thomas Reiss, “The Development of Synthetic Biology: a Patent 
Analysis,” Systems and Synthetic Biology, 2013, vol. 7, no. 4: 209-220. The language in the literature uses synthetic 
biology and synbio interchangeably.  
 
91  Doren, et. al., ““The Development of Synthetic Biology: a Patent Analysis,” 213. 
 
92  Anne E. Osbourn, Paul E O’Maille, Susan J. Rosser, Keith Lindsey, “Synthetic Biology,” New Phytologist 196, 
no. 3 (2012), 673. In this example, rather than turning to artemisinin one could also look at In 2012 in Bristol, 
UK, Northwestern University (Chicago, USA) professor Sam Stupp presented strategies in which chemical 
structures were capable of signaling the mechanisms necessary for tissue growth, which hold “enormous 
potential for the formation of human tissues and organs in regenerative medicine and for the development of 
cell-like micro scale objects that can be targeted for therapeutic purposes (e.g. artery repair, drug delivery).” 
Stupp’s research is an example of the constructive and applicative nature of synthetic biology to medical 
research.  
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 The WHO estimates that 3.4 billion people are at risk of contracting malaria, and in 
2013 the disease was responsible for close to 600,000 deaths, most of whom were African 
children.93 African children are the most vulnerable population for contracting malaria, and 
despite reducing mortality rates by 58% since 2000, one child in Africa dies each minute as a 
result of the disease.94 Given malaria’s disproportionate inclination to infect persons living in 
low and middle-income countries in the global south and the limited resources for research 
on the disease within these areas, taking up malaria research addresses an unjust disparity in 
research and disease burden that affects the global south. Yet, the possibilities of eradicating 
or controlling malaria are often cited as being too costly due to drug resistant strains.  
 Drug resistant strains of malaria are typically treated with artemisinin-based 
combination therapies (ACTs); however, acquiring artemisinin naturally is a costly and labor-
intensive process. To harvest the necessary artemisinin-base begins with its extraction from 
dried leaves of the herb a. annua, a sweet wormwood plant found in Asia and East Africa. In 
order to produce five kilograms of artemisinin, 1000 kilograms of dried leaves have to be 
planted and cultivated from approximately 17,000 hectares (ha) or 42,000 acres of land.95 
While recent efforts at increasing the total acreage have begun, the global yield falls far 
below the global demand.  This has led Jay Keasling, and others conducting research in 
synthetic biology, to explore the possibilities of producing the precursor to artemisinin, 
artemisinic acid.  
                                                
93 World Health Organization, “Malaria,” http://www.who.int/mediacentre/factsheets/fs094/en/, December 
2014, (accessed April 3, 2015). 
 
94 Ibid. 
 
95  Victoria Hale, et al., “Microbially Derived Artemisinin: A Biotechnology Solution to the Global Problem of 
Access to Affordable Antimalarial Drugs,” American Journal of Tropical Medicine and Hygiene 77, no. 6 (2007), 198. 
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 Keasling’s research looks to construct a new metabolic pathway that allows for the 
possibility of producing the artemisinic acid necessary for ACTs. He and his team at the 
University of California-Berkeley developed a biosynthetic pathway that consists of bacteria, 
yeast, and the plant’s own gene, to identify the specific genes that initiate a annua’s 
production of artemisinic acid. The bacteria, yeast, and genes were placed into a “bacterial 
chassis,” an instrument capable of synthesizing a plentiful supply of “isoprenoid precursors” 
that do not typically function outside of the biological acid producing process in the a annua. 
Through the synthesizing process, researchers were able to identify a single-gene that 
catalyzed the three oxidation steps necessary to produce artemisinic acid. Though the 
process detailed above is complex, it can be broken down in a way that demonstrates how all 
of the parts work together to create this synthetic product. The biological part is the a annua. 
The biotechnology used is both the chassis, which allows for the systematic deconstruction 
of the genes to their microbial function, and the technology that enables the insertion of the 
specific biosynthetic gene into this process of creating artemisinic acid.  It is the 
reproduction of the naturally occurring three-step oxidation that makes this a work of 
synthetic biology.  
 The work of Keasling serves as one example, though an important one, of the 
possibilities that basic science research holds for future breakthroughs in global health 
research. While the focus on this particular endeavor is highly technical, its potential for 
broad application could go a long way in addressing the injustices of malaria’s disease 
burden. One challenge, however, is that this type of research is not cheap. Keasling’s work 
has been made possible in part by a $53.3 million gift from the Bill and Melinda Gates 
Foundation and the collaborative efforts of UC-Berkeley, the nonprofit organization PATH, 
Amyris a leading synthetic biology innovator, and the France-based pharmaceutical company 
48 
 
 
Sanofi.96  While successful collaboration is important and implementation of the project 
could provide ACT treatment to over 200 million malaria infected persons, Keasling and his 
researchers have only been able to produce the artemisinic acid necessary for initial testing of 
new ACT-based malaria treatments. Thus, uncertainty still surrounds this research, which 
will be costly and in need of support without a guaranteed return on investment.  
 Nevertheless, the success of Keasling’s project reinforces a common theme 
throughout the development of medical research in this third phase, which is the importance 
of an interdisciplinary and institutionally collaborative approach. The example of malaria 
research, requires the efforts of educational, pharmaceutical, biotechnology, private 
foundations, and non-profits entities to put the research efforts of Keasling and his team 
into practice. Without this collaborative approach global health challenges that unjustly 
affect the lower income countries of the global south might continue to go unmet.  
Conclusion 
 Medical research from the end of the nineteenth century to the present day has 
balanced prioritizing the health needs of individuals against those of the larger community. 
The definitions of medical research given by international institutes for research, described at 
the beginning of the chapter, articulate the wide range of values operative when considering 
the rationale behind investing in medical research. The U.S., U.K., and France each 
emphasize the importance of health research focuses on economic returns and technological 
innovation. In contrast, India’s Council for Medical Research places a higher value on 
research that demonstrated clear public health benefits with little value focused on the 
technological or economic contribution of research. A low-tech public health approach was 
                                                
96 Robert Sanders, “Launch of Antimalarial Drug a Triumph for UC Berkeley, Synthetic Biology,” 
http://newscenter.berkeley.edu/2013/04/11/launch-of-antimalarial-drug-a-triumph-for-uc-berkeley-synthetic-
biology/, April 11, 2013, (accessed April 2, 2015).  
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characteristic of the first period of research highlighted by John Snow, Robert Koch, and the 
multiple sanitary commissions, where efforts centered on improving the health of the 
international community. The goal of improving public health served both the interests of 
the community in which research was being conducted,  but also held political and economic 
importance for those communities.  
 The second phase of research, from the early 1900s into the 1950s, was characterized 
by focusing on the health of particular communities. The efforts of the yellow fever 
experiments of the Rockefeller Foundation centered on communities in South America 
upon the opening of the Panama Canal, in order to ensure that yellow fever did not easily 
spread through the new trade routes. Perhaps initially unexpected, yellow fever research 
came to provide a great benefit to the war efforts by enabling the vaccination of some six 
million U.S. and U.K. military personnel, contrasted with only 60,000 Brazilians. This 
disparity in benefits of research is one that will continue to be raised throughout the 
dissertation and highlights the importance social justice when considering research ethics.  
 Research ethics—the focus of the next chapter—has more traditionally focused on 
protecting the rights of research subjects. While the protection of research subjects has been 
vital, particularly during the periods when the rights of certain minority groups have been 
ignored, research ethics should also be concerned with social ethics issues. One such 
concern should aim to ensure that research efforts do not become too narrowly focused on 
one particular group, neglecting more urgent health needs of other groups. It is the 
temptation to focus on particular health needs of individuals and particular groups over 
others that proves endemic to the examples in the second phase of research development. 
However, the examples from the third phase of the development of medical research 
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indicates ways in which a balance might be struck between addressing public and individual 
health needs.  
 The efforts in synthetic biology signal the type of basic science research needed to 
address increasingly more complex global health challenges. The smallpox eradication efforts 
demonstrated the potential that large-scale research and public health efforts can have 
through institutional collaborations. Collaboration was at the heart of Freis’s successful 
hypertension studies between the VA hospitals. While at the time hypertension was only 
emerging as a U.S. problem, the research that has developed from Freis’s work proved 
foundational to addressing the global problem of heart disease related to high blood 
pressure. This third period, in particular, demonstrated the importance of institutional and 
interdisciplinary collaboration, which would not have occurred without financial and 
intellectual investments in a variety of public and private entities.  
 This First Chapter has drawn attention to the multiplicity of players that have 
contributed, and continue to contribute, to the progress and priorities of medical research. 
While examples from the final phase focused on medical research that specifically addresses 
global health challenges, these challenges often go neglected. In fact, as will be outlined in 
more detail in Chapter Four, the most urgent health needs of people in low-income 
countries tend to be under researched compared to the health needs in high-income 
countries.  
 Estimates indicate that 90% of the medical research conducted, stands to benefit 
only 10% of the global population.97 This unjust disparity indicates that the current state of 
                                                
97 Research and Development to Meet Health Needs in Developing Countries: Strengthening Global Financing 
and Coordination Report of the Consultative Expert Working Group on Research and Development: 
Financing and Coordination, Research and Development to Meet Health Needs in Developing Countries: Strengthening 
Global Financing and Coordination (Geneva, Switzerland: World Health Organization, 2012), 32. 
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research priorities needs to be reevaluated if global health needs of the majority of the world 
are to be addressed. While research ethics, the focus of the next chapter, offers a way of 
protecting the rights of research subjects, it fails to address the social inequities within the 
practice of research itself. Thus, after considering the important role of research ethics—
despite its limitations—Chapter Three will argue that an epistemological shift of medical 
research is needed in order to consider more seriously the health needs of the “poor 
majority” that often go neglected. 
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CHAPTER TWO 
 
THE CODIFCATION OF RESEARCH ETHICS  
Introduction 
 In the midst of the medical research innovations from the middle of the Nineteenth 
Century to the current technological practices of the Twenty-first Century, human subjects 
begin to play an increasingly important role in the process of conducting research. The 
paradigmatic examples in the previous chapter trace the development of medical research, 
but paralleling these developments were questions about the ethics of research and the rights 
of research subjects. These debates reach a crescendo after the Holocaust with the 
development of the Nuremberg Code.  
 The code, while responding to the use of unethical and illegal practices against 
Jewish prisoners, draws upon prior unethical practices of research. The previous legal cases 
raise questions pertaining to research perpetrated against prisoners and prostitutes, who were 
frequently enrolled as unknowing or uninformed participants in scientific research. However, 
even after the condemnation of Nazi research at the Nuremberg trial, violations of the rights 
of research subjects continues to occur. The continuance of unethical research practices 
results in the development of guidelines aiming to prevent the unethical and illegal conduct 
of medical research.1
                                                
1  Jenny Hazelgrove, “British Research Ethics After the Second World War: The Controversy at the British 
Postgraduate Medical School, Hammersmith Hospital,” in Twentieth Century Ethics of Human Subjects Research: 
Historical Perspectives on Values, Practices, and Regulations, ed. Volker Roelcke and Giovanni Maio (Stuttgart: Franz 
Steiner Verlag, 2004), 181. 
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  The Nuremberg Code, followed by Declaration of Helsinki (1964), and the 
Belmont Report (1978), establish  necessary ethical foundations intended to guide research 
on human subjects. In one way or another, each of these international codes takes up ethical 
and legal questions arising from medical research practices that reflect social questions of the 
day. Despite the complex social and ethical questions surrounding the origins of these 
documents, the implementation of normative guidelines foster only a minimum ethical 
requirement protecting individual rights or the urging the physician to take responsibility to 
do no harm. Therefore, regulations guiding the ethical conduct of research concentrates on 
the individual participants, at the expense of the socio-ethical questions that surround the 
origins of the documents. 
 The social and historical context provides a necessary dialectic for developing a 
research ethic capable of responding to question of individual and social ethics for research. 
Without this dialectic, research ethics functions more as a formulaic checklist of do’s and 
don’ts. While a checklist proves beneficial, it cannot be the sole consideration when 
evaluating the ethics of a research study. Moreover, the parameters of the ethical conduct of 
research have to consider the social contexts in which research takes place.  
 This chapter emphasizes the importance of the socio-historic contexts in which these 
foundational international documents took shape, a nuance that becomes minimized in their 
practical application to research.. It does so in the hope of reconsidering discussions around 
both medical research and research ethics within a framework of social ethics. Part one 
explores the Nuremberg Code, which is often considered to be the first document detailing 
the ethics of human experimentation. The Nuremberg Code served as a reflection and 
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codification of already established ethical norms that the Nazis simply disregarded.2 Even 
after the issuance of the Nuremberg code, researchers were slow to fully adopt some of its 
key elements. In part, this was due to the historical events surrounding Nuremberg, which 
made the code difficult to translate to “normal” settings of research. Thus, shortly after 
Nuremberg, in 1954, the doctors of the World Medical Association (WMA) began their own 
conversations to develop ethical guidelines for the practice of research.  
 The Declaration of Helsinki, finalized in 1964, is the second set of guidelines 
explored in this chapter and draws from both the Nuremberg Code and the Declaration of 
Human Rights, promulgated in 1948. Despite Nuremberg, the Declaration of Human 
Rights, and Helsinki, research practices in the U.S. still made it necessary for another 
normative document targeted at U.S. researchers. The third section of this chapter focuses 
on the Belmont Report.  
 The Belmont Report, more than Nuremberg or Helsinki, remains foundational to 
the U.S. approach to questions concerning the ethical conduct of research but, like the 
others, cannot be appreciated fully outside of the context in which it develops. Its 
development came on the heals of Tuskegee syphilis experiments, in which the rights of 
vulnerable research subjects due to racism and poverty began to take on increasing import. I 
conclude this chapter with a brief look at global bioethics, an area of research that has 
become important over the last decade.  
  Global bioethics addresses questions of population health, distributive justice, and 
vulnerable populations. All of these topics addressed by global health, are in someway 
representative of concerns expressed in Nuremberg, Helsinki and Belmont that have been 
                                                
2  Michael Grodin, “Historical Origins of the Nuremberg Code,” in The Nazi Doctors and the Nuremberg Code: 
Human Rights in Human Experimentation, ed. George Annas and Michael Grodin (New York: Oxford University 
Press, 1992), 125. 
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lost. I suggest that some of the concerns expressed by global bioethicists signal the 
importance of an epistemological shift for both medical research and research ethics, a topic 
reserved for Chapter Three. While some of the richness of these international and national 
guidelines for research ethics have faded over time, their influence on the development of 
research ethics, broadly speaking, cannot be underestimated.  
The Nuremberg Code 
An Established Precedent  
 The Nuremberg Code, while frequently viewed as the first document that established 
an ethical and legal precedent for conducting research on human subjects, drew upon two 
key cases of research misconduct that laid the groundwork for a legal case against the Nazi 
doctors. The first of these came about in 1898 when a case was brought against Albert 
Nessier, a professor of dermatology and venereology at the University of Breslau in 
Germany.3 Nessier’s study set out to analyze the success of a vaccine for preventing the 
spread of syphilis. In order to study the vaccine, he enrolled patients who had been admitted 
to the university hospital. He utilized patients admitted with syphilis and several others who 
did not have the disease. For those who did not have syphilis, and in the interest of finding a 
preventive method, “he injected cell free serum from patients with syphilis into patients who 
were admitted for other medical conditions.”4 He would then test his vaccine on the patients 
recently injected with the disease, which frequently failed to prevent the contraction of the 
disease. While this would be reason enough to challenge the research, the unique aspect of 
his study was that the majority of his research subjects, who did not have syphilis prior to 
                                                
3  George Annas and Michael Grodin, “Introduction,” in The Nazi Doctors and the Nuremberg Code: Human Rights 
and the Nuremberg Code, ed. George Annas and Michael Grodin (New York: Oxford University Press, 1992), 6. 
 
4  Jochen Vollman and Rolf Winau, “Informed Consent in Human Experimentation before the Nuremberg 
Code.” British Medical Journal (International Edition) 313, no. 7070 (1996), 1444. 
 56 
their hospital admission, were prostitutes. Nessier specifically chose his subjects because 
he felt that these women had a higher potential of contracting syphilis of their own accord. 
In his trial, despite it being untrue, he claimed that these women must have contracted the 
disease by other means. Nessier was brought to trial and fined because he had ignored the 
Prussian directive on informed consent issued in 1891, which was designed to protect 
potentially vulnerable research subjects.  
 In 1891, the interior minister of Prussia issued a directive in response to questions 
regarding the forced inoculation of prisoners against tuberculosis, which stated that it should 
not be done against the patient’s will.5 The directive proved significant in the Nessier case 
and influenced Nuremberg for a couple of reasons. First, the Prussian Code concerned the 
rights of the imprisoned to refuse treatment. In this way, a precedent had been established 
for protecting the right to refuse participation in an experiment or to receive treatment. 
Equally significant was the extension of rights to those thought to have less worth in society. 
Secondly, the Prussian Code established the legal responsibility of the medical personnel 
conducting the treatment, or experiment, to obtain consent.6 Thus, when Nessier was 
brought to trial for not obtaining informed consent, his conduct was not only unethical, but 
also illegal.7 Discussions surrounding the importance of informed consent and the ethical 
conduct of research did not end with Nessier. 
                                                
5 Vollman and Wolf, “Informed Consent,” 1444. 
 
6 Ibid, 1446. 
 
7 Ibid, 1445. Nessier offered as a defense that the women did not contract syphilis from the injection, but 
rather from their line of work. The court, furthermore, was less concerned with the scientific risk involved and 
held an exclusive concern on the lack of consent on the part of the patients at the hospital. A further 
complication can be deduced that these patients sought treatment at the hospital with the expectation of any 
injections aimed at improving their health and not involved in a research. An important ethical conversation 
that continues to evolve is the relationship between medical treatment and medical research, and the overlap 
that exists in certain instances.  
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 In 1928, the German journal Ethik began publishing a series of essays on the 
ethics of human subjects research. The authors exchanged ideas and methods for conducting 
research on human beings in a way that minimized harm.8 One physician stated, 
“experiments by which patients may be harmed, however, I consider to be completely 
inadmissible and have never tolerated them in my clinic.”9 This counter-argument 
considered the potential of limiting scientific progress. Another commentator posited, “No 
law and no supervision, no matter how strict will prevent ‘human experiment’…”10 At least 
in practice, it seemed that harming one’s patients, who were often research subjects, was out 
of the question for some but common practice for others. Further commentaries in the 
issues of the late 1920s raised topics of vulnerable subjects, with a particular emphasis on 
children and the physician’s obligation to “do no harm.”11 It was particularly the harm 
brought to children that forced the issue, resulting in publishing guidelines for research by 
the Reich Minister of the Interior.  
 In 1931, the Reich Interior Minister issued guidelines on “medical experiments” 
intended to curb abuses in human subjects research stemming from a failed experiment 
involving research on children. These guidelines were issued partly in response to a 1930 
experiment that resulted in the death of 75 children in Lubeck, Germany. The Lubeck study 
focused on developing a vaccine for children against tuberculosis.12 The Reich Circular, the 
                                                
8  Andreas Frewer, “Debates on Human Experimentation in Weimar and Early Nazi Germany as Reflected in 
the Journal ‘Ethik’ (1922-1938) and its Context,” in Twentieth Century Ethics of Human Subjects Research: Historical 
Perspectives on Values, Practices, and Regulations, ed. Volker Roelcke and Giovanni Maio (Stuttgart: Franz Steiner 
Verlag, 2004), 138-141.  
 
9  Ibid., 139.  
 
10  Ibid., 140. 
 
11  Ibid., 141. 
 
12  Ibid., 142-43; Grodin, Historical Origins of the Nuremberg Code, 129. 
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name of the guidelines, attempted to balance the public’s interest in research for 
developing a vaccine for TB or syphilis with the protection of the rights of the research 
subjects. In both instances, it was the rights of the subjects that rightly gained legal 
protection. While there was support for experimentation to discover cures and improve 
patient care, this research required consent from a patient capable of considering the risks 
and understanding the process of the experimentation.13 Informed consent, the distinction 
between therapeutic and non-therapeutic research, and research on vulnerable groups, all 
proved foundational to the development of the Nuremberg Code.14 
The Trial 
 The Nuremberg Trial resulted in the prosecution of 23 Nazi physician defendants 
charged with human rights violations that, in part, stemmed from scientific experimentation 
on human subjects. Some of these experiments had a therapeutic purpose and focused on 
diseases like malaria, tuberculosis, and typhoid. Other experiments, however, reproduced 
and then attempted to treat the ill-effects that soldiers suffered in the midst of war: high 
altitude, extreme cold, pressure change, poisoning, and a variety of war wounds. The legal 
defense argued that during times of war survival was dependent on the knowledge acquired 
during these experiments and “extreme circumstances demand extreme action.”15 The 
experiments, they argued, were further justified by the fact that the research subjects were 
already prisoners. They considered research on this population to be an acceptable practice 
                                                
13  Vollman and Rolf, “Informed Consent,” 129. 
 
14 Ibid. While the Nazis ignored most of these guidelines, they did outlaw cruelty to animals. Grodin noted, “if 
this law for the protection of animals were seen as including human beings as a type of animal, most, if not, all 
Nazi human experimentation would also have been outlawed.” Nevertheless, the Nazi’s utter disregard of the 
key ethical and legal parameters of the Prussian Code and the Reich Circular played an essential role for the 
prosecution at the Nuremberg Trial. 
 
15 Ibid., 132. 
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because even prisoners had an obligation to contribute to the war effort.16 They insisted, 
moreover, that no legal or ethical code had been established to guide research and that the 
Nessier case and Reich Circular proved ambiguous in the midst of war. The defense 
challenged that legal precedent had been established, and the gravity of the experiments 
proved too much to ignore. Two of the cases cited by the prosecution highlighted the Nazi 
perspective on therapeutic research, one on infectious disease and the other on treating war 
wounds.  
 In his opening statement, U.S. prosecutor Telford Taylor described two experiments 
that attempted to test vaccines and treatments to be used for Nazi soldiers. The first 
experiments lasted between February 1942 and April 1945, in which over 1200 involuntary 
research subjects were given malaria and treated with various drugs to test its efficacy. Dr. 
Klaus Schilling led these experiments, which led to countless deaths.17 The second set of 
experiments took place at Sachsenhausen and Natzweiler concentration camps. Grawitz and 
Himmler, two of the physicians on trial, described the need to inject humans with germs and 
diseases from animals—not the revers. Brandt, another of the physicians on trial, stated, “In 
order to enlarge our knowledge, so far based only on inoculation of animals with germs 
taken from humans it would be necessary to reverse the procedure and inoculate human 
beings with germs cultivated in animals. Casualties must be anticipated.”18 This statement 
was reflective of the guidelines instituted by Hitler that placed restrictions on research 
                                                
16 Ibid. 
 
17  Taylor Telford, “Judgment and Aftermath,” in The Nazi Doctors and the Nuremberg Code: Human Rights in 
Human Experimentation, eds. George Annas and Michael Grodin (New York: Oxford University Press, 1992), 
98. 
 
18  Telford Taylor, “Opening Statement of the Prosecution, December 9, 1946,” in The Nazi Doctors and the 
Nuremberg Code: Human Rights in Human Experimentation, ed. George Annas and Michael Grodin (New York: 
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prohibiting cruelty to animals. However, these provisions did not extend to human 
beings.19.  
 Taylor and his team, which included two U.S. physicians Leo Alexander and Andrew 
Ivy, outlined the known history of research ethics in the prosecution of the defendants. 
Alexander and Ivy, who played a significant role in the development of the American 
Medical Association’s (AMA) code of ethics, both presented research guidelines compiled 
from key thinkers in medicine and medical ethics. They drew upon the thought of 
Hippocrates—though he never references research explicitly—Thomas Percival (1740-
1804), William Beaumont (1785-1853), and Claude Bernard (1813-1878). Each of these 
thinkers established the ethical necessity of receiving consent from patients and ensuring 
that no harm was done. Beaumont noted the importance of securing consent from patients, 
emphasizing that experiments should be discontinued if any stress was brought about for the 
research subject.20 His French colleague, Claude Bernard, also cautioned that scientific 
advancement should not be placed ahead of the benefit of the patient or research subject.21 
However, when a benefit could be derived for the patient, Bernard felt that physicians had a 
duty and right to perform an experiment in order to save a life, cure, or positively impact a 
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patient’s health.22 More broadly, Thomas Percival, in his book Medical Ethics, argued that 
while research itself was rooted in the public good, all research should be undertaken only 
after extensive conversation with other colleagues regarding the nature of the case and 
potential benefits and burdens that could come about from its undertaking.23 Thus, the 
prosecution’s use of Percival, Bernard, and Beaumont highlighted three important aspects of 
medical research that emphasized the tension between individual rights and obligations and 
the social dynamic of research.  
 Ivy and Alexander’s articulation of the ethical norms for research emphasized: 1) the 
rights of research subjects and patients; 2) the responsibility of the researcher to do no harm; 
and 3) the social nature of research, which included a consultative process to weigh the 
benefits and burdens of research beyond its impact on the subject. Ivy’s understanding of 
research ethics appeared in the Journal of the American Medical Association (JAMA), while 
Alexander submitted his argument as a memorandum to the United States Chief of Council 
for War Crimes.24 Their essays not only provided information on the Nuremberg Trial to 
those in the U.S., but also described the framework for the ethical conduct of research to the 
medical and legal community.  
 In drawing together this diversity of thinkers, Alexander and Ivy established key 
components of research ethics, including: informed consent; the necessity of balancing the 
burden or risk of research against its potential benefit for the patient; the importance of 
research that promotes the common good—or as Alexander referenced it, “humanitarian 
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benefit”—and the importance of dialogue about the experiments that cite the common 
good as a rationale for its pursuit. Their guidelines, coupled with those issued by the Reich 
Interior Ministry in 1931, and the Prussian code of 1900, supplied the prosecution with 
ample evidence that the Nazi experiments were outside the boundaries of established legal 
and ethical norms for research. However, the Nuremberg Code, while incorporating many of 
these norms when it was issued, failed to initiate a broad impact on the practice of medical 
research.  
Impact of the Nuremberg Code (1949) 
  When the dust had finally settled on the Nuremberg trial, the testimony of 85 
witnesses had been heard, resulting in 11,538 pages of transcript that laid groundwork for 
the ethical and legal parameters for human subjects research. Though the trial was about far 
more than research ethics, the arguments of the prosecution at the trial established a 
normative foundation for research ethics. The code itself incorporated much of Ivy and 
Alexander’s testimony, including the importance of informed consent, researcher 
responsibility, balancing of risks and benefits, and establishing human benefit as a standard 
for ethical research. However, the atrocities of the experiments made it difficult for other 
researchers to relate to the ethical violations of the Nazi doctors. In many instances the code 
simply could not break free from the context in which it developed.  
 Few researchers, even those who were also violating the rights of their research 
subjects as described in the Code, saw their experiments as unethical or illegal because of its 
relationship to the Shoah. 25 In many ways, the single most important takeaway that 
researchers considered following the Nuremberg Code was informed consent, which was 
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only the first point of the code and, given the other violations of human rights, was the 
least obvious grievance against the Nazis. While informed consent was, and is, crucial to 
ethical research practices, the document emphasized equally that research ought to offer a 
benefit to humanity and, when possible, to the research subject directly. The socio-ethical 
considerations within the code have become somewhat muted over time, though they prove 
fundamental to the legacy of the document and essential to the function of research ethics 
overall. 26  
 Beyond informed consent, the first point of the code, the remaining nine focus on 
the tension between the individual responsibilities and rights within the research process and 
the social aim of research itself. Thus, the second and third directives underscore that 
research should anticipate its potential to “yield fruitful results for the good of society.” The 
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onus for this responsibility does not fall exclusively on the researcher, but extends to the 
research community as a whole. This is a crucial point in the Nuremberg Code that becomes 
lost over time, but is worth reconsidering.  
 Nuremberg’s lasting norm for the ethical conduct of research rested on ensuring the 
protection of the research subject. However, Nuremberg also suggests that the research 
community as a whole should affirm whether a research experiment has public value. It is 
the responsibility of the research community to ensure that research stands to benefit the 
society; presumably this protection extends to the majority of human beings suffering from 
poor health conditions. However, institutional policies, not just international guidelines, need 
to reinforce this notion.27 Ultimately, the historical context from which Nuremberg 
developed limited its reception, but failures to adopt the Nuremberg code as a political and 
institutional standard undercut its potential reception, as well. Given the limitedness of its 
reception and the continuance of unethical research practices, the Nuremberg Code gave 
way to other ethical guidelines to guide research.  
The Declaration of Helsinki 
Preparing the Declaration 
 Between 1949-1952, the WMA established a permanent committee on medical ethics 
that concerned itself with violation of human rights within the medical community. After 
Nuremberg and the United Nations (UN) Declaration of Human Rights in 1948, there was 
an emphasis placed on the importance of protecting rights globally. Though the rights of 
research subjects were never explicitly included in the UN Declaration, the WMA saw these 
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topics intimately connected. After several years of conversations at the WMA, which first 
convened in 1946, formal discussions of guidelines for research ethics began.28 
 In 1953, the ethical questions that arose about the use of human subjects in research 
generated dialogue both within the WMA and the ethics committees of its member nations. 
Among the member nation delegates was Paul Cibrie of France. Cibrie served as the chair of 
the WMA’s medical ethics committee responsible for leading the inquiry around human 
subjects research.29 By 1954, Cibrie’s committee developed a formal document, largely 
reflective of his previous work in France, that highlighted important distinctions between 
research conducted on healthy subjects versus research conducted on sick subjects. 
Beginning in France and continuing through his work at the WMA, Cibrie concluded that 
physicians had both a right and duty to conduct experiments on human subjects, but only if 
they were informed volunteers who capable of accepting or rejecting interventions.30 While 
the Nuremberg Code generally emphasized the necessity of fully informed consent—raising 
questions about research on children, mentally disabled, and the imprisoned—the WMA 
committee nuanced these parameters to include provisions for parents and guardians to 
consent when the subject was unable.   
 The 1954 document stated that individuals should understand the nature of the 
experiment, the rationale behind it, and the risk posed to the research subject.  In the event 
that the patient or subject were unable to make an informed decision “consent should be 
                                                
28  Richard E. Ashcroft, “The Declaration of Helsinki,” in The Oxford Textbook for Research Ethics, eds. Ezekiel J. 
Emanuel, et al. (2008: Oxford University Press, 2008), 141. 
 
29  Susan E. Lederer, “Research without Borders: The Origins of the Declaration of Helsinki,” in Twentieth 
Century Ethics of Human Subjects Research: Historical Perspectives on Values, Practices, and Regulations, ed. Volker 
Roelcke and Giovanni Maio (Stuttgart: Franz Steiner Verlag, 2004), 199. 
 
30  Ibid, 202. 
 66 
obtained from the individual who is legally responsible for the individual.”31 Additionally, 
questions concerned whether sick persons in need of treatment could offer consent, 
particularly when the therapeutic benefit was unknown. In many ways, the working 
documents of the WMA between 1954 and 1959 focused on identifying particular groups of 
persons for whom consenting to participate in a research study might be either 
compromised or impossible. In part, these efforts reinforced the focus on informed consent 
within the research community. Yet, the work on “compromised” subjects, led to the 
identification of research subject populations that could be taken advantage of more easily. 
 In 1959, Hugh Clegg assumed the responsibilities of the WMA’s ethics committee 
and began building on Cibrie’s 1954 document by identifying groups whose ability to 
consent voluntarily was in question. The first group Clegg considered were medical students. 
Medical students were frequently used to study the side effects of the medication. The 
second focused on research with already sick persons regarding the possibility of using 
preventive inoculations on certain persons, while having an uninoculated control group 
which would remain untreated. The third group focused on research involving hospital 
patients and their ability to distinguish between research and clinical treatment. The fourth 
focused on those participating in controlled therapeutic trials of a new drug, while the fifth 
took into account the use of prisoners or the institutionalized in controlled prophylactic or 
therapeutic trials.32 The identification of these groups signaled the importance of considering 
ethical issues beyond those pertaining to the researcher and research subject.  
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 In September of 1960, after considerable debate about how to address the issues 
of these populations, Clegg and the committee considered simply adopting the Nuremberg 
Code as the standard guide for research. However, the group “found it necessary to draft a 
code which could serve at least as a guide to doctors working in different conditions and in 
different countries.”33 The working group demonstrated concern not only about the 
vulnerability of particular groups, but also enabled successful implementation of realistic 
guidelines for physician researchers in diverse working contexts. Given the reality that many 
physician-researchers ignored the ethical guidelines of Nuremberg, the WMA’s attempt to 
re-contextualize ethical guidelines for research proved important, and so they circulated a 
draft for discussion in 1962.34 
 The publication of the 1962 “Draft Code of Ethics on Human Experimentation” in 
the British Medical Journal allowed for peers to review the document that had been devised 
after years of conversation. The document was divided into three sub-headings: General 
Principles and Definitions, Experiments for the Benefit of the Patient, and Experiments 
Conducted Solely for the Acquisition of Knowledge. This working document essentially 
summarized the efforts of Clegg’s and Cibrie’s committees by detailing the practice of 
informed consent and identifying groups whose ability to consent voluntarily could be 
compromised. While the first section defined an experiment as “an act whereby the 
investigator deliberately changes the internal or external environment in order to observe the 
effects of such a change;” the second point clarified the conditions under which an 
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experiment could take place.35 Here one saw the efforts of the WMA to re-contextualize 
the guidelines for research ethics and informed consent outside of Nuremberg’s shadow.   
 In order for a research study to begin, the risks had to be explained in order to 
obtain consent from the research subject or his/her proxy. Research subjects had to 
demonstrate that they understood they could withdraw from the study at any time and  that 
the researcher conducting the experiment was qualified.36 The latter two sections on the 
Helsinki draft of 1962, focused on clarifying the ethical standards of research when applied 
to the immediate benefit of persons versus research undertaken with the primary objective 
of furthering scientific or medical knowledge.   
 In the case of experimentation for the direct benefit of a patient, it was important to 
maintain the patient’s trust and have completed sufficient tests in a laboratory or on animals 
prior to human experimentation. However, “the doctor should be free to perform an 
experiment for the first time if in his judgment it offers the only hope of saving or alleviating 
pain and suffering” but only after consent had been obtained.37  If the research would not be 
of direct benefit to patients on whom the research was being conducted, then extra caution 
should be utilized to ensure that the subject had the “mental, physical, and legal state as to 
be able to exercise fully his power of choice.”38 Here, the discussions of Clegg and his 
committee proved of particular importance for those who have a limited ability to consent. 
In many ways, this section affirmed the Nuremberg Code’s inclusion of restrictions 
involving prisoners of war or civilians detained because of a military invasions or political 
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reasons, but Helsinki re-framed the guideline in an effort to distance from Nuremberg and 
extended protections to other vulnerable groups.  
The Declaration of Helsinki (1964) 
 
 The 1964 Declaration of Helsinki on the ethics of human experimentation matured 
from its 1962 draft into a more linguistically precise document that the WMA adopted at its 
eighteenth meeting. While the document maintained the three-fold structure of the previous 
draft, a key change shifted the language of “experimentation” to the term “clinical research.” 
The use of clinical research again signaled a move away from the use of “experimentation” 
in the Nuremberg Code, and represented another effort to establish itself as a distinct 
document that took a more medical and research focus than its precursor.39 The document 
explicitly referenced its own International Code of Medical Ethics, which aligned itself 
specifically with all doctors involved in clinical research.40 Helsinki emphasized both the 
researcher’s obligation to uphold the right to health and well-being and the rights of the 
research subject’s to informed consent.  
 The Declaration’s three sections reflected the themes of informed consent by 
distinguishing between consent for therapeutic and non-therapeutic clinical research. 
Though these themes had been reflected in the 1962 draft, the language became more 
precise in the official declaration. Therapeutic research was defined as caring for a sick 
patient “if in his judgment it offers hope of saving life, re-establishing health, or alleviating 
suffering.”41 This can be contrasted with the purpose of non-therapeutic research, which 
enhanced the understanding of scientific knowledge as its true aim. In this case, the research 
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subject does not stand to benefit from the investigation directly. In both instances, 
however, the doctor continued to have the obligation to “remain the protector of life and 
health of that person on whom clinical research is being carried out.”42 This obligation 
extended to research subjects with a limited ability to consent directly to participating in a 
study.  The idea of consent being granted from a person other than the research subject 
represented an important development, but one that placed additional responsibilities and 
formalities for the researchers to address. 
 Constructed by physicians and, at the time, for physician-researchers, the document 
was framed from the outset with the intention of guiding responsible research. Thus, the 
“Basic Principles” focused specifically on the obligations that the researcher undertook. The 
research must be rooted in standard moral and scientific practices and established fact. The 
researcher should be qualified to conduct the scientific study and it should be carried out “in 
proportion to the inherent risk to the subject.”43 The burden to assess the risk, and benefit in 
therapeutic research, was placed squarely on the physician. This was particularly true when 
the “personality of the subject...is to be altered by drugs or experimental procedure.”44 While 
consideration of whether to participate or not rested with the decision-making capacity of an 
individual or her surrogate, the primary onus placed on the researcher was deciding whether 
a research project ought to be pursued or not. One of the critiques, though lasting influences 
of the document was its emphasis on the responsibility of the researcher to lead experiments 
rooted in the promotion of health and well-being. While Declaration of Helsinki has seen 
several revisions, its connection with the promotion of health and well-being has remained a 
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constant. Subsequent revisions, however, continue to revisit new challenges in the ethical 
conduct of research that have influenced the way in which countries, as well as international 
organizations, have articulated their own guidelines for research.  
Helsinki’s Impact 
 Since its original pinning, the Declaration of Helsinki has undergone seven revisions 
of varying degrees, as well as issuing two notes of clarification in 2002 and 2004. The latest 
revision took place in October 2013 at the 64th General Assembly of the WMA held in 
Brazil, while the first revision occurred at the WMA’s meeting in Tokyo in 1975. The 
consistent revisions of the document continue to address ongoing developments within the 
landscape of research ethics. The constant updates signals the importance of creating a 
document that reflects the context in which research and research ethics is practiced.  
 The 1975 Tokyo revision emphasizes the context by further developing the 
protection of research subjects by arguing that their interest should always prevail over those 
of science and society.45 In an effort to institutionalize this practice, this revision centered on 
the necessity of forming committees to review of research studies by an institutional review 
board (IRB) or research ethics committees. By emphasizing the importance of IRBs, the 
1975 revision pointed to the importance of institutional practices focused on maintaining 
responsible research.  Through local control of research initiatives IRBs can identify more 
easily potentially vulnerable research subjects and questionable research practices on the 
local level.  
 A second impact of the Helsinki revision came from Edinburgh in 2000. The 
protection of research participants continued to be a primary focus of the document. In this 
version, these protections were tied explicitly to the health and human rights, which 
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represented new language for the document itself and more explicitly acknowledging the 
origins in the internationalization of human rights following World War II. The 2000 
revision included the importance of recognizing the economic status of particular groups as 
a potential source of a research subject’s vulnerability. A group that became a central focus 
in this document, were vulnerable research populations that reflected concerns for those 
suffering from HIV/AIDS. It stated, “research risks are justified only ‘if there is a reasonable 
likelihood that the populations in which the research is carried out stand to benefit from the 
results of the research.”46 . These particular concerns are specifically addressed in paragraph 
30, and recommended against the use of placebo control trials in vulnerable populations, 
which are standard in the development phase of a new drug.47 This proved to be one of the 
more controversial revisions, and one that caused the U.S. to drop references to Helsinki 
beyond its 1989 revision.48 The guidance on the use of placebo-controlled trials was 
reiterated in the latest revision, 2013, and included that extra consideration should given to 
ensure that vulnerable groups receive a “fair level of additional benefits.”  
 A final impact generated from the Helsinki declaration has been the international 
influence of the document itself. The importance of Helsinki can best be attributed to the 
emphasis placed on the development of guidelines that address the changing reality in which 
research is conducted. The Declaration contributed greatly to the development of other 
international documents produced by the World Health Organization (WHO), Council for 
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the International Organizations of Medical Sciences (CIOMS), and also countries that 
have established their own ethical standards for research.   
 A representative, though not exhaustive, list of countries that have referenced the 
Declaration in developing their national standards for research includes: Australia, Belgium, 
Brazil, China, Germany, India, Israel, Japan, New Zealand, Norway, Switzerland, Uganda, 
United Kingdom, United States, and South Africa.49 In addition to its influence on national 
policies, the Declaration continued to make contributions to the development of standards 
within research and particularly the research ethics focused on lower income countries.  The 
focus of the CIOMS/WHO guidelines draw on Helsinki to describe:  
how the ethical principles that should guide the conduct of biomedical research 
involving human subjects, as set forth in the Declaration of Helsinki, could be 
effectively applied, particularly in developing countries, given their socioeconomic 
circumstances, laws and regulations, and executive and administrative 
arrangements.50  
 
The introduction to the CIOMS guidelines explicitly referenced Helsinki and further 
contextualized the document’s concerns about research conducted in low and lower-middle 
income countries. The further revisions of both Helsinki and the CIOMS guidelines, in 
many ways, have led to increased efforts within the area of global bioethics—considered in 
the final section of this chapter—that promotes the ethical conduct of research in a way that 
more justly considers the needs of the communities in which it works.  
 Helsinki has proven important in constructing ethical research guidelines that take 
seriously the social context and impact of research can have on health and well-being of 
both persons and communities. The initial document and subsequent revisions draw 
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attention to the reality of vulnerable persons and populations due to disease and socio-
economic factors. While the document has been well received in most parts of the world, it 
has seen limited reception in the United States, appearing neither in the Common Rule nor 
the Food and Drug Administration’s guidelines for research since its elimination in after 
1989. Despite its omission from the FDA guidelines, Helsinki provides an important 
reference point for the discussions regarding the ethical conduct of research and the 
protection of human subjects when they began in the U.S. through the work of the National 
Commission for the Protection of Human Subjects (National Commission).  
The Belmont Report 
Concerns Before the Report 
 The circumstances that led to the creation of the National Commission, and the 
subsequent Belmont Report, stemmed from developments in the U.S. that brought attention 
to unethical and/or illegal research practices following the increased funding of research 
between World War I and II. As shown in Chapter One, the period surrounding the World 
Wars led to necessary innovations in medical research that continued after the the Second 
World War. In the years following the Wars, research funding from the U.S. National 
Institute for Health (NIH) increased from $700,000 in 1945 to over $36 million by 1955. 
Within 20 years, funding had increased to an astonishing $436 million dollars that resulted in 
11,000 grant awards, one-third of which required experiments to be conducted on human 
beings.51 Included in this study were some of the catalysts for the ethical reform of research 
brought about by the National Commission, Willowbrook, Tuskegee, and a lesser known 
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syphilis study conducted over several years in Guatemala.52 Given increasing concern 
about the responsible conduct of research internationally and the growth in research 
domestically, James Shannon, who directed the NIH and worked closely with Dr. Freis 
during his VA anti-hypertensive studies, sought to implement changes to ensure the ethical 
conduct of research.  
 In 1964, Shannon formed a committee through the NIH Division of Research 
Facilities and Resources to review ethical issues in human experimentation. In developing 
their guidelines, the committee drew from the Livingston Report that critiqued the 
guidelines of Helsinki and Nuremberg because they placed too much responsibility on the 
researcher. Shannon’s NIH group, taking into consideration the previous critiques, proposed 
that research protocols should be reviewed by outside committees so as to alleviate some of 
the burden placed on researchers. Of secondary importance, however, was the self-interest 
of the NIH, which did not want to assume responsibility for potentially inhibiting the 
development of future research.53  
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 The group arrived at the decision to empower local ethics committees to oversee 
and approve institutional research initiatives to more evenly distribute the responsibility and 
commitment to ethical research to a wider group.54 These local ethics committees charged 
with evaluating research were referred to as Institutional Review Boards (IRB), instituting a 
practice called for in the 1975 revision of the Helsinki Declaration. The utilization of IRBs 
could not have been better timed given the concurrent release of two exposés of unethical 
and/or illegal research practices in the U.K. and U.S.  
 Maurice Pappworth and Henry Beecher raised important issues surrounding the 
nature of research ethics and the need to protect the rights of research subjects by calling 
attention to unethical and/or illegal research in the U.S. and U.K. Pappworth, from the 
U.K., highlighted these questionable studies in both a 1962 essay and 1967 book. Beecher, a 
U.S. physician, exposed his concerns about ethically questionable research in a 1966 essay 
published in the New England Journal of Medicine. 55 While Beecher has frequently received 
more credit for his essay, Pappworth’s efforts should not be overlooked.56  
 Both Pappworth and Beecher highlighted unethical research that targeted vulnerable 
populations, failed to obtain informed consent, and engaged in practices that not only 
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offered no benefit, but deliberately brought harm to patients. In a 1990 retrospective, 
Pappworth described one study in which 43 diabetic patients were induced into a diabetic 
coma by having their insulin deliberately withheld. Once in the coma, the researchers 
biopsied liver and kidney samples in order to better observe the effects of the coma on these 
organs.57 In his New England Journal of Medicine piece, Beecher’s 22 post-war research studies 
drew attention to unethical research practices out of concern that “bad ethics would 
undercut the pursuit of good science, and the result would be widespread ignorance and old-
fashioned quackery.”58 Though Beecher recognized the complexity of research and that 
properly obtaining informed consent was laden with difficulties, he found it imperative to 
the practice of research. One of the more infamous studies that both Beecher and 
Pappworth included in their retrospectives was the Willowbrook Study.   
 Willowbrook was an intuition for mentally handicap children in Staten Island, NY 
where Saul Krugman led a study trying to understand and mitigate a strand of hepatitis that 
chronically affected the health of the residents. Beecher described the experiment, which 
began in the mid-1950s, as a “study directed toward determining the period of infectivity of 
infectious hepatitis…carried out in an institution for mentally defective children in which a 
mild form of hepatitis was endemic.”59 At the time, Krugman estimated that 40-50 patients 
per every 1000 would contract the disease annually. By injecting them with a mild form of 
the disease, Krugman hoped that the residents would develop a resistance to more potent 
hepatitis strains. The residents were unable to consent as minors, but also because of their 
diminished cognitive function that made them unable to understand the risks or benefits of 
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the study. In keeping up with the norms of proxy consent, however, Krugman did acquire 
consent from the children’s parents or guardians, the caveat being that parents were under 
the impression that the school would close if the hepatitis problem was not controlled. 
Pappworth argued that this constituted a form of coercion because parents thought that 
participation could help them keep the school open. 
 A second concern raised by Beecher and Pappworth focused on the deliberate 
infection of individuals without therapeutic or prophylactic indications. Beecher charged, 
“There is no right to risk an injury to one person for the benefit of others.”60 Pappworth 
likewise argued that therapuetic benefit should be a prerequisite for any research done with 
children. 61 Moreover, both men raised the objection that these children appeared to be 
targets for questionable research because they were vulnerable and “devalued” members of 
society.62 In other words, this type of experiment would not have been able to be conducted 
on other non-institutionalized children or children of more advanced cognition. The fact 
that this research targeted marginalized members of society has led some to refer to 
Willowbrook as the “Pediatric Tuskegee.”63  
 “The Tuskegee Study of Untreated Syphilis in the Negro Male,” came to be the 
example of unethical research practices in the U.S. The study targeted a marginalized 
population, lacked any therapeutic benefit, and never informed the research subjects that 
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they were participating in a study. The study itself, however, was very clear in its aim. The 
study would focus on black males with syphilis and observe, without intervention, the 
natural progression of syphilis if left untreated.  
 The study began in 1932, and received repeated approval by the Alabama Health 
Department. At that time, no cure existed for syphilis, though there were varying treatment 
options. None of these options were extended to those used in the study.64 By 1945, 
penicillin had emerged as an effective treatment for patients with syphilis, but these research 
subjects were barred from receiving the treatment or seeking medical attention outside of the 
medical exams provided as participants in the study.65 From 1945 until the conclusion of the 
study in 1972—predicted originally to last only six months to a year— patients continued to 
suffer from painful procedures and the ill-effects of the disease while a medical treatment 
existed.66  
 In that time over 399 African-American men with syphilis were enrolled 
unknowingly in the study aimed at understanding the effects of the disease on black males. 
However, none of these men consented to participate in an “experiment.” Rather, they 
believed they were receiving treatment for “bad blood.”67 In addition to the 399 men with 
syphilis, an additional 201 men without syphilis were also recruited to serve as a control 
group.  It has been estimated that 100 men died as a direct result from the study. However, 
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once the study was brought to light—though not by Beecher or Pappworth, but rather by 
a story by Jena Heller from the Associated Press—a special commission led by Edward 
Kennedy closed the study. Kennedy then began pushing for national reforms for the 
conduct of research. In 1974, the National Commission was established, beginning a 
national conversation about the ethics of research that resulted in the development of the 
Belmont Report.  
The Belmont Report (1978) 
 The National Commission first convened in December of 1974 and concluded with 
its 43rd meeting on September 8, 1978. The task of the Commission was to develop 
guidelines for the ethical conduct of research involving human beings. In 1976, the 
commission requested several leading scholars to contribute essays in philosophy and ethics 
to be incorporated as a part of the ongoing conversation for constructing guiding principles 
of research.68 Two essayists prominently influenced the position of the Commission on the 
ethics of research, though neither were a part of the commission initially.  
 The essay by H. Tristam Engelhardt, a physician and philosopher, crystalized the 
aims of the commission by distilling the ethics of research into translatable principles that 
explored the breadth of research practices into a coherent and accessible format. He 
described his principles as: “respect for persons as free moral agents, concern to support the 
best interests of human subjects in research, intent to assure that the use of human subjects 
of experimentation will on the sum redound to benefit society.”69  Engelhardt points, like 
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many of the other documents before, distilled the ethics of research into goals of 
protecting research subjects in pursuing only research that would benefit society. What the 
commission found lacking in Engelhardt’s essay, however, was an articulation of the role 
justice played in research ethics. 
 Thomas Beauchamp—who was not a member of the national commission, but 
eventually wrote the Belmont Report—penned an essay, “Distributive Justice and Morally 
Relevant Differences,” highlighting not only the importance of justice in establishing 
ethically appropriate volunteers for research, but also for determining whom should benefit 
from the fruits of research itself.  Beauchamp’s essay was the only essay the Commission 
considered that referenced justice as related to the importance of selecting research subjects. 
Though not explicitly expressed, the just-selection of subjects was rooted in a concern for 
vulnerable research subjects. Secondly, a particular nuance of his essay—ultimately lost in 
the practical application of the Commission’s report—emphasized distributive justice. With 
the focus on distributing the fruits of research as an explicit goal of the commission, 
research ethics took on a social dimension that proved important for the structure of the 
document itself, even if limited in the document’s reception. 
 The National Commission’s Belmont Report settled on three principles as the 
bedrock of ethical research: respect for persons, beneficence, and justice.70 Though the 
report itself did not mandate specific regulatory recommendations, it did advise that the 
overall construction and utilization of these three principles be adopted in their entirety as a 
guide for all research endeavors. The document was divided into three parts. Part A offered 
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important clarifications about the boundaries of medical practice and research, while parts 
B and C, which constituted the substance of the document, explained the principles and 
their application.  
 Given that the practice of medicine and medical research can and do occur together, 
it was often challenging for patients and research subjects to distinguish between the two.  
Thus, the commission offered a working definition of both medical practice and medical 
research. It defined practice as, “interventions that are designed solely to enhance the well-
being of an individual patient or client and that have a reasonable expectation of success. 
The purpose of medical or behavioral practice is to provide diagnosis, preventative treatment 
or therapy to particular individuals.”71 In medical practice, the purpose was always to be 
focused on the health and well-being of a specific individual. Research, however, “designates 
an activity designed to test an hypothesis, permit conclusions to be drawn, and thereby to 
develop or contribute to generalizable knowledge…is usually described in a form a protocol 
that sets forth an objective and a set of procedures designed to reach that objective.”72 In 
contrast to medical practice, medical research functioned more objectively, placing an 
emphasis on generalizable knowledge with the potential to benefit society. The remainder of 
the document focused on describing ways that the Belmont principles could guide the ethical 
practice of medical research.  
 The principles—respect for persons, beneficence, and justice—established an 
accessible way to articulate the ethical values at stake when conducting research. While the 
content and conversation surrounding the development of the principles was academically 
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robust, the descriptions incorporated into the document had to be intelligible and 
applicable to a wider audience. In an effort to achieve this, principles were broken up into 
two sections. The first, section (part B) defined the principles and part C discussed their 
application. 
  The first principle, “respect for persons,” found practical application in informed 
consent. Respect for persons articulated that autonomous choices were not to be overridden 
or disrespected, and “that persons who are not adequately autonomous be protected by the 
consent of an authorized third party likely to appreciate their circumstances and who will 
look after their best interest.”73 This principle also included the requirement that researchers 
ensure that the research participants have comprehended the information they had been 
given about the study. Here the burden of responsibility was placed on the researcher, which 
was particularly important with subjects who had diminished autonomy. The committee, 
moreover, wanted to ensure respect for persons and noted three possible applications: 1) 
ensuring that participants understood the information pertaining to their participation in the 
study; 2) that the individual knew their participation was voluntary and could withdraw at 
any time; and 3) that the subject comprehended the risks/benefits of the study. In the 
process of obtaining consent, the researcher had to take into account the well being of the 
research subjects, which formed the bedrock of the second principle, beneficence.  
 The Hippocratic ideal of “do not harm” provided the minimal aim of the principle 
of beneficence.74 The importance here was that the possible benefits were to be maximized 
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while minimizing harm.75 Furthermore, these risks and benefits were to be systematically, 
not arbitrarily, presented to the individual and also considered by an IRB. In this way, 
beneficence extended beyond the responsibility of individual investigators to their subjects 
and more broadly to representatives of the community—local, institutional, and scientific. 
The Belmont Report empowered IRB committees to weigh the benefit and risk that a 
proposed study posed to society at large. They were “obliged to recognize the longer term 
benefits and risks that may result from the improvement of knowledge and from the 
development of novel medical, psychotherapeutic, and social procedures.”76 The intent of 
the principle of beneficence was to take into account the need for application of the 
principle within the social context of research in which both individual participants and 
potential beneficiaries are affected. It was the final principle of justice that sought to balance 
more deeply the effects of research and its impact on society.   
 The principle of justice focused on both the selection of research subjects and the 
distribution of post-research results by more broadly considering those who ought to receive 
benefits of research versus those forced to bear its burden. The report required fair 
distribution of both burdens and benefits of research with special levels of protection for 
vulnerable and disadvantaged parties. Included in the principle of justice, developed from 
Beauchamp’s original essay, was concern over the competition that existed for benefits of 
research. This competition has only increased since the early 1980’s. While research 
continues to be heavily funded, it has been funded disproportionately for a small minority of 
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the population’s health. Given the scarcity of certain benefits, it was, and continues to be, 
important to ensure that resources developed from research receive just-distribution. 
Reflecting on the description of the principle of justice in the document, Beauchamp 
described his concern as follows:  
The over utilization of readily available, often compromised, segments of the U.S. 
population was a matter of deep moral concern to the National Commission. The 
theme of justice and proper selection of research participants was the Belmont Report’s 
way of saying that because medical research is a social enterprise for the public good, 
it must be accomplished in a broadly inclusive and participatory way.77  
 
The social dynamic of research aimed at benefit of the public good demonstrates the 
principle’s emphasis on both the inclusivity of research, particularly concerning the benefits 
and burdens of research, but also the importance of public participation in shaping research 
as a social enterprise.   
Belmont’s Impact 
 The Belmont Report established a framework for an expansive discussion of the 
ethics of research from both an individual and social perspective, which laid the foundation 
for the U.S. Common Rule. The U.S. Common Rule outlines the federal regulations that 
guide the conduct of research in the U.S. The clearest expression of the report’s enduring 
impact was its inclusion as the foundation for revisions to the 1981 Code of Federal 
Regulation 45 part 46 (45 CFR part 46), later known as the Common Rule. 45 CFR part 46 
was originally published in 1974 as a part of the National Research Act, and was revised 
initially in 1981 and again in 1991. A third revision of the Common Rule began in 2013 in an 
effort to reflect the changes that have taken place in the conduct of research since 1991. 
Despite these revisions, the core of the document remains rooted in the initial principles of 
the Belmont Report.  
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 The Common Rule places significant emphasis on instructive guidelines for the 
practice of IRBs and other departments within the federal government.78 45 CFR part 46 is 
into four parts, subparts A-D. Subpart A, which is the part of the regulations referred to as 
the Common Rule, establishes necessary provisions in order to protect human subjects by 
providing key definitions and descriptions of the requirements for the composition and 
operation of an IRB. One key stipulation in subpart A contains important guidance 
regarding the conduct of research outside the U.S. In these instances, the Common Rule 
should be used unless stricter regulations existed in the country in which the research was 
being conducted. While subpart A defined the parameters of the regulation of research 
involving human subjects, subparts B, C, and, D detail additional regulations for the 
protection of vulnerable population. Subpart B concerns, pregnant women, human fetuses, 
and neonates, subpart C, prisoners, and subpart D, children. Noticeably absent from these 
descriptive guidelines however, is explicit reference to any of the Belmont principles. While 
legal regulations prove to be fundamental to the protection of human subjects in research, 
ensuring compliance with them waters down the robust personal and social implications for 
research ethics that were foundational to the Belmont Report. The National Commission’s 
conversations that resulted in 45 CFR part 46 focus on implementing a minimum standard 
for protecting the rights of research subjects lacks the fullness to which the Belmont 
principles aspired.  
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 Lost in the application of the Belmont principles and their role in the formation of 
the Common Rule is the broader social considerations of research, foundational to the 
origins of the document. In a retrospective volume recounting the development of the 
Belmont Report, Karen Lebacqz criticizes the lack of the social dimension and the simple 
application of complex principles. Lebacqz, one of the original members of the National 
Commission, argues that the vagueness of the principles allows for reinterpretations that 
elude the depth of their original meanings. Of particular concern for her is the emphasis 
placed on respect for persons. “First, respect for persons became interpreted solely in the 
language of respect for autonomy. Second, autonomy itself became interpreted in restricted 
ways.”79 The principle shifts its focus to center on a person’s opinion and the need to respect 
their desire to refrain from pursuing, or deciding to pursue, certain choices and/or activities. 
A further contributing factor that influences the reception of Belmont are Beauchamp and 
Childress’s own distinct principle-based ethic.   
 In Tom Beauchamp and James Childress’s, The Principles of Biomedical Ethics, respect 
for autonomy serves as one of the foundational principles for bioethics. Though Beauchamp 
notes that the Belmont principles differ greatly from his and Childress’s approach, and 
emphasize equally the importance of beneficence and justice. Nevertheless,  respect for 
persons has translated into autonomy and continues to rule the day. Lebacqz laments:  
As respect for persons is reduced to autonomy and autonomy to self-determination 
or freedom of choice, the logical outcome is that the broad ranging principle of 
respect for persons is then truncated into the rule of ‘informed consent.’ The only 
question we ask is whether one consented to medical interventions or use of 
technologies. Any question as to whether such interventions or technologies are right 
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is utterly lost.80 
 
The social dynamic of the human person and the Belmont principles can become lost. 
Moreover, when the principles themselves are reduced, as Yesley surmises, to informed 
consent, weighing of individual risk/benefit, and the selection of research subjects, the 
scientific endeavor itself loses its social context. Yet, it is precisely the social context from 
which illegal and unethical violations of the rights of human subjects arose, not only in the 
U.S., but globally. 
 In an application of the Belmont principles, it is worth considering the broader social 
contexts that bear on the way in which the regulatory efforts are applied. While broader 
applications, and in some instances expansion, of the principles have begun in newer areas 
of bioethical inquiry, such as global bioethics, a broader framework capable of keeping the 
focus on the social dimension of research in tension with the regulatory protections of 
individual human rights research proves crucial. Global bioethics is an area of ethical inquiry 
that has developed over the last two decades and focuses on the role of research, health, and 
human flourishing.  
Global Bioethics 
 Global bioethics concerns itself with three areas: 1) the discourse pertaining to 
international research; 2) the importance of benefit sharing and protection that promotes 
human existence and flourishing; 3) the cognizance of participation in global community or 
world moral community.81 These categories are interconnected and raise the awareness of 
one’s mutual participation in the construction of a global community.  The concept of global 
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bioethics originated in 1988 with Van Rensselaer Potter, a U.S. oncologist whose work in 
bioethics focused on human survival and flourishing. Potter’s influential text Global Bioethics,  
which has been more influential outside of the U.S., serves as a follow-up to his 1971 
Bioethics: Bridge to the Future.82 His earlier argument, nevertheless, laid the groundwork for 
considering global bioethics as a field that linked humanitarian values with the disciplines of 
science and medicine. Potter integrates concerns about the development of society and care 
for the environment as constitutive issues for bioethics to address. His global approach to 
bioethics, however, has been rarely taken up by U.S. bioethicists, until recently.83  
 The groundwork Potter laid in global bioethics has increasingly become a subject of 
interest within current trends in bioethics, reflecting on bioethics as a discipline at the 
intersection of science and human values in a socio-political context. Daniel Wikler and Dan 
Brock describe global bioethics as taking a “birds-eye” view of bioethics, moving beyond the 
particularly individual focus of bioethics, instead settling on issues of justice and politics of 
health.84 With a more comprehensive approach to bioethics, questions regarding global 
preparedness for the spread of infections disease, distributive justice, and practices that 
promote or limit positive health come into focus.85 This broader perspective de-centers 
autonomy as the dominant bellwether for bioethics and lends itself to consider the the 
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intersection of bioethics and justice.86 
 Eric Meslin and Ruth Macklin have distinguished themselves as two of the leading 
figures taking up issues of justice related to research in a global context. For Macklin and 
Meslin, justice functions as the lynchpin to debates concerning medical research and its 
distribution. Macklin argues that concerns regarding global bioethics come at the intersection 
of questions about global justice and research ethics.  She raises the importance of the 
particular question of reducing the gap between health status and life expectancy between 
the rich and the poor.87 With respect to ensuring justice between the rich and the poor, 
questions of justice have to be raised at a policy level in order to address, not only the health 
gap between the rich and the poor, but also the research gap.   
 The research gap, discussed in greater detail in Chapter Four, refers to the disparity 
in research in which 90% of research stands to benefit only 10% of the population.88 Eric 
Meslin argues that concern over the research gap needs to be addressed from the “bottom-
up.” Meslin characterizes Macklin’s approach to justice as global bioethics “from above” or a 
“top down.” In contrast, he proposes that the issues of justice in global bioethics focus on 
capacity building and collaboration with those communities that lack the ability to participate 
and govern their own research practices. Meslin describes the approach taken by Indiana 
University’s Medical School in building its own hospital, developing an exchange program 
for training medical students, and helping to support a local IRB in the Rift Valley in 
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Eldoret, Kenya as an example of an approach from below.89 Meslin’s approach in many 
ways echoes the approach of this dissertation.  
 While Meslin and Macklin rightly highlight justice as the place to consider challenges 
in global research ethics, these considerations have to be done in conjunction with 
collaborative partners and from the experience and place of those that suffer injustices. 
Thus, it is not only important that collaboration occurs with communities of need, but that 
the projects developed truly reflect their needs, and not those of an outside institution—a 
challenging task. Therefore, even a preconceived notion of justice can prove difficult to 
reconcile with the experience of injustices within local communities. In order to address this 
important distinction, I turn to the perspective of liberation theology, in which questions of 
justice begin with experiences of injustice. 
Conclusion 
 The Nuremberg Code, Declaration of Helsinki, and Belmont Report develop as a 
result of illegal and/or unethical practices in medical research from particular socio-historic 
contexts. These contexts provide a basis for the content of these documents. To interpret 
and implement these documents as regulatory requirements absent of a consideration of the 
communities from which they developed undervalues their importance for research ethics. 
The narrative of individuals and the communities that were victimized in the process of 
research form the foundation of each of these documents. Ezekiel Emanuel has been an 
outspoken critic of both the revisions of the Declaration of Helsinki and the Belmont 
Report in large part because of their inadequate consideration of communities. He articulates 
the importance of incorporating “respect for communities” as a key component of ethical 
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research.90 Yet, respect does not go far enough, and global bioethics articulates more 
clearly the challenge as one rooted in justice.  
 For global bioethics, justice allows for a social ethics approach to burdens of disease, 
standard of and access to care, foreign research practices, and the development of bioethics 
internationally. Global bioethics highlights the increasingly global impact of medical 
research, which has become lost particularly in many of the international documents. While 
the applicative dimensions of Nuremberg, Helsinki, and Belmont remain essential for the 
protection of individual rights included in research ethics, emphasizing the current injustices 
within research practices proves necessary. “[A] broader understanding of justice would 
require looking not simply at the selection of research subjects but at entire systems and 
structures and how they distribute power and privilege.”91 While this approach inevitably 
creates new challenges and potential obstacles for research and research ethics, it would also 
promote a more serious consideration of the social dynamics of the practice of research 
itself. The next chapter proposes that increased consideration of justice within the practice 
of medical research, however, will require an epistemological reframing of the task of 
medical research itself.  
 Chapter Three draws on the work of Ignacio Ellacuría who provides important 
insights as a philosopher, theologian, and university president. As a former university 
president, Ellacuría readily acknowledged the important role that research plays for 
institutions, insofar as that research remains grounded in historical reality. For Ellacuría, 
                                                
90  Emanuel Weijer, “Ethics. Protecting Communities in Biomedical Research.” Science 289, no. 5482 (2000); 
Green, Donovan, and Jauss, Global Bioethics, 352; Sirkku Hellsten, “Global Bioethics: Utopia Or Reality,” 
Developing World Bioethics 8, no. 2 (2008), 70.; Henk A. M. ten Have, “Global Bioethics and Communitarianism,” 
Theoretical Medicine and Bioethics 32, no. 5 (2011), 315.; Van Rensselaer Potter, Global Bioethics; Joseph Millum and 
Ezekiel J. Emanuel, eds., Global Justice and Bioethics (New York: Oxford, 2012), 315. 
 
91  Lebacqz, We Sure are Older but are we Wiser, 107 
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historical reality comprises the object of philosophy by considering “history’s actors, 
authors, editors, players, and parts of all the parts that make up reality.”92 The ethics of 
research, rooted in reality, maintains the importance of protecting the rights of human 
subjects, but in a way that remains cognizant of those who benefit and bear the burdens of 
research. By attending to issues such as participation, power, economics, culture, and 
politics, one can better account for the complexity of ensuring a consideration of the social 
and ethical conduct of research.  
                                                
92   Kevin F. Burke, The Ground Beneath the Cross: The Theology of Ignacio Ellacuría (Washington, D.C.: Georgetown 
University Press, 2000). 
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CHAPTER THREE 
LIBERATING MEDICAL RESEARCH 
Introduction 
 The historical development of research ethics has centered on the protection of the 
individual rights of the research subjects without considering adequately the social context in 
which research develops. Thus, the horizon of research and research ethics has concentrated 
its efforts on preservation and protection, rather than prospectively addressing any social 
inequalities created by the practice of research itself. By considering more seriously social 
questions within research ethics, a greater awareness of the social injustices present within 
medical research emerge. In this chapter, I argue that an epistemological shift proves 
necessary in order to recognize the injustices present within the practice of medical research. 
While the current epistemology of medical research centers on the development of new 
objective knowledge, it fails to adequately consider the research needs for the majority of the 
world. Recasting medical research from the epistemological lens of liberation theology 
requires the reimagining of medical research in concert with the needs of the poor.  
 The epistemological importance of a preferential option for the poor, foundational 
to a liberationist and Catholic approach, requires an agenda capable of addressing the 
structural injustices of medical research. Before addressing the structural inequalities, the 
focus of Chapter Four, it proves necessary to articulate what it means to address the practice 
of medical research from the perspective of the poor. In describing this process, I follow the 
thought of philosopher, theologian and university president Ignacio Ellacuría.
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 The chapter will develop, first, by considering the person and thought of Ignacio 
Ellacuría, followed by the influence of his mentor and collaborator Xavier Zubiri, a 
twentieth century Spanish philosopher. Section three reflects on Ellacuría’s anthropological 
vision, which understands the human person through the Zubirian term, reality animal. With 
this anthropological foundation, the fourth section will explore Ellacuría’s three-fold 
understanding of intellection as a praxis-based encounter with historical reality. It is this 
praxis-based encounter that not only informs the task of human intellection, but also the 
tasks of socio-historic institutions, e.g. university-based medical research. The final section of 
this chapter, then, takes up the Ellacuría’s understanding of the university as an institution 
positioned to confront the social injustices that exist in reality and begins to move towards 
transforming that reality. Drawing upon the thought of Ellacuría, the Catholic university, 
given its prioritization of the poor and commitment to justice, should be a place from which 
the socio-ethical and theological dimension of medical research is considered.  
Why Ellacuría?  
 Ellacuría was a Spanish-born Jesuit priest who spent most of his professional life 
living and working in San Salvador, El Salvador. Up until his death, on November 16, 1989, 
Ellacuría served as the president and rector of the University of Central America. On that ill-
fated night, he and five other Jesuits, the cook for the seminary, Elba Ramos, and her 
daughter, Celina, were all murdered by a government death squad, a special group of military 
personnel trained for assassinations. While the details and political motivations have been 
well documented elsewhere, what holds significance for the purposes of this dissertation is 
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Ellacuría’s influence as the president of the UCA.1 Buttressed by his philosophical and 
theological vision, Ellacuría urged the Catholic universities, and in particular his own, 
address the injustices present in historical reality.  
Key Terms 
 “Historical reality,” a term frequently utilized by Ellacuría to describe the world as a 
presently experienced, complex, and deliberate construction that results from choices made 
in the past, are currently being made, and will continue to be made in the future. While this 
may seem simplistic—historical action creates the present reality—historical reality 
necessitates not just a deeper exploration of the present reality and the injustices present 
within it, but also of one’s individual and collective role in creating these injustices. 
Reflecting on historical reality reveals that the minority of persons have utilized their power 
in a way that has created a reality in which the majority have limited access to resources and 
a diminished capacity to participate in shaping historical reality. Thus, they are subjected to 
participate in a reality neither of their own choosing, nor one in which they have they have 
the capacity to alter. Ellacuría references the term frequently in his philosophical, theological, 
and political writings, and is interested not only in how historical reality is understood, but 
how it can be transformed from the perspective of the “poor majority.”  
 From the perspective of the poor majority, i.e. the majority of human beings unable 
to fully participating in construction of historical reality, injustices become more readily 
visible. The poor majority includes human beings that suffer from illness, premature death, 
and lack the opportunities to participate in the political and economic construction of !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1  Robert Lassalle-Klein, Blood and Ink: Ignacio Ellacuría, Jon Sobrino, and the Jesuit Martyrs of the University of Central 
America (Maryknoll, NY: Orbis Books, 2014), xvii-xxii; Kevin F. Burke, The Ground Beneath the Cross: The Theology 
of Ignacio Ellacuría (Washington, D.C.: Georgetown University Press, 2000); Teresa Whitfield, Paying the Price: 
Ignacio Ellacuría and the Murdered Jesuits of El Salvador (Philadelphia: Temple University Press, 1994). 
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society. For Ellacuría, the poor majority has both a political and theologically function. 
 Politically, they force reflection on the structures that perpetuate disparities and 
inequalities and look for avenues through which to transform them. Theologically, Ellacuría 
argues the poor call attention to God’s revelation in scripture as taking place through those 
who are rejected in history. He gives particular attention to the Exodus account, Isaiah’s 
suffering servant, and, finally, to the person of Jesus. More will be said about the theological 
function of the poor majority in fourth section of this chapter (p. 114) when discussing 
Ellacuría’s epistemology, but it bears mentioning here, because it is his epistemological 
framework that framed his political and theological vision as the president of the University 
of Central America (UCA) in the midst of civil war in El Salvador.  
Social Projection and the UCA 
 The history of El Salvador resulted in stark divisions between the economically and 
politically rich and poor. Ellacuría saw the task of the Catholic university to project the 
Salvadoran reality in the university’s tasks of teaching, research, and service.  “Social 
projection” at the university argues that these university practices should study and reflect 
upon the reality—socio-economic, political, theological, philosophical, etc.—in a way that 
sets out to transform it in favor of the poor majority. One of his efforts at social projection 
of the Salvadoran reality was a series of dialogues established by the UCA to discuss, in a 
neutral setting, the challenges of living in a war-torn country. Rather than joining sides with 
the right-winged government or the left-leaning FMLN (Frente Farabundo Martí para la 
Liberación Nacional), Ellacuría proposed a third force by sponsoring a series of dialogues at 
the university between the poor majority and the wealthy minority about the realities of El 
Salvador.  
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 Through this third way not only did the poor majority find a voice, but the wealthy 
minority also began to hear their voice. Lassalle-Klein notes, “Ellacuría stresses that this 
third force is not a political organization but a social one, and he links it to an emerging 
theme in Catholic Social Teaching, namely, social organization and civil society as an 
important means through which individuals’ interests can be defended against oppressive 
state power.”2  While any university could hold these talks, Ellacuría sees it as the unique task 
of Catholic universities to serve as places that promote social movements that allow greater 
inclusion of the poor in society.   
 The UCA promotes the participation of the poor and the social projection of reality 
through academic writing in university-run journals, to students through course instruction, 
and as a guide for the university’s research agenda. Ellacuría argues that the Christian 
university serves as a place that ought to engage in the practice of social projection, a process 
that takes on the injustices present in reality and works to transform these injustices present 
in society. The university has a responsibility to take up these concerns as their own, 
prioritizing the poor as constitutive to their institutional priorities, actions, and practices.  
 For medical research, the epistemic shift requires the gathering of information to 
improve health, but to gather information aimed at improving the health of those who are 
most likely to have poor health. This reprioritization would require a research agenda to shift 
from one that has focused increasingly on individual health to one that focuses on the health 
of the public. Prioritizing the poor offers an epistemological corrective for research and 
research ethics by drawing attention to the majority of humanity that is excluded from 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
2  Lassalle-Klein, Blood and Ink: Ignacio Ellacuría, Jon Sobrino, and the Jesuit Martyrs of the University of Central America, 
172. 
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receiving the benefits of medical research. Moreover, the epistemological shift calls Catholic 
universities engaged in medical research to take up that practice from the place of the poor.  
 The Catholic university, like other institutions of higher education, has become 
entangled in the social structure of medical research that tends to benefit a select few rather 
than a suffering majority. Though liberation theologians and philosophers have taken up the 
option for the poor as the ethical lens through which historical actions should be considered, 
science and research has always prided itself on objective and neutral perspective. 
Nevertheless, the research decisions are not made from a place of neutrality and, in fact, this 
false impression has contributed to the disparities in health which medical research aspires to 
address. While these tasks are not explicitly theological, they are deeply theologal.  
 The theologal is a term that Ellacuría develops along with his mentor Xavier Zubiri 
to describe the “God dimension” of reality.3 The theologal dimension of reality is all-
encompassing and the choices made within history participate, in some way, in that ultimate 
sense of reality. Ellacuría’s utilization of the term theologal is borrowed from his mentor 
Xavier Zubiri, and is described in more depth below (p. 100-101). While the theologal 
grounds the thought of both Ellacuría and Zubiri, Zubiri’s influence extends beyond that 
and affects the way in which Ellacuría understands a wide variety of topics, in particular, his 
understanding of human intellection and the role of science.    
Zubiri’s Influence on Ellacuría 
 For Ellacuría, no mentor had greater influence on his thinking than that of the 
Spanish philosopher Xavier Zubiri. Zubiri’s philosophy came to be understood as a 
phenomenology of “fundamental reality” that develops through his encounters with some of !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
3 Burke, The Ground Beneath the Cross: the Theology of Ignacio Ellacuría, 40, n48. 
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the great scientific, mathematic, and philosophical minds of his day: Einstein, Schrödinger, 
Zermelo, Jaeger, and Plank. Immersed in their world, Zubiri starts grappling with new ways 
of envisioning the philosophy of science. While Zubiri’s understanding of science is 
important to understanding the function of medical research, ultimately his understanding 
does not differ from his description of human intellection. For Zubiri, the notion of 
intellection is a process that functions both rational and sentientiently and greatly shapes 
Ellacuría’s own thinking. For Zubiri, and Ellacuría, all knowledge is situated within particular 
space and time. This understanding leads to Zubiri’s critical stance towards the epistemology 
that guides science. 
Zubiri on Science 
 Zubiri’s critique of scientific knowing counters science’s claim of neutrality and 
objectivity as the highest form of intellectual pursuits. The privileged status of scientific 
thinking, while having its origins in the Enlightenment, becomes synonymous with Francis 
Bacon’s articulation of the scientific enterprise. For Bacon, science functions as way to 
constantly improve upon the condition in which humanity finds itself.4 Scientific 
experiments allow for a deeper understanding about the material world in which human 
beings exist. Bacon’s method of improving knowledge centers on an evidence-based process 
that increases scientific understanding through “progressive stages of certainty.”5  Medical 
research, and medicine in general, tends to operate within this perspective. Thus, the more 
research conducted and applied to the improvement of medicine, the more progress is 
achieved. Jeffrey Bishop, a physician and philosopher, reflects on Bacon’s scientific !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
4  Francis Bacon, The Works of Francis Bacon, Vol. VIII (Boston: Houghton, Mifflin and Company, 2007), 38-39. 
 
5 Ibid.!
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epistemology and cautions,“medicine tends to perpetuate a certain naïve understanding of its 
progress. Namely, we are moving to more and better knowledge and we will be able to 
deploy new technologies to assist in bettering the human condition.”6 This imperative for 
research and improvement can still be seen in the efforts within biotechnology and genetic 
innovations of today.  
 In the scientific efforts at the beginning of the 20th century through to the present 
day, there has been an increased shift toward reasoning rooted in materialism. “Science,” 
Bishop argues, moves single-mindedly, without regard for sentient life.”7 In disregarding the 
sentient and intellectual nature of human beings, the science of medicine effectively reduces 
life to notions of cause and effect. Thus, the more information accumulated the better 
chance of understanding, and controlling, the cause of disease through treatment. Research 
understood in this sense, however, centers on control, not knowledge. For Zubiri, the 
knowledge derived from scientific inquiry was not about control, but rather about deepening 
an understanding of the pluriformity of reality.  
 Zubiri did not understand science as an isolated and objective discipline that 
operates separate from reality. Instead, Zubiri argued that acquiring knowledge both 
contributes to and shapes reality. Zubiri’s corrective to a Baconian understanding posits a 
non-materialism that perceives reality thorough the senses and reason. “While we do directly 
perceive reality, we do not do so in an absolute, detached sense envisioned by classical 
science.”8 Thus, scientific knowing represents only one of the necessary pieces for 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
6  Jeffrey Paul Bishop, The Anticipatory Corpse : Medicine, Power, and the Care of the Dying (Notre Dame, Ind.: 
University of Notre Dame Press, 2011), 62. 
 
7 Ibid.!
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comprehending reality. While scientific understanding represents an important piece of the 
puzzle, it does not represent the highest form of knowledge. It is science, coupled with other 
disciplines, like philosophy, that benefit from and need each other to more deeply 
understand the infinitely open reality in which they exist. Zubiri’s philosophy came to more 
seriously consider the limitedness of all forms of human knowing, including philosophy and 
science. It is the limited perspective of intellectual disciplines, however, that makes research 
fundamental to understanding reality.   
 Zubiri describes research as an investigation of reality by seeking the precise and 
detailed constitution of reality. “To research is to dedicate oneself to the true reality…this 
force consists in configuring and conforming our mind according to the demonstration of 
reality and to offer that which is seen for others.”9 However, Zubiri notes, not unlike Bacon, 
that given the openness of reality research functions as an infinite task of observation and 
communication of that which is seen. Though, in contrast to Bacon, the results of the 
research are always situated, partial, and pluriform. The pluriformity of reality exists, “not 
only because things have many distinct properties, but also for the reason that from my 
perspective there is always something deeper: because that which is open is its own proper 
character of reality.”10 It is scientific task that takes up the study of reality in itself, as it is 
seen and experienced materially, while philosophy works cooperatively with science to reflect !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
8 Thomas Fowler, “The Great Paradigm Shift: Xavier Zubiri and the Scientific Revolution, 1890-1990,” Faith 
and Reason 20, No. 2 (1994): 170. 
 
9 Xavier Zubiri, “¿Que es investigar?” The Zubiri Foundation of North America, October 19, 1982, 
(http://www.zubiri.org/works/spanishworks/investigar.htm, accessed January 15, 2015). All translations 
provided are my own, unless otherwise noted. When possible, I will provide the original Spanish text in the 
corresponding footnotes. Investigar es dedicarse a la realidad verdadero…esta fuerza consiste en configurar o conformar 
nuestra mente según la mostración de la realidad, y ofrecer lo que así se nos muestra a la consideración de los de mas 
 
10 Zubiri, “¿Que es investigar?” “no solo porque las cosas tienen muchas propiedades distintas, sino también por una razón a 
mi modo de ver más hondo: porque lo que es abierto es su propio carácter de realidad.” 
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on the reality experienced, “there is always something deeper” to explore. For both Zubiri 
and Ellacuría, within reality lies a constitutive and inaccessible dynamic that they describe as 
the theologal dimension of reality.  
The Theologal Dimension of Reality 
 Zubiri posits that the theologal dimension of reality imbues and forms the 
fundament of reality itself. It is important to underscore that the theologal not be confused 
with the theological. Zubiri does not intend to offer proofs for God’s existence, nor to place 
God “on top of” reality. Instead, the theologal conveys the endless desire for human beings 
to know more and discover “something deeper.” Zubiri posits it is God, not the God of 
theology, but the God of reality that drives the endless task to know more about reality. The 
totality of reality, however, is not increasingly understood through the advances and control 
achieved through science, nor the musings of philosophy. However, both philosophic and 
scientific inquiry together can lead to a deeper understanding of reality, but not exhaust it. 
 The theologal power of the real is that which propels and compels human beings 
forward, to discover more, with the expectation that the more one comprehends reality, the 
more aware one should become of power one has to shape reality itself. 
Reality is a “more,” but not one that is in addition to a thing, but rather a ‘more’ in 
the thing itself. That is why in being with “this reality,” where I am is in “reality.” 
Likewise, it is because of that “which this reality” can impose on me that it adopts a 
form in “reality.” It is not a question of concepts, but of a physical character of the 
power of the real.11  
 
The emphasis Zubiri places on the shaping of reality comes to influence Ellacuría’s own 
thinking and the importance of human actions that shape history. Thus, reflecting on one’s 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
11  Michael Edward Lee, Bearing the Weight of Salvation: The Soteriology of Ignacio Ellacuría (New York: Crossroad 
Pub. Co., 2008), 54.  
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actions and understanding the reality in which those actions occur are fundamental to the 
sentient and intellectual function of the human knowing.  
Sentient Intelligence 
 Zubiri refers to sentient intelligence as the process of human intellection in which 
one is always interpreting, understanding, and acting from a particular perspective and out of 
a set of experiences that make sensitive impressions on the intellect.  This impression, 
however, is only experienced contextually and partially. The impression, while contextual, 
sentient, and partial, remains infinitely open to the possibility of other realities and to a 
deeper understanding of one’s own personal reality.  In an example used by Zubiri, he argues 
that one cannot isolate a piece of reality, e.g. the color red, without at the same time 
considering a multiplicity of factors being present within that experience. Moreover, one has 
to recognize that the impression “I” have when seeing “red” might be different than “your” 
impression, but neither renders the other less “real.” It worth noting that Zubiri does not 
equate the “real” with truth; thus, one can have a false perception of reality by not taking 
into account other valid experiences from different places. Continuing with his example of 
color, while a person who is colorblind experiences “red” differently than a person without 
color-blindness, it does not render either experience less real, even if the scientific reality of 
their experience of red does not match the material properties of the color red.12 
Comparatively, science offers material insights into reality, though the knowledge acquired is 
only partial. By uniting the senses and the intellect Zubiri demonstrates his efforts to !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
12  Lassalle-Klein, Blood and Ink, 206. Lassalle-Klein draws from an example of Zubiri’s to make the point of 
sentient intelligence via the way in which human beings perceive color. The passage, taken from Inteligencia 
Sentiente, is worth noting: “The color is not produced by the wave (as critical realism holds)...the visual 
perception of color is the electromagnetic wave in the perception…within the ambit of perception (an only 
there), the [perceptual] qualities and the [electromagnetic] waves are…one and the same thing, not two, as they 
would have been if the waves had been caused by the qualities. Sensible qualities are realities, within the ambit 
of perception…of something beyond them in the cosmos...” 
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overcome the prioritization of reason and observable reality within scientific and 
philosophical thought in an effort to counter what he describes as the “logification of 
intelligence.”  
 Zubiri observed a similar trend in western philosophy, similar to Baconian science, in 
which the intellective process tends to be reduced to a rational function that only needs to 
be understood through reason isolated from the senses. He describes the logification of 
intelligence as the process through which intellection becomes rooted in reason alone and 
reduces the senses to the interpretation of sense data. “This form of intellection comes to 
function formally as a faculty of affirmation in a way that neither reality, nor the beings of 
things would be accessible to human beings without this modality of intelligence 
characterized by logos and reason.”13 Reason only allows for an interpretation of reality in 
itself and reality makes an impression that is at once sensitive and rational. This sensitive and 
rational impression of reality, however, makes the whole of reality present, not just what is 
most immediate. Reality in its totality, though formally present in the intellective process, 
cannot be reduced to a purely rational function, as science is wont to do.14  
 Through sentient intelligence, science takes on the role of deepening the knowledge of 
reality as it is materially, while philosophy searches for the meaning of reality in its totality. It !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
13  Héctor Samour, Crítica y Liberación: Ellacuría Y La Realidad Histórica Contemporánea, (Madrid : Universidad 
Carlos III de Madrid, 2012), 95. Por logificación de la inteligencia Ellacuría entiende aquella consideración de la inteligencia 
por la cual se la concibe formalmente como la facultad de afirmación, de tal manera que ni la realidad ni el ser de las cosas les 
serían accesibles al ser humano sin en esa modalidad de la inteligencia caracterizada por el logos y la razón. Translation is my 
own.  
 
14 Zubiri also raises another philosophical concern in which meaning is reduced to “being”. While this concern 
goes beyond the scope of this section, the entification of reality was another epistemic concern. The Spanish 
ente or entity, thing—and the logification of intelligence converge when reason is reduced to being and being 
comes from the ability to reason. From Zubiri’s perspective, “being” can only be understood in and through 
reality and is not the ground of that reality. That which is considered intellectively and sensitively, is a “being” 
in and of itself, but a being who participates within a reality that exits beyond itself and beyond the immediately 
perceived reality.  
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is the “of its ownness” of intramundane reality that functions as the object of philosophy, 
and science proves a necessary complement to the philosophical task through the 
exploration of reality that is perceptually—intellectively and sensitively—present “in itself.”  
Moving toward the real that exists outside the perception of sensible qualities. Every 
quality is perceived not only in and of itself as such and such a quality, but also as a 
pointing toward. The reality of the qualities that are only in the perception is exactly 
what constitutes their radical insufficiency as moments of the real. They are real, but 
they are really insufficient. In their insufficiency, however, these 
qualities…are…pointing toward the real that is outside the perception. Indeed, this is 
what gives rise to science.15 
 
For Zubiri, science and scientific research functions as a mode of more deeply reflecting on 
reality as it is experienced. However, the reflection on perceived reality does not exhaust 
reality, an understanding that was not lost on Ellacuría.  
 The theologal dimension of reality, sentient intelligence, and the role of science serve 
as three aspects of Zubiri’s thought that Ellacuría embraced. The influence of Zubiri on 
science can be seen in Ellacuría’s role as president of the UCA and the way in which he 
spoke of the importance of research, along with service and teaching as the means by which 
the university reflected reality. It is the term reality, however, from which Ellacuría began to 
build on the work of Zubiri. For Ellacuría, Zubiri’s notion of reality did not sufficiently 
describe the praxical dimension of reality in which human actions continually give shape to 
reality as it is experienced. The next section describes Ellacuría’s understanding of reality and 
the role of human beings in shaping that reality. 
From Intramundane to Historical Reality 
 Ellacuría nuances Zubiri’s description of intramundane reality by describing the 
object of philosophy as historical reality. Historical reality, as briefly mentioned in the !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
15  Lassalle-Klein, Blood and Ink: Ignacio Ellacuría, Jon Sobrino, and the Jesuit Martyrs of the University of Central America, 
215-216. Here Lassalle-Klein is quoting Zubiri from Intigencia sentiente, (Madrid: Alianza, 1981), 184.  
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introduction, is a unified and global understanding of all “real things,” which constitute a 
physical and dynamic unity through which all things come to be through one another and, in 
one way or another, constitute the interdependent structure of the real.16  Ellacuría’s notion 
of historical reality is not merely a theoretical exploration of historical circumstances, nor is it 
simply the sequential retelling of historical events and occurrences, though it includes these 
components. Kevin Burke notes that Ellacuría’s definition of historical reality refers: 
to the field, sphere, or area of reality that serves as reality’s realm of ultimate 
realization, and to the unity underlying the various historical happenings, the 
contents of realization…It emerges through the totality of history’s actors, authors, 
editors, auditors, all the players, all the parts, the audience, the stage, and every other 
aspect of cosmic theater, but the unity as such is not imposed by any of these.17 
 
Insofar as reality is made up of a diversity of historical players and places, a key distinction 
develops between Ellacuría’s description of historical reality and Zubiri’s intramundane 
reality.  
The Importance of Praxis 
 The key distinction between historical reality and intramundane reality rests on 
Ellacuría’s emphasis on the praxical dimension of reality. In this way, Ellacuría nuances the 
Zubirian focus on the apprehension of reality through sentient intelligence.  For Ellacuría, 
one comes to know in order to transform. Intramundane reality does not emphasize strongly 
enough the fact that, through human action in reality, human beings make history and shape 
historical reality. Thus, Ellacuría gives particular attention not only to human thought, but 
also human actions as the grounds through which historical reality—i.e. the pluriformity of 
conditions, contexts, and circumstances—is experienced and transformed by human beings. !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
16  Ignacio Ellacuría, Filosofía de la Realidad Histórica (San Salvador, El Salvador: UCA Editores, 1990), 45. 
 
17  Burke, The Ground Beneath the Cross, 59. 
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 Ellacuría describes human beings as reality animals—a description borrowed from 
Zubiri—who operate through both social and individual dimensions in which historical 
reality comes to be realized.  Ellacuría describes the human person as a distinct kind of 
creature that remains open to the immediate reality in which she is situated but aware that 
other realities are simultaneously present and shape the experience of one’s particular reality. 
Human beings, like animals, are immersed in situations and are “subjects to” all that 
situations require of them.18 However, human beings also have the capacity and 
responsibility to transcend the particularities of their circumstances and recognize the reality 
of others.  For Ellacuría, it is the fact that human action alters historical reality that marks an 
evolution from Zubiri’s notion of intramundane reality and emphasizes the fundamentally 
ethical dimension of the human person.  
 Ellacuría argues that historical reality is “of itself,” and that reality’s “of itselfness” is, 
in part, a result of human actions that lead to the construction of reality as it is. This reality is 
reflective of both one’s own actions and the actions of others, which jointly shape a unified 
reality for one’s self and other selves. In this way, the ethical construction of historical reality 
necessarily moves beyond the individual experience, because that particular experience, 
though holding on to a dimension of reality “itself,” is a reality that is conterminously shaped 
by and with others. Thus, reality as it is experienced is a function of a dialectic between one’s 
self and other selves, both of whom give shape to the experienced historical reality. 
Historical reality then is “co-real,” meaning that each of these experiences or encounters can 
only be understood as real with others, “because the reality of the others forms part of my !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
18 Ignacio Ellacuría, “Fundamentación biológica de la ética,” in Escritos Filosóficos, Vol. 3, (San Salvador, El 
Salvador: UCA Editores, 2001), 255. Los hombres, como los animales, están inmersas en situaciones; en este sentido, tanto los 
hombres como los animales están ‘sujetos-a’ todo aquello que las situaciones les exigente. 
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own reality.”19 This co-construction of reality takes place through options and decisions 
made by oneself and others by responding to options as presented naturally, in the midst of 
conditions that have been commonly constructed.20  
The Biological Fundament of Ethics 
 Ellacuría reflects on what is “common” to humanity as a biological fundament that 
provides the most basic commonality amongst human beings. Thus, what is most common 
to human beings is biological in nature and does not necessarily pertain to a community or 
society.21 Rather, the construction of communities and societies evolves from deliberate 
human choices, which have the capacity to foster a sense of community and to form just-
societies that allow for the equal participation of all its members, or not.  
 It may strike one as odd that Ellacuría grounds ethics in biology, however, this move 
is deliberate and not intended to argue some “ethics gene” inherent in human beings. 
Ellacuría argues that injustices can be seen where people continually lose their lives at a 
disproportionate rate than is biologically necessary. In this way, the biological fundament 
takes a socio-ethical position that calls one’s attention to the perspective of people who, as 
Gustavo Gutiérrez says, “die before their time.” The biological fundament, moreover, 
requires critique of systems or structures that perpetuate this injustice.22  
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
19  Ibid., 255; Burke, The Ground Beneath the Cross: The Theology of Ignacio Ellacuría, 79-80. 
 
20 Ellacuria, “Fundmaentación biológica,” 256-67. 
 
21  Ignacio Ellacuría, Filosofía De La Realidad Histórica, (San Salvador, El Salvador, CA: UCA Editores, 1990), 
386. 
 
22 Chapter Four will focus explicitly on the construction of the social practice of medical research through 
collaborations between the U.S. government, academia, and the pharmaceutical industry. These collaborative 
efforts have participated in the shaping of a research structure that denies opportunities to gain the benefits of 
medical research, which are due in large part to the economics of research.  
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 By calling attention to this socio-ethical position, Ellacuría raises the possibility that 
choices made by particular people tend to have more influence on the shape of history than 
the choices of others. It is the disparity in loss of life between high-income and low-income 
countries that Ellacuría points to as demonstrative of unjust social arrangements. Thus, in 
order to correct these injustices, greater attention needs to be focused on those places in 
society in which people die, not of natural causes, but because of unjust structures. For 
Ellacuría:  
Society and history, above all, are not able to be (ser) what human beings decide; 
what society and history are going to be depends on the structuring of real and 
complex factors following the structure of law, but also between these factors, how 
we see them in their place, they have there proper place (puesto), their own position 
(posición), what human beings do and want to do.23  
 
Thus, Ellacuría’s initial socio-ethical question is not, what ought one do, but rather, where 
ought one begin to think about what one ought to do. It is the place from which one enters 
into a praxis-based encounter with reality that proves crucial to Ellacuría’s philosophical and 
theological method.  
A Praxis-Based Encounter with Reality 
 Ellacuría’s three-fold praxical encounter with reality and its particular impact on 
theology is described in a 1975 address that develops his philosophical foundations of a 
Latin American theology. Ellacuría argues that if intellection is a process that is 
simultaneously sentient and rational, then, “Every reading, every interpretation is motivated 
by interests, be they existential or social. The important thing is realizing what this interest is 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
23 Ellacuría, Filosofía de la Realidad Histórica, 387. La sociedad y la historia, sobre todo, no pueden ser lo que los hombre 
decidan; lo que la sociedad y la historia vayan a ser depende de la estructuración compleja de factores reales según leyes estructurales, 
anuqué entre estos factores, como veremos en su lugar, tenga su puesto propio, su posición propia, lo que los hombres hacen y quieren 
hacer.   
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and how this interest conditions our way of approaching and comprehending reality.”24 The 
way in which one uncovers the motivations for particular interpretations of reality is rooted 
both in the hermeneutic through which one interprets reality and also the process by which 
one engages it.  
 Ellacuría offers a three-fold method of engaging with reality that argues the human 
person comes to understand, interpret, and take responsibly for historical reality through a 
praxis-based encounter that begins from the place of the poor. While there are three aspects 
to his method, these should not be seen as sequential developments. Rather, each of these 
components functions as a spiral and proves necessary for responsibly encountering reality 
as it is, in order to shape it as it ought to be. This process, however, does not stop with finite 
conclusions. Once one acts, the reality in which one has acted is now transformed to some 
degree. Therefore, the entire process begins again from a new point and within a new reality. 
In order to act responsibly, according to Ellacuría, one must realize the weight of reality (el 
hacerse cargo de la realidad); shoulder the weight of reality (el cargar con la realidad); and take 
charge of the weight of reality (el encargarse de la realidad).25 Ellacuría’s methodology is 
designed not as an intellective move to observe, judge, and act from a third party standpoint, 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
24  Michael Lee, ed., Ignacio Ellacuria: Essays on History, Liberation, and Salvation, (Maryknoll: Orbis Books, 2013), 
70. 
 
25  Burke, The Ground Beneath the Cross. The translations of the three components of Ellacuría’s method follow 
those that Burke, Ashley, Lee, have used. Gandolfo, Lassalle-Klein opt for a slightly modified translation. I 
follow Lee, Burke, and Ashley to maintain consistency in translation. Additionally, Lee has an important and 
helpful note that these three phrases El hacerse cargo de la realidad; El cargar con la realidad; El encargarse de la realidad, 
could all be correctly be translated as “taking charge of reality,” though the Spanish uses are more nuanced than 
their English counterparts, which is what the varied translations aim to articulate. Interesting to note, that a 
more literal translation of the Spanish phrases each contains a phrase in which one bears responsibility for the 
reality with which not only one confronts, but this responsibility weighs one down. In a sense there is not just 
the intellectual knowledge of this responsibility, but rather one feels it weighing on her, i.e. it is sentient. 
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but to see oneself as intimately involved with and responsible for the reality as it is 
continually being co-constructed.  
Realizing the Weight of Reality 
  “Realizing the weight of reality” means being present to it formally. In other words, 
realizing reality’s weight is more than a rational or cognitive task; it is a task that requires an 
active mediation.26 Jose González Faus emphasizes, “Realizing the weight of reality involves 
a conception of knowing more profound than the mere objective accumulation of data. 
Spanish expressions such as ¡ahora me hago cargo! (Now I get it!) or hazte cargo (you must 
understand) allude to a comprehension which goes far beyond mere objective knowing and 
links knowing and empathy.”27  These type of expressions point not just to the intellectual 
grasping of a concept, e.g. an algebraic equation, but to an owning of the concept so much 
so that it becomes a part of one’s identity. Therefore, the knowledge becomes one’s own and 
is literally “taken on.” By realizing reality, one comes to understand one’s own participation 
in the shaping of reality as it is. In the midst of realizing reality, one has to bear responsibility 
for a historical reality in which the majority is poor and vulnerable. Upon realizing the weight 
of reality, one is confronted with an ethical responsibility within a commonly shared reality.  
Shouldering the Weight of Reality  
 El cargar con la realidad, could be literally translated as “loaded with reality,” which 
gives the physical sense of what Ellacuría intends to convey. As one recognizes the role of 
reality to be an inherently ethical role, the question then shifts to how one should “shoulder 
the weight of reality.” As reality imposes itself on the reality animal, one necessarily has to !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
26  Lee, Ignacio Ellacuría, 80. 
 
27  Burke, The Ground Beneath the Cross, 116, n.8.  
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decide how to act and react within the environment. The fundamentally ethical character of 
intelligence “has not been given to us so that we could evade our real commitments, but 
rather to take upon ourselves what things really are and what they really demand.”28 It is in 
this aspect of his methodology that the place from which one encounters reality shapes how 
one acts.  
 Making an option regarding the place—not necessarily a physically location but more 
of an intellective/ethical locus—from which one acts is important. Theologically, Ellacuría 
describes an ethical place as that which is “most likely to inspire a living faith in Jesus and a 
corresponding praxis of discipleship (the praxis-oriented dimension), and the place most apt 
to stimulate a lively, authentic theological understanding of faith (the noetic dimension).”29 
Ellacuría describes the place from which human beings, of faith and no faith, should opt to 
act is from the place of the poor.  
 Ellacuría describes the poor as: 
the vast bulk of humanity whose standard of living is such that they can scarcely 
satisfy their most basic needs; this majority whose material standard does not permit 
them sufficient human development, who do not have access in an equitable way to 
the resources now available to humanity and who are marginalized in relations to 
elite minorities who…dispose of the greater part of available resources for their own 
immediate benefit; and those majorities whose dispossession is not due to natural 
law or personal or group laziness, but rather to historic social arrangements that have 
relegated them to situations in which they not only lack, but are deprived of, what 
they should have, whether because of exploitation in the strict sense or because they 
have been hindered indirectly from enjoying the fruits of either their labor or their 
political initiative.30  !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
28  Lee, Ignacio Ellacuría, 80. 
 
29 Ignacio Ellacuría, “Los pobres, lugar teologico en América Latina,” September 6, 1981, 
http://www.uca.edu.sv/martires/CasoJesuitas/ponenciaellacuria.php (accessed January 22, 2015). Lugar teolo ́gico 
se entiende aquí, en segundo lugar, el lugar más apto para la vivencia de la fe en Jesús y para la correspondiente praxis de 
seguimiento.  
 
30  Ignacio Ellacuría, “The Challenge of the Poor Majority,” in Towards a Society that Serves its People: The Intellectual 
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Thus, this is not a unique subset of the population, but the collective of individuals that 
comprise the majority of persons within historical reality. He argues, moreover, that the poor 
are poor because, “The rich have dispossessed the poor from what was theirs…if the poor 
are impoverished, the rich are the poverty-makers; if the poor are dispossessed, the rich are 
the possessors; if the poor are the oppressed and repressed, then the rich are the oppressors 
and repressors…”31 The disparity between the rich and the poor is present, too, in medical 
research.   
 In the last chapter, I referenced the research gap in which 90% of medical research 
benefits only 10% of the population. In large part, these disparities stem from the 
institutions that establish the research agenda—high-income resource rich nations or high 
powered economically solvent pharmaceutical industry—whose priorities primarily focus on  
how to yield an economic return on investment.32 However, for Catholic universities, while 
economics cannot be dismissed, they cannot occupy the central concern of what research 
opportunities to pursue. Insofar as medical research at Catholic universities reflects the 
national funding priorities that do not benefit the poor majority, an issue addressed in 
Chapter Four, then these institutions participate in the dispossession of the poor as Ellacuría 
rightly points out. The importance of place, highlighted in the ethical dimension of 
Ellacuría’s epistemology, is helpful in framing the ethical problem, however, it does not 
readily identify a solution. Thus, from the place of the poor one not only has to interpret and !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Contribution of El Salvador’s Murdered Jesuits, ed. John J. Hassett and Hugh Lacey (Washington, D.C.: Georgetown 
University Press, 1991), 208. 
 
31 Ellacuría, “Los pobres, lugar teológico.” Si los pobres son los empobrecidos, los ricos son los empobrecedores; si los pobres 
son los desposei ́dos los ricos son los poseedores; si los pobres son los oprimidos y reprimidos, los ricos son los opresores y los 
represores.  
 
32 This claim will be more fully considered in the next chapter.!!
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understand, but ultimately one has to take responsibility for the transformation of historical 
reality.  
Taking Charge of the Weight of Reality 
 The final dimension of Ellacuría’s methodology focuses on “taking charge of the 
weight of reality” (el encargarse de la realidad) by engaging in responsible action that considers 
more broadly one’s responsibility not only to oneself, but also for and with others. For 
Ellacuría, it is the praxical character of intelligence that proves necessary for human 
intellection to become a completed process. The “praxical character of intelligence…only 
fulfills its function, including its character of knowing reality and comprehending its 
meaning, when it assumes as its burden doing something real.”33 In other words, what takes 
place in human intellection only comes to fruition when one takes charge of reality in a way 
that leads to an active transformation of that reality to make it more “real,” meaning more 
human(e). The only way to shape reality, however, requires “engaging, remembering, and 
ultimately undoing its terrible negativity. In a word, it demands conversion, a conversion of 
the human heart and a conversion in historical reality.”34 The conversion of the human 
person starts with taking the poor majority as the heuristic through which one interprets and 
critiques reality, thus, opening oneself to a praxis-based engagement with reality that “comes 
from and returns to the configuring of a specific social structure.”35 Thus, there is a need to 
take seriously the praxical responsibility one has in shaping social structures grounded in the 
theologal dimension of reality.  
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
33  Lee, Ignacio Ellacuría, 80. 
 
34  Burke, The Ground Beneath the Cross, 106. 
 
35  Lee, Ignacio Ellacuría, 82.  
!!
116 
The Theologal Dimension of Reality (Reprised) 
 In the theologal dimension that Zubiri develops and Ellacuría takes up, God does 
not exist above or along side of historical reality, but rather God’s transcendence takes place 
in and through reality.36 Thus, there are not two realities—God’s and humanity’s—but a 
single historical reality that God and humanity share. Ellacuría points to the story of God’s 
revelation in the Exodus story, Isaiah’s suffering servant, and finally through the life, death, 
resurrection of Jesus. God’s transcendence comes to be made known, not by taking 
something away, but rather by pushing something forward. In the Exodus account, Moses 
leads God’s people from captivity and oppression to the Promised Land. In Isaiah, while the 
suffering servant, “has bourne our infirmities and carried our diseases…wounded for our 
transgressions, crushed for our iniquities” (Is. 53:4-5), the servant also serves as a light to the 
nations “that [God’s] salvation may reach the end of the earth” (Is. 42:6, 49:6).37 While not 
superseding the suffering servant, through continuing the story of God’s revelation in and 
through those who suffer, Jesus’ suffering and death emerges as the central Christian 
narrative through whom God comes to be known most fully. It is through the oppressed 
and marginalized and in the person of Jesus that demonstrates most fully God’s presence in 
history.  
Thus this fundamental article of faith does not refer to God alone, to a God apart 
from human history, nor even to a God who gives meaning to individual life and 
whose fullness is projected beyond history. On the contrary, it is from and in history 
itself that God becomes present as the fundamental and foundational religious event, 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
36 This is Ellacuría’s foundational insight that forms the bedrock of his soteriology. Kevin Burke and Michael 
Lee have both written on the implication of Ellacuría’s theology, Burke more exploratory and Lee on its 
implications for Christian discipleship.  
 
37 Jon Sobrino, Jesus the Liberator: A Historical-Theological View, (Maryknoll, NY: Orbis Books, 1993), 261.  
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not only not separated from the sociopolitical processes but established and re-lived 
in that process.38  
 
Here Ellacuría calls attention to the structural transformation implied through God’s action 
in history in which captives are freed, the suffering serve as a light to the nations, and the 
dead are raised.  
Utopia and Prophetism 
 In one of Ellacuría’s final essays, he argues that the God’s action in history takes on 
both a utopic and prophetic function that must remain dialectically in tension.39  He argues, 
“The Christian utopia can only be constructed from propheticism, and the Christian 
propheticism must take into account the necessity and the characteristics of the Christian 
utopia.”40  Propheticism in this sense does not mean simply a critique of the structures, but it 
is a critique that calls for structural change, change that is more in line with the utopic vision 
of God’s kingdom. The dialectic between prophetism and utopia “gives present reality to 
what is formally an historical possibility…”41 The formal and historical possibilities are made 
known because of God’s transcendence in and through history and have been revealed most !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
38  Ignacio Ellacuría and Jon Sobrino, Mysterium Liberationis: Fundamental Concepts of Liberation Theology (Maryknoll: 
Orbis Books, 1993), 260. 
 
39  Ignacio Ellacuría, “Utopía Y Profetismo Desde América Latina: Un Ensayo Concreto De Soteriología 
Histórica,” Revista Latinoamericana De Teologia 17, Mayo/Agosto (1989); Ignacio Ellacuría, “Utopia and Prophesy 
in Latin America,” in Towards a Society that Serves its People: The Intellectual Contribution of El Salvador´s Murdered 
Jesuits [Utopia y profestismo en Latino America], ed. John J. Hassett and Hugh Lacey, trans. S. J. James 
Brockmann (Washington, D.C.: Georgetown University Press, 1991d), 44-90.; James Matthew Ashley, A 
Grammar of Justice : The Legacy of Ignacio Ellacuría, 2014), 7-56. The latest translation presented in A Grammar of 
Justice, alters Brockman’s translation from “prophesy” to “propheticism,” an infrequently used word, but on 
Ashley and Burke thought better conveyed the structural change called for with the Spanish word profetismo. In 
their introductory comments they state: “Propheticism implies something beyond the discrete word or act of 
prophecy it refers to an integrated and integrating vision, a structuring principle, a way of life.” I follow their 
lead in translating profetismo as propheticism. 
 
40  Ellacuría, “Utopía Y Profetismo Desde América Latina: Un Ensayo Concreto de Soteriología Histórica,” 
142. La utopía Cristiana sólo puede ser construida desde el profetismo y el profetismo cristiano debe tomar en cuenta la necesidad y 
las características de la utopía Cristiana. Follows Ashley and Burke translation.  
 
41 Ibid. Actualizarlo significa…dar realidad actual a lo que formalmente es una posibilidad histórica…”!
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fully in those who suffer on the margins of society. He argues that the place from which 
theology most authentically develops should be set by the historical reality of the people of 
God, most fully witnessed in the poor and marginalized as the continuation of the 
incarnation of the crucified Jesus in history.42   
 Ellacuría and his contemporary, Jon Sobrino, note the historical suffering of the 
majority of the world today functions as the historical sign of Jesus’ continued crucifixion in 
history. The “crucified people” represent the result of the deliberate choice and freedom for 
human beings to choose against God. “This crucifixion results from historical decisions, 
actions, traditions, and structures and represents, in Ellacuría’s view, the most urgent and 
theologically dense of all the contemporary signs of the times.”43 The crucified people, 
continue to make the crucified Christ present in history, also making present the reality of 
his, and their, ultimate resurrection. Thus, the crucified people push forward within the 
present reality a utopic vision in need of actualization.  
  Catholic universities participate in this propheticism in a particular way by taking up 
this Christian utopic vision that prioritizes the poor.  This vision calls attention to the 
injustices that exist in the world, and works towards reform of those structures. Ellacuría 
saw this as a vital role that universities could and should play. For Ellacuría, the Catholic 
university functions as a mission-based institution striving to embody the Christian utopic 
vision rooted in an option for the poor. This perspective on the role of the Catholic 
university proves fundamental to his leadership of the UCA and continually calls for action 
in the midst of an unjust reality.  !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
42 Lee, Ignacio Ellacuria, 84; Burke, The Ground Beneath the Cross, 109. 
 
43 Burke, 181. 
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Ellacuría and the University 
 In the immediate years preceding his assassination, Ignacio Ellacuría served as an 
important public figure in El Salvador as the president and rector at the UCA. In his time 
there as both a professor and administrator, his philosophy and theology of liberation 
reflected the way in which he viewed the function of the university. While he wrote only a 
few essays on the topic of the university, his inquiries led him to reimagine its role as an 
institution that addressed social injustices, and the injustices in El Salvador at the time were 
plentiful. Faced with that reality, he argued that a Catholic university, like the UCA, should 
undertake social projection (proyecion social) as its fundamental task.44  
Social Projection 
 Social projection conveys that all components of the university—faculty, students, 
staff, teaching, service initiatives, and research, etc.—ought to reflect the socio-historical 
reality in which the university operates. The work of the university, then, goes against the 
“ivory tower” or disengaged notion of the university, arguing that it should reflect and aim 
to transform the social context in which the university exists. “Social projection understands 
itself here as a function that puts the totality of the university, although through its parts, in !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
44 Adolfo Nicholas, S.J., “Depth, Universality, and Shared Ministry: Challenges to Jesuit Higher Education 
Today,” (presented at Networking Jesuit Higher Education: Shaping the Future for a Humane, Just, Sustainable 
Globe, Mexico City, April 23, 2010) http://www.sjweb.info/documents/ansj/ 100423_Mexico%20City_ 
Higher%20Education%20Today_ENG.pdf; Brad Hinze, “The Tasks of Theology in the Proyecto Social of the 
University's Mission” Horizons. 39, no.2 (2012): 282-309; Dean Brackley, “Higher Standards for Higher 
Education: The Christian University and Solidarity,” address delivered at Creighton University (Omaha, NE), 
November 4, 1999, http://onlineministries.creighton.edu/Collaborative 
Ministry/brackley.html. The term social projection has increasingly been influential on reflecting on the way in 
which Jesuit universities themselves operate. While Ellacuría uses the term “Christian” university, he is 
speaking more specifically about Catholic universities and his thought has been most frequently been 
incorporated into the thinking of Jesuit universities. Referencing the above description, if it is faith in Jesus that 
lay at the foundation of the action of these institutions, then it is faith in Jesus who continually targeted his 
mission to the poor and marginalized of society. Given this foundation in Jesus, rather than the institutional 
churches themselves. my argument in particular is addressed to Catholic universities, which already exist as part 
of an organized and unified network through which international projects and policies play an important role, 
especially when considering issues of global health.  
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direct relationship with social forces and processes.”45 While each of the parts of the 
university, departments, academic disciplines, students, etc. have their particular roles to play, 
these develop most effectively and beneficially through relationships with those persons and 
institutions outside of the university itself and amongst the community in which it operates. 
 Rather than using the university’s teaching, education, and service for self-promotion 
and/or aggrandizement, these tasks, which are fundamental to the university, should most 
clearly reflect the needs and concerns facing historical reality. “[Social] Projection 
operationalizes the contribution to the creation, modification, and configuration of the 
collective conscience in its totalitizing structural dimension or partial structural dimension.”46 
David Gandolfo comments that the university as social projection must insert itself 
effectively in society. In so doing, the university recognizes its responsibility by allowing the 
needs of society to penetrate and permeate the university “determining its curriculum and 
research agendas.”47  Therefore, the university projects reality on to reality by being 
reflective—the intake of data for processing—and projective—identifying solutions, 
critiques, and working to provide the necessary resources in order to transform the unjust 
immediate reality.  
 Thus, social projection functions representatively of the social situation and, 
additionally, strives to transform that same situation as needed. The university’s method of 
social projection, however, remains focused on the central tasks of the university. Teaching, !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
45  Ignacio Ellacuría, “Universidad y Política,” in Escritos Universitarios (San Salvador, El Salvador: UCA 
Editores, 1999), 186. Por proyección social se entiende aquí aquella función que pone a la universidad como totalidad, aunque a 
través de su parte, en relación directo con las fuerzas y los procesos sociales. 
 
46 Ellacuría, “Universidad y Política,” 186. La proyección se operativiza en la contribución a la creación, modificación y 
configuración de la conciencia en su dimensión estructural totalizante o en dimensiones estructurales parciales. 
 
47 Gandolfo, Forthcoming manuscript to appear in A Grammar of Justice, 4.  
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research, and service rooted in social projection aims at the transformation of society beyond 
educating students for a profession, providing instead, an education that addresses the 
complexities and injustices of reality. At the time, Ellacuría argued, “the UCA needs to look, 
to offer, and to support universitarily the process conducive to more justice, freedom, and 
solidarity in El Salvador and Central America.”48 It is this emphasis that points to the 
political function of the university, a function that holds up the poor majority as the horizon 
for university action.  
University Politics 
 Structuring the university’s activity from the place of the poor majority and striving 
to transform the injustices of the present reality makes the university political. The politics of 
the university does not mean explicit support for a political party, but the political task of the 
university results from engaging and confronting political structures that creates an unjust 
situation for the majority.49 
The university is in and of itself, a reality that moves within the camp of social forces 
and that, in the abstract, is able to prescind from this political environment of state 
power, even though not from the environment of social classes, nevertheless, here is 
where the state converts into a sustainer of social structures that are fundamentally 
unjust and irrational and constitute themselves as a validator on the part of society 
against the other, this is, in favor of one social class, here the university necessarily 
enters the conflict as a social force, it is here where the university puts itself on the 
side of truth and justice.50 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
48  Ignacio Ellacuría, “Funciones fundamentales de la universidad y su operativización,” in Escritos Universitarios 
(San Salvador, El Salvador: UCA Editores, 1999), 107. … la UCA debe buscar, ofrecer y apoyar universitariamente los 
proceso que propicien una convivencia mas justa, libre, y solidaria en El Salvador y Centroamerica. 
 
49  Ellacuría, The Challenge of the Poor Majority, 171 
 
50  Ellacuría, Universidad y Política, 185-186. La universidad es de suyo una realidad que se mueve en el campo de 
las fuerzas sociales y que, en abstracto, puede prescindir del ámbito político del poder estatal, aunque no del 
ámbito de las clases sociales; sin embargo, allí donde el Estado se convierte en sostenedor de una estructura 
social fundamentalmente injusta e irracional y se constituye en valedor de una parte de la sociedad en contra de 
la otra, esto es, en favor de una clase social, necesariamente entra en conflicto con esa fuerza social que es la 
universidad, si es que ésta se ha puesto de lado de la verdad y de la justicia 
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The university’s political task emerges in its recognition as an institution that operates as a 
counter-structure to unjust structures. While this does not mean siding with a political party, 
it does requires that the university honestly reflects on, critiques, and offers solutions for the 
injustices present within its context. One way in which it critiques injustices stems from 
Ellacuría’s epistemology.  
 Ellacuría holds that all knowledge is derived from a particular perspective and from 
experiences. Therefore, he encourages the UCA, and implicitly other Catholic universities, to 
readily call out any “pretense of scientific neutrality and professionalism that negates 
‘interestedness and ideologizationally,’ the political reality of the university in order to make 
it, surreptitiously, a political instrument at the service of the dominate structure, which may 
or may not conflict with society.” 51 Rather than encouraging objectivity in its research 
practices, which does not exist, Ellacuría challenges the university to embrace this lack of 
“disinterestedness” and to embrace an ideology that explicitly prioritizes justice for the poor. 
Thus, while engaging the community through the public and private interests of business 
and government therein, the university must be conscious and vigilant in its mission to 
socially project reality in a way that prioritizes justice for those who have none. An explicit 
focus on justice from the perspective of the poor requires an epistemological shift that 
emphasizes the theological mission of the Catholic university.  
Theological Mission 
 The option for the poor captures both an epistemological insight and theologically 
shapes how the Catholic university realizes, shoulders, and takes charge of reality. The !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
51 Ellacuría, Universidad y Política, 186. Nos encontramos, en un extreme, con la pretensión de la neutralidad científica y 
profesionalizante que niega 'interesada e ideologizadamente' la realidad política de la universidad para hacker de ella, 
subrepticiamente, un instrumentos politizado al servicio de la estructura dominante, haya o no haya conflictividad en la sociedad 
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Christian inspiration of the university necessitates engagement in activities that foster the 
continuation of the actions of Jesus in history. Yet, there is certainly a counter-cultural 
dimension to Jesus’ mission, which was preached in a particular way to the marginalized—
the economically poor and the social outcasts, including those who were ill. 
Epistemologically, for Christians knowing changes with the experience of Jesus in history. 
God is understood as human, not one of privilege, but one who was marginalized. Jesus did 
not live a long life, but rather one cut short by dying an innocent death. His mission was one 
of inclusion that challenged existing social structures. The Catholic university participates in 
the continuation of this theological mission by consciously embodying an option for the 
poor.  
A university is a Christian university when its horizon is the people of the very poor 
who are demanding their liberation and struggling for it. [Thus, it is] a university 
whose fundamental commitment is to change both structures and persons with a 
view towards a growing solidarity; a university which is willing to engage in 
dangerous struggle on behalf of justice; a university whose inspiration for making 
ethical judgments of situations and solutions and for the means to use in moving 
from such situations to solutions is the inspiration of the gospel. It is also—some of 
us believe—the different university that our country needs.52  
 
Thus, the way in which Ellacuría frames the Catholic-nature of the university does not rest 
on a doctrinal assent, but on the commitment of a praxis that engages the world as Jesus did, 
by making an option for the poor. Making this option, however, will narrow the focus of 
how the Catholic university goes about its tasks of teaching, service, and research.53 
 Teaching, research, and service that take the poor majority as the horizon of its 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
52  Ignacio Ellacuría, “Is a Different Kind of University Possible?” 207. 
 
53 For medical research this poses a particular challenge. The breadth of what can be researched is expansive, 
however, funding for research that addresses the health needs of low-income countries is relatively limited. 
Chapter Four highlights the injustices within the current structure of medical research, while Chapter Five 
concludes by offering possibilities of challenging these existing structures.  
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activity, aims at the transformation of society by promoting the common good, but 
minimally avoiding common harm.54  In a brief essay, Ellacuría argues that the common 
good offers a formal and abstract horizon that attempts to shape one’s actions. However, it 
is difficult to agree on the exact characteristics that make up the common good, which 
Ellacuría argues is not the sum of all individual goods. Thus, he proposes that a focus on the 
common harm might generate some consensus on morally responsible actions.  
 He describes the common harm as those actions that result in harm to the majority 
of persons.55 While the common good can be defined inversely, it still remains somewhat 
nebulous as to how to construct the common good, particularly in the midst of unjust 
situations. Thus, in educating against the common harm, the UCA aims to develop initiatives 
that worked against “the structural oppression of the majority of Salvadoran people, the 
UCA should look, offer, and support universitarily the process conducive to more justice, 
freedom, and solidarity in El Salvador and Central America.”56  Yet, the way in which this is 
to be done is not uniform, but rather is a dynamic process that works interdisciplinarily 
through the activities of the university by beginning with the experiences of those who suffer 
injustices. Beginning with experiences of injustice requires that scientific and medical 
research be reimagined in order to address the needs of those who suffer most.  
 
 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
54 Ignacio Ellacuría, “El mal común y los derechos humanos,” Escritos Filosóficos, Vol. 3, (San Salvador, El 
Salvador: UCA Editores, 2001).  
 
55 Ellacuría, “El mal común,” 448.  
 
56  Ellacuría, Funciones fundamentales de la universidad y su operativización, 107. En y ante una situacion real de opresion 
estructural de la mayoria del pueblo salvadoreno, la UCA debe buscar, ofrecer y apoyar universitariamente los proceso que propicien 
una convivencia mas justa, libre, y solidaria en El Salvador y Centroamerica. 
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Research and the University 
 Research prioritizes the objective pursuit of knowledge by more deeply 
understanding reality and discovering new ways of engaging it.  One of the potential pitfalls 
of research is its tendency to understand itself as an isolated and neutral task, devoid of 
interests, aside from scientific progress. An argument for objectivity proves particularly 
challenging in the pursuit of research that explicitly strives for technological or scientific 
advancements that fails to address the immediate needs of the present reality. Research for 
advancement becomes, in essence, a “race to stay ahead,” rather than socially projected 
research. Ellacuría notes: 
other research agencies are so far ahead of us in this respect we can never catch 
them. Rather, it would be a kind of research that can help resolve the huge problems 
of a national reality whose chief defining feature [now] is the existence of popular 
majorities who see their fundamental human rights violated and a blockade of the 
potential pattern towards a life emerging from the true cultural and political self-
determination.57   
 
For medical research, Ellacuría’s insight is important to consider. University funding for 
medical research at Catholic universities is limited. Insofar as Catholic universities attempt to 
keep up with the Harvard’s, Oxfords, and Freiburgs, there success will often fail to address 
the “big problems” in need of addressing, like malaria, TB, Ebola, etc.58 Ellacuría’s challenge 
requires that research focus on addressing “huge problems” that violate the rights of 
individuals and communities and inhibit full participation in society both culturally and !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
57  Ignacio Ellacuría, “The University, Human Rights, and the Poor Majority,” in Towards a Society that Serves its 
People: The Intellectual Contribution of El Salvador's Murdered Jesuits, ed. John J. Hassett and Hugh Lacey, trans. 
Phillip Berryman (Washington, D.C.: Georgetown University Press, 1991), 218. 
 
58 Harvard University, Oxford University, and Freiburg University represent globally some of the leading 
research institutions. League of European Research Universities, “Membership Criteria,” 
http://www.leru.org/files/general/leru_membership_criteria.pdf. (accessed: April 10, 2015). Chapter Five will 
give greater attention to the way in which Catholic universities can participate continue to participate in medical 
research, but to do so by deliberately and collaboratively addressing injustices in health.!!
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politically. Positively asserted, then, medical research has a responsibility to target those 
places where a lack of health restricts a person’s ability to flourish. Ellacuría describes 
research that allows for greater participation in the shaping of historical reality as humanized 
and historicized research. 
Humanization, Hominization, and Historicization 
 Humanized research strives for outcomes that allow for greater participation and 
flourishing of human beings, which becomes historicized in and through human praxis. In 
short, Ellacuría’s notion of humanized research is rooted in the biological fundament of 
ethics, namely, that research should promote biological possibility of participation in history 
(hominization). By this he does not mean biological enhancement or a constant perfection of 
human beings, but simply research that sustains life where life is most often threatened, 
amongst the poor. Research for biological sustenance, hominization, represents the baseline 
criteria for ethical research. Ellacuría argues, however, for a move beyond “hominzied” 
research in pursuing the humanization of research. 
 The humanization of research allows for the historicization of fewer injustices that 
limit human persons from greater participation in the actualization and shaping of historical 
reality.  “Humanization of the species presents itself as an ethical corrective and 
prolongation of the biological process of hominization. Humanization has to be conceived, 
then, as a process that optionally and projectively, continues and prolongs the biological 
process of hominization.”59  The process of humanization, therefore is not separated 
completely from hominization. The goal of humanized research, however, is not the 
postponing of death, and instead, humanized research allows for those who have historically !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
59 Ellacuría, “Fundamentacion,” 260. 
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been limited from participating in historical reality a better opportunity to shape the reality in 
which they live. The verification of the success or failure of humanized research takes place 
through the historicization .  
 The historicization of research requires some verification of the fuller participation 
of those who have been dispossessed by history is realized. The historicization of research 
takes place through the increased ability of human persons to “make history from nature and 
with nature…and educes the determinative influence of human praxis upon historical 
reality.”60 With respect to medical research, greater attention needs to be paid to measures 
such as Quality Adjusted Life Years (QALYs) and Disability Adjusted Life Years (DALYs). 
These quantitative public health measures, described in greater detail in the next chapter, 
give tangible content by which to measure research’s historicization. For Ellacuría, 
humanized and historicized research is socially responsible research that allows for human 
flourishing for those whose lives unjustly end before their time.61  
 While human existence is not all about biological life, it constitutes the first of 
human rights, a right that is not always realized.62 Often, this inability to realize this basic 
right to life can be limited by the technological capacity to deliver what is necessary to 
further human life. This is certainly true in many areas of the world in which not only 
medical technology is limited due to a variety of factors, but also basic necessities such as 
access to healthy foods, clean water, or health care remains unavailable to the majority. Thus, 
historicization and humanization of research, particularly medical research, cannot be !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
60  Burke, The Ground Beneath the Cross, 123. 
 
61 Ellacuría, “Fundamentacion” 261. 
 
62 Ignacio Ellacuría, “Historicization derechos humanos,” Escritos Filosóficos. Vol. 3, (San Salvador, El Salvador: 
UCA Editores, 2001): 439-440. 
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discussed apart from the science and technology that can address these pressing health 
needs.  
The Role of Technology 
 Technology and scientific advancements form a creative potential in the world that 
has resulted in both the ability to sustain itself against environmental threat and a desire to 
seek absolute control over that same environment.63 While both technology and science have 
been used in positive and transformative ways, Ellacuría notes that technology itself has 
been utilized increasingly as an instrument of control over the physical world that has 
resulted in the domination of the other. “Domination, above all, of the physical nature, by 
the knowledge of its laws and potentialities; domination of other human beings, but 
managing its disabilities and desires; domination of people, those that appear impotent 
before those that hold the power of technology.”64 Recalling the historical examples of 
medical research, the positive uses and the abuses of emerging research technologies can be 
seen throughout.   
 In particular, the juxtaposition of the development of the yellow fever or small pox 
vaccines with that of the global eugenic practices of the early 1900s reveals a stark contrast in 
the use of technology. While the vaccine programs sought control of a disease that was 
disproportionately affecting large groups of people, eugenics research sought to manipulate 
and control human beings by using technology that enabled certain lives to be valued more 
than others. Thus, it was not about enhancing participation in the construction of historical !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
63 Ignacio Ellacuría, “Tecnología apropriada,” Escritos Filosóficos. Vol. 3, (San Salvador, El Salvador: UCA 
Editores, 2001): 234.  
 
64 Ibid., 235, Dominación, ante todo, de la naturaleza física, médiate el conocimiento de sus leyes y potencialidades; dominación de 
los otros hombres, médiate el manejo de su debilidades y apetencias; dominación de los pueblos, que se bien impotentes ante quienes 
detentan el perdió técnico.  
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reality, but rather further restricting this participation. Today, though perhaps less 
maliciously, the vast majority of human beings who have limited access to benefits of 
technological advancements in medicine tend to be those economically disadvantaged in the 
two-thirds world. Thus, an ethical approach to the use and distribution of the benefits of 
research ought to be considered. This is particularly important because greater access to 
these technologies correlates with greater participation in the co-construction of historical 
reality.  
Just-Research 
 For Ellacuría, just-research confronts and takes responsibility for reality by 
addressing the fundamental necessities of the poor majority, a responsibility that can be 
easily be lost in the technological and financial scope of medical research. Technology and 
research holds the power to “create a humane or inhumane world, it can be an oppressor or 
a liberator, it can construct or destroy.” 65 Without historicizing the use of technology, its 
potential impact on greater participation of the majority in the development of historical 
reality can be lost. He argues, “A technology taken as a whole, that produces bad effects for 
the majority of humanity or that simply does not put their resources towards resolving the 
fundamental necessities for the majority of humanity is a bad technology.”66 If Christian 
universities continue to engage in medical research, then it is a theological, ethical, and 
epistemological imperative that this engagement prioritizes an option for the poor.  
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
65 Ellacuría, “Tecnología,” 240. La técnica puede hacer un mundo humano o inhumano, puede ser opresora o liberadora, 
puede construir o destruir, puede ocultar o revelar. 
 
66 Ellacuría, “Tecnología,” 248. Una tecnología que, tomada en su conjunto, produjera males profundos a la mayoría de los 
hombre o que simplemente no pusiera su recursos actuales a resolver las necesidades fundamentales a la mayoría de la humanidad, 
es una tecnología mala. 
!!
130 
 The university, in taking up social projection of reality as a fundamental task, has the 
option of focusing on the needs of the poor majority, or not. Ellacuría argues that the 
Christian university is in a unique place to choose to focus on the needs of the poor and 
vulnerable. “The university can best offer a scope for action in basic ways for political and 
structural change and begin to organize appropriate techniques for dealing with an 
independent voice; provide a number of upright professionals working for deep rapid 
change primarily in education and public sector; serve as a voice for the voiceless; provide 
immediate help to neediest through social outreach.”67 Essentially, the teaching, research, 
and service that takes place at universities has the opportunity to transform the way in which 
students, faculty, and staff contemplate issues of justice and how they can confront the 
injustices in society. While I will explore examples of just-research more comprehensively in 
Chapter Five, Ellacuría lays the groundwork for a just-research agenda that targets both 
preventive and curative research that stands to benefit those who consistently and unjustly 
bear the global burden of disease. 
 Advancing a global medical research agenda necessitates intentional and local 
collaborations with institutions outside the Catholic university who hold a shared sense of 
the mission of social projection. “Whether the new mission of the university is carried out, 
however, will depend primarily on what it is prepared to do in its own proper sphere of 
activity. The university must embody and implement its professed dedication to changing 
social structures in its threefold functions of teaching, research, and social outreach.”68 Given 
the limited control institutions have over available grants for investigations that aim at social !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
67  Ellacuría, “Is a Different Kind of University Possible?” 197-198. 
 
68  Ellacuría, “Is a Different Kind of University Possible?” 198. 
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transformation of the poor majority, this socially projected task presents unique challenges 
that I will address in the next chapter. However, despite these challenges, Ellacuría’s vision 
of a Catholic university—in particular his emphasis on social projection and the 
historicization of humanized research—offers valuable insights from which certain 
parameters can be established that allow for a more socially responsible approach to medical 
research.69 
Towards Socially Responsible Medical Research 
 
 Medical research functions as multi-disciplinary endeavor that requires the input of 
biologists, chemists, businesses, governmental and non-governmental agencies. At times, 
however, the most important people in medical research, the people affected by disease, 
remain excluded. Thus, developing a socially responsible and socially projected research 
agenda requires an emphasis on working with those in need of the benefits of medical 
research and against the very structures limit research on these diseases. For Catholic 
universities, in following Ellacuría’s liberationist approach, this necessarily considers research 
that promotes health and humanization globally.  
 Given that universities themselves are a part of a global network of institutions 
throughout low, middle, and high-income countries, it is important that global issues are 
reflected in their research agenda. 70  If Catholic universities were to project that reality in 
their research agendas, tangible repercussions would develop that would affect the way in 
which research priorities and methods were established. Building on Ellacuría’s insights as a !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
69 In addition to the challenges that one might pose to Ellacuría’s approach, examples will be given of instances 
of medical research project that demonstrate the possibility of a different approaches to medical research.  
 
70 This in fact was one of the key points of Fr. Adolfo Nicholas’s, Superior General of the Jesuits, address in 
Mexico City in 2010. He argued that there is increased competition amongst Jesuit universities and that the 
globalization of the world has not resulted in more collaboration, but rather increased isolation amongst 
institutions.  
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university president, philosopher, and theologian the five theses below draw out implications 
of his thought that would be reflected in the construction of a medical research agenda with 
an option for the poor. These five theses provide the foundation from which the rest of this 
dissertation will develop. 
Thesis One 
Medical research functions “communally” and shapes historical reality, which is unified and shared. 
  Ellacuría argues that what human beings share in “common” pertains to our 
biological nature, which is concretely affected by the historical actions of human beings. As 
the shapers of a unified historical reality in which all things come to be through one another, 
human beings, in one way or another, constitute the interdependent structure of historical 
reality. These unified historical actions undertaken by human beings, participate in the co-
construction of our commonly experienced reality. Medical research necessarily participates 
in the formation of the “common,” but medical researchers, often believed to be acting 
objectively making, can overlook the potential impact of research on society. Thus, medical 
research’s impact on society happens accidentally rather than deliberately.  
 A deliberate and targeted approach to medical research more intentionally 
participates in the development of research that aims to reflect research priorities that can 
transform the interdependent historical reality in which it exists.71 If historical reality is a 
unified reality, and human actions participate in the co-construction of that which is real, 
then medical research necessarily shapes the commonly experienced historical reality, both 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
71 While Ellacuría anticipated, perhaps sooner than others, the globalized world in which the university 
operates, the “community” in which research is conducted necessarily includes the institutions immediate and 
local community. However, given the internationalization of university collaborators, this “community-based” 
approach would necessarily include the social projection of the local and global community, as applicable. This 
opens up its own unique set of challenges and possibilities that will be taken up in chapter four.   
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currently experienced and in the future. It therefore follows that those engaged in the 
practice of medical research are faced with an epistemological option of choosing the place 
from which they will engage this task. Within this understanding, place can function both as 
a physical location and as the capacity for human beings to transcend one’s place and put 
oneself in the place of another human being.    
Thesis Two 
Medical research from the place of the poor reflects the Christian university’s mission and should promote 
research that allows for both homonization and humanization.  
 For Ellacuría and the perspective of liberation theology, it is the place of the poor—
understood as both a physical and intellectual place embodied by the socially, economically, 
and biologically disadvantaged—that provides the most authentic ground from which 
medical research ought to begin its inquiries. In many respects, the injustices and limitations 
experienced by the poor disproportionately result in premature death and higher propensity 
for contracting disease than those living in high-income countries. 72 Insofar as medical 
research, at least at its most fundamental level, is about the promotion of human health then 
it holds a minimum obligation to concentrate research efforts that allow for the hominization 
of the human person.  
 The hominization of research provides the foundation upon which a person is more 
fully able to participate in the construction of historical reality. At its most basic level, 
medical research focused on allowing for biological development to continue proves 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
72 A contemporary of Ellacuría’s and one of the foundational figures of liberation theology, Gustavo Gutierrez, 
defines the poor quite simply as those that die before their time. While this definition may raise questions, 
when this definition is applied to notions of healthcare and medical research there are people to whom this 
definition directly applies. More often than not they are correlate with Ellacuría’s socially and economically 
based definition above, see n. 35.  
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constitutive of human activity in history. Ellacuría’s emphasis on the place of the poor draws 
attention to the socio-historic locations where unjust poverty and the burden of disease limit 
the full participation of human beings in the co-construction of reality. Yet, the 
homonization of research does not adequately address the injustices often suffered. Rather, 
it is the humanization of research that proves most needed and serves as the goal of Catholic 
medical research.  
 The humanization of medical research promotes investigations that allow for greater 
participation of the poor majority who are de-humanized through a research process that 
ignores their needs. If homonized research promotes life, humanized research works to 
allow for the greater functioning of that life. 73 However, consideration of the exact research 
endeavors needs to begin by considering de-humanized research, i.e. those practices that fail 
to address the needs of the poor majority.74 If medical research does not foster the 
possibility of, and not necessarily the realization of, greater participation of the poor in the 
co-construction of historical reality, then this research fails to meet the standard of research 
that should be conducted at Catholic universities.  
Thesis Three 
Historicized medical research works through social structures to understand and reflect back a research 
agenda that is representative of reality. 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
73 In Chapter Five, I describe Comparative Effectiveness Research (CER) as a type of research currently 
supported by existing national funding structures that promotes improving quality health care outcomes by 
focusing on disease prevention, diagnosis, and treatment. CER centers its efforts on community participation 
in developing targets for research, as well as ensuring that the same community benefits from the research 
undertaken.! !
 
74 An example of dehumanizing research practices are those that allow disease like Ebola and cholera to 
continue to go under researched until arriving at a crisis point that is likely to impact Western, high-income 
nations. I consider both of these examples of neglect in medical research in the next chapter, focusing explicitly 
on the Ebola outbreak that started in 2014 and Haiti’s cholera epidemic that began in 2010.  
!!
135 
 The historicization of medical research provides the verification of humanized 
research through witnessing greater participation of populations that have statistically and 
experientially failed to thrive. The task of historicization is a foundational component of the 
university’s social projection. It is in and through the socially projected reality that the 
university is better able to target its approach to research approach in a way that allows for 
fuller participation of the poor majority in history. The historicization of research is not 
validated by making “historical” breakthroughs in medical research, but rather through 
participating in the development of new populations with whom to collaborate. Thus, 
through the process of historicizing medical research, it is necessary to identify barriers to 
humanized research and collaborators with whom overcoming these obstacles is possible.  
Thesis Four 
Medical research, which develops from sentient intelligence, should work cooperatively with other academic 
disciplines, including theology and philosophy, to ensure that its interests and values address reality as it is 
seen and experienced by others. 
 A tendency exists in medical research to pursue newer technologies and innovations 
in a presumed objective and scientific way. However, if all intellection—inclusive of 
scientific thought—is sentient and rational, then despite medical research’s attempts to be 
objective, it operates within a particular and defined set of values, motivations, and interest. 
Moreover, following Zubiri and Ellacuría, these values, motivations, and interests are not 
necessarily intrinsic to medical research itself, but have been shaped by other historical actors 
whose interests, motivations, and values co-construct the reality in which research takes 
place. Therefore, those engaged in medical research must pay attention to the extrinsic 
influences on the priorities established for research agendas by collaborating with other 
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academic disciplines. The intra-university collaboration on the specific task of medical 
research, particularly, with the disciplines of theology and philosophy, broadens the 
reflective nature of the research task and its foundation in the university’s mission with 
respect to justice.  
 For liberation theology, questions of justice arise from stories and experiences of 
injustice, presenting a unique set of concerns and values that can complement, challenge, 
and/or affirm the task of medical research. Liberation theology and philosophy, in particular, 
would be highly critical of medical research that appeared to be motivated by economic 
incentives or that deliberately sought to benefit the wealthy majority who could pay for 
treatments and medications, over the poor. By approaching medical research from the 
perspective of liberation theology, an emphasis would be placed on validating the experience 
of suffering and working with the poor in search of an alternative. It is here that other 
academic disciplines prove necessary in an effort to reimagine medical research through the 
lens of under-researched populations.   
Thesis Five 
Developing a research agenda focused on the poor majority functions as a necessary political task that leads to 
both confrontation and collaboration with public and private institutions engaged in medical research.  
 A university-based medical research agenda developing from the place of the poor 
occurs in an historicized way and necessarily turns to partners outside the university to serve 
as collaborators. These collaborative partners prove fundamental in determining the 
appropriateness of medical research within a particular population. In this way, it is not the 
university grantees or the public/private grantors who establish the medical research agenda, 
but rather those immersed with in the social reality of the poor majority. However, given the 
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current process for funding research initiatives, humanized research aimed at addressing 
social inequalities in health requires a targeted approach to pursuing grants currently 
available in existing funding structures, but also with the flexibility and willingness to seek 
alternative sources for funding.  
 Ensuring that a university’s research agenda takes the poor majority as the horizon of 
its activity may require the partnering and dialoguing with institutions that do not necessarily 
share the same mission. As will be explored in the final two chapters, academia and industry 
have two different objectives—education and profit—and have historically been important 
collaborators that have allowed for the development of both institutions. However, the 
university’s task—guided by social projection—also operates within its own sphere of the 
values, one of which is justice.  
 Just-research, then, works to create structures that can contribute to social change. 
One strength of Ellacuría’s model for the university is its openness to dialogue with others 
that elicits the stories and experiences of injustice in order to transform structures that 
perpetuate its prevalence.  By engaging the ideological other and remaining grounded in the 
values and motivations at the heart of the Catholic university, potential collaborative 
partners may emerge that advocate for a broader understanding of medical research that will 
better enable and promote value-based research that takes the poor majority as the horizon. 
While this liberated approach to medical research presents its own challenges and critiques, 
in certain instances, examples of this type of research already exist. Before taking up these 
examples in the concluding section of Chapter Five, I now turn to the injustices prevalent in 
the practice of medical research itself.  
 
!!
138 
Conclusion 
 University-based medical research that meets the needs of the poor majority presents 
a challenging task given the diverse actors that shape the research agenda. However, 
Ellacuría’s philosophical and theological project provides a fundamental epistemological 
shift from the scientific agenda that characterized the Enlightenment and Baconian science.75 
The emphasis on expanding the horizons of science and developing new technologies 
perpetuates a social practice that ignores those who suffer from the most acute forms of 
health challenges that remain neglected. Through the socio-critical lens of liberation 
theology, the injustices within this practice are unmasked when viewed from the perspective 
of the poor.   
 For Catholic universities the option for the poor represents a normative foundation 
from which to address issues of justice. While the universities articulate their commitment to 
justice with respect to service and education, it remains unclear how justice shapes the 
practice of medical research. In the next chapter I will describe the development of the social 
practice of medical research and how it has emerged within academia as increasingly 
economic driven task. The task of the Catholic university, explored in Chapter Five, centers 
on how to be an institution that participates in the shaping of a more socially responsible 
research agenda.!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
75  Bishop, The Anticipatory Corpse. Bishop takes up a genealogical approach, drawing on Foucault, to describe 
the way in which the technologization of the body has generated a fundamental discord between the medical 
approach to death and dying compared to one rooted in Christianity. What I want to do is similar, but using 
medical research and the emphasis on the poor as an epistemic category by which to make a similar shift. Thus, 
by maintaining a Baconian and technology perspective, one loses the context in which research is conducted 
and who stands to benefit. 
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CHAPTER FOUR 
RESEARCHING REALITY 
Introduction 
 In this chapter, I follow Zubiri and Ellacuría’s claim that human intellection 
functions simultaneously as a sentient and rational process to argue that science and medical 
research, therefore, never operate as a purely neutral or objective practice. Scientific research, 
like all other forms of human activity, both shape and are shaped by historical reality. Thus, 
the context from which research one approaches medical research influences how it 
develops and who benefits from those developments. In this chapter, I am particularly 
concerned with socio-political values within the development of medical research, who has 
benefited over time from the development of research, and, conversely, who did not. Finally, 
I address the ways in which research can begin to recognize and advocate for those who 
have been unjustly overlooked within the practice of medical research.  
 In his neo-Aristotelian ethics, Alasdair MacIntrye argues that all practices have a 
social dynamic that must be established as a “good” activity. The good of a particular activity 
both comes from and develops in relationship to social contexts. Within this activity, agreed 
upon goods of particular practices emerge that prove constitutive of the human activity in 
and of itself. Thus, a practice is: 
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any coherent and complex form of socially established cooperative human activity 
through which goods internal to that form of activity are realized in the course of  
trying to achieve those standards of excellence which are appropriate to, and partially 
definitive of that form of activity, with the result that human powers to achieve   
excellence, and human conceptions of the ends and goods involved, are 
systematically extended.1  
 
Here, MacIntrye speaks to the cooperative nature of human practices and the inherent goods 
particular to them. At the same time, these goods have to be identifiable and, through 
“human powers,” are brought to fruition. In Chapter One, I addressed the notion of medical 
research as a practice that at its most basic level concerns itself with the promotion of health. 
In this chapter, I argue health has not always been seen as the goal of medical research.  
Within the development of research funding, serious questions emerge whether the 
improvement of health played as prominent of role as it should have in creating funding 
structures for medical research.  
 A variety of factors influenced the development of funding practices for medical 
research. These developments, however, should not be viewed as distinct from the goal of 
medical research itself, serving instead as a complement to the process. Chief among these 
developments has been the important relationship between industry and academia. Industry, 
in this case, is understood as businesses whose primary aims are the buying, selling, 
marketing, and development of goods able to be sold as they pertain to health. The first 
section of this chapter focuses on the gradual development of the relationship of academia 
with the pharmaceutical industry.  
 The origins of this collaboration in the U.S. center on developments both prior to, 
and in the midst of, the World Wars. It was at this time that the U.S. government formed !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1 Alasdair C. MacIntyre, After Virtue: A Study in Moral Theory (Notre Dame, Ind.: University of Notre Dame 
Press, 1981). 187. See also, MacIntyre, “Social Structures and their Threats to Moral Agency,” Philosophy, 74, no. 
2, (1999), 311-29.  
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collaborative relationships with universities. During the Wars, government, university, and 
industry officials focused on developing wartime technology. However, at the conclusion of 
the Wars, there was a desire to both continue the progress made in research and to find new 
researchers capable of expanding these efforts to fields beyond wartime technology.  
 The second section of this chapter, then, describes the evolution of the collaborative 
relationships between government, industry, and academia as essential to the way funding 
structures were established for research, with economics becoming a key motivator of both. 
The prioritization of economic gain influences the decision to pursue certain research 
endeavors over others. These choices contribute to disparities between those who benefit 
from medical research and those whose needs go unnoticed in the establishment of research 
priorities.   
 The disparities in research manifest themselves between the diseases suffered by 
persons from low and middle-income countries compared to those of high-income 
countries. People living in low and middle income countries comprise the majority of 
persons in the world who, incidentally, disproportionately bear the global burden of disease, 
as measured by disability adjusted life years (DALY). DALYs serve as a statistical 
measurement for the total number of life-years lost due to death and/or disability. Thus, in 
order to create an agenda that aims to improve health, DALYs prove an important tool that 
indicates the geographic location of those whom have the greatest unmet health needs. Yet, 
despite knowing those who suffer the greatest burden of disease, relatively little has been 
done to significantly close the research gap, which I will explore in section four. In fact, the 
research efforts of high-income countries largely ignore the needs of these countries. One 
need look no further than the most recent failures of the global management of the Ebola 
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outbreak, which resulted, in part to insufficient attention to a disease that had confined itself 
primarily to West Africa.   
 In section five, I turn to a commentary by Paul Farmer, physician, global health 
expert, and medical anthropologist, on the recent Ebola outbreak. Farmer argues that 
improving a population’s health begins with a health care delivery system, public health 
infrastructure, and general readiness with developments from medical research to care for 
the health of another human being.2 It was only when Ebola entered the Western world that 
a bevy of concerned persons began to raise awareness about the need to research Ebola and 
other global diseases that disproportionately target the poor majority.  
 The final two sections address the importance of raising awareness about diseases by 
highlighting the role advocacy groups have played in altering the research agenda. One of the 
primary successes of advocates, particularly within the HIV/AIDS movement, has been 
their ability to communicate the stories of the patients to the general public. Too often, the 
stories of the poor and marginalized go unheard. If medical research is going to be a practice 
that improves health, then the stories of the “unhealthy” have to be heard. While advocacy 
and narrative efforts are not cure-alls, they can impact the way in which research is 
conducted.  
 The social practice of medical research functions as a complex and financially 
incentivized collaboration that often undervalues the health needs of the majority of the 
world. Yet, within this structure institutions have a responsibility to maintain the focus of 
medical research on health. Advocacy efforts prove important to this process by speaking 
for the research and health needs of those who unjustly bear the burden of curable and/or !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
2 Paul Farmer, “Ebola,” London of Books, 36, no.20 (2014), 38-39, accessed: November 3, 2014, 
http://www.lrb.co.uk/v36/n20/paul-farmer/diary Review. 
!!
143!
controllable diseases. While this chapter takes up the social challenges within medical 
research, the final chapter will draw examples of research practices that maintain a focus on 
health and just-research practices that befit Catholic universities.  
The Industry-Academia Collaboration 
 Policies adopted by the U.S. government fueled collaborative efforts between 
academia and industry.3 As shown in Chapter One, during World War I and II, the 
government had partnered with universities and industry officials to develop new 
technologies for the immediate use in war. As the war drew to a close, it was realized that a 
model had been established for generating new knowledge that, at the same time, provided 
an economic stimulus for the U.S. The creation of new knowledge allowed for the 
production of goods that could then be sold on the market. However, a challenge after the 
war arose from the need to put new knowledge and products to non-wartime use.   
 While some health related research had been going on as part of the war efforts—
development of vaccines to be used in the geographical areas in which soldiers were fighting, 
as described in Chapter One—the investments made by the government were minimal. 
Post-war, the U.S. continued to invest in technology-based research but also expanded its 
scientific research relating to health. The leader of this effort was Vannevar Bush, head of 
the U.S. Office of Scientific Research and Development (OSRD) during and after World 
War II.  
 
 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
3 The focus of this chapter centers on U.S. based research practices because they are the largest funders of 
government-based bio-medical research. Moreover, the intellectual property policies developed here are similar 
to, and in certain cases established the model that many other high-income countries follow.  
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Vannevar Bush and the Endless Frontier 
 Bush’s proposal to Roosevelt outlined the importance of the government’s post-war 
investment in research through the education of soldiers who would serve as the next 
generation of scientists, and emphasized the importance of continuing to fund university-
based research.  On both fronts, the hope was that these efforts could lead to a source of 
revenue for the U.S. economy through the production of new knowledge. Bush’s landmark 
report, Science the Endless Frontier, signaled two important concerns that the nation faced 
following the war’s conclusion. 4 The first highlighted the need to put soldiers to work 
returning from war, and the second concerned continuing the economic dividends that the 
U.S. reaped by investing heavily in scientific research during the war. While these 
investments were primarily technology-based, Bush argued for new forms of research that 
would invest in the public good, one of these goods being health. As Bush’s ideas began to 
take form, the National Institute of Health started investing its research dollars into 
universities and medical schools.  
  Medical schools and universities served as the ideal places to make investments in 
scientific research because of their ability to serve as centers of education and their track 
record of collaborating with government and industry.5 First, universities were able to meet 
the need of educating returning soldiers for new jobs in scientific research. Bush 
commented, “Many had begun their studies before they went to war. Others with capacity !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
4 Vannevar Bush, Science, the Endless Frontier: A Report to the President (Washington: U.S. Government, 1945). 
 
5 Richard C. Atkinson and William Blanpied, “Research Universities: Core of the US Science and Technology 
System.” Technology in Society 30 (2008): 30-4. Chief among these collaborations came from University of 
Chicago, Columbia University, and Massachusetts Institute of Technology, all of made important contributions 
to the development of the atomic bomb. Thus, not only were universities collaborating with government and 
industry, they were doing so on some of the most top secret and significant developments—albeit a quite 
sinister one—of the twentieth century.  
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for scientific education went to war after finishing high school. The most immediate 
prospect of making up some of the deficit in scientific personnel is by salvaging scientific 
talent from the generation in uniform.”6 Bush saw academia as playing the role of re-
supplying the scientific work force with returning soldiers for future research. Bush and 
others, moreover, hoped that increasing the number of scientists at work in education held 
potential for stimulating industrial development emerging from new innovations.  
 At this time, most of the health-related research centered on diseases that could be 
contracted overseas during the war: yellow fever, typhus, malaria, and various sexually 
transmitted diseases. The funding for this research came from a combination of private 
investment, e.g. Rockefeller Institute, and public grants targeting academia and industry 
researchers willing to participate in the war effort. The OSRD was working closely with both 
industry and academia “to develop penicillin, synthetic antimalarial drugs, steroids, and 
replacement blood products, the companies used their preexisting connections with 
academic researchers to meet the wartime demands.”7 Thus, the collaborative relationship 
Bush proposed was nothing new, but rather an attempt to expand the success generated 
during the war effort.   
 Post-war research efforts shifted, however, to focus on cancer, cardiovascular, polio, 
sexually transmitted diseases, e.g. syphilis, and the development of neurological drugs.8 While 
Bush understood that scientific progress itself was not a “panacea for individual, social, and 
economic ills,” it was essential for ensuring “health, prosperity, and security as a nation in !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
6 Bush, Science, the Endless Frontier.  
 
7 Dominique A. Tobbell, “Allied Against Reform: Pharmaceutical Industry–Academic Physician Relations in 
the United States, 1945–1970,” Bulletin of the History of Medicine 82, no. 4 (2008), 882. 
 
8 Paul Starr, The Social Transformation of American Medicine: The Rise of a Sovereign Profession and the Making of a Vast 
Industry (New York: Basic Books, 1982), 343-347. 
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the modern world.”9 As an example, research efforts around cancer engendered widespread 
marketing campaigns and fundraising efforts, which helped to raise awareness about the 
positive impact that research can have on the lives of Americans.10 In addition to generating 
public support, the U.S. government saw investment in research as a way to emphasize the 
importance of strong science behind the development of new drugs.  
Scientific Support 
 The U.S. government’s emphasis on the basic sciences as the heart of a medical 
education allowed for the strengthening of the regulations for new drugs with the support of 
scientific data.11 Thus, universities with schools of medicine saw an influx of scientific 
researchers and an opportunity to interrogate the questionable science behind many of the 
drugs on the market in the early half of the twentieth century. One such case resulted in the 
death of some 107 people following the consumption of a new drug Elixir Sulfanilamide.12 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
9 Bush, Science, the Endless Frontier. 
 
10 Ken Burns’s recent documentary utilizes the historical narrative of Siddhartha Mukherjee, The Emperor of All 
Maladies: A Biography of Cancer, (New York: Scribner, 2010). The documentary is: Barak Goodman, director, 
“Cancer: The Emperor of All Maladies,” PBS Video, March 30 – April 1, 2015, 
http://www.pbs.org/kenburns/cancer-emperor-of-all-maladies/home/.  
 
11 Abraham Flexner and Daniel Updike, Medical Education in the United States and Canada: A Report to the Carnegie 
Foundation for the Advancement of Teaching (New York: Merrymount Press, 1910); Lawrence H. Diller, “100 Years 
Later, the Flexner Report is Still Relevant,” Hastings Center Report 40, no. 5 (2010), 5.; Starr, The Social 
Transformation of American Medicine, 118-126. By turning to medical schools, the government sought benefit from 
the renewed emphasis on the basic sciences as the heart of a medical education. The influx of scientific 
researchers in university and medical education would allow for the government to be more assured that the 
scientific developments that could be applied would be more rigorously studied. The government’s concern 
about the questionable science behind many of the drugs that were on the market in the early half of the 20th 
century was reflected in the tightening of regulations controlling the selling and marketing of drugs. In short, 
universities and medical schools came to serve as an important interchange between publicly funded research 
and potential economic returns in an increasingly regulated drug industry. 
 
12 Peter Temin, The Origin of Compulsory Drug Prescriptions (Cambridge, Mass.: Dept. of Economics, Massachusetts 
Institute of Technology, 1978); Peter Temin, “The Origin of Compulsory Drug Prescriptions.” The Journal of 
Law and Economics 22, no. 1 (1979), 91; Hany Marks, “Revisiting the Origins of Compulsory Drug 
Prescriptions,” American Journal of Public Health 85, no. 1 (1995), 109. 
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Though there were prior Food and Drug Administration regulations, the 1938 regulations 
reinforced the importance of sound science behind the development of new drugs.  
 The regulation standards for the marketing and selling of drugs had come under 
heightened scrutiny by the FDA through policy developments in 1906 and 1938. In 1906, 
the “Pure, Food, and Drug Act” outlawed the use of false or misleading drug labels. In 1938, 
the “Food, Drug, and Cosmetic Act” adjured these same companies to demonstrate the 
safety of their products before the FDA approved them for marketing. Academic scientists 
found their domain of expertise in demand on multiple fronts, as educators, as regulators, 
and as innovators. From the government’s perspective, universities and medical schools 
provided the space in which new discoveries could be made and the science behind the new 
drug discoveries could be verified. Industry, given the increased regulations, likewise, needed 
to partner with academia in order to comply with FDA guidelines. The drug industry knew 
that it needed its products to be more scientifically sound, but additionally saw future 
possibilities in collaborating with academic researchers.  
 Through the initial relationships between industry and academic institutions, the 
drug companies ensured their products were up to FDA standards, which led to financial 
arrangements with academic research centers. In detailing the history of industry and 
academic partnerships, Tobbell described how one of Harvard University’s vice-presidents 
courted a relationship with George Merck to “advance biomedical education and 
research…”13 When this courtship succeeded, the money received did not have any 
stipulation that Harvard would put it toward a particular research endeavor, but rather would 
be used for the overall development of students and infrastructure. From the perspective of !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
13 Tobbell, Allied Against Reform, 884. 
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the industry, however, these relationships built up academic allies who could offer scientific 
support for their products. Recognizing the need for collaborating with scientists, industry 
officials, e.g. George Merck, Eli Lilly, reached out to universities to form partnerships.  
 As the possibilities of collaboration were realized between universities and industry 
officials, the government increased funding for research, and the FDA increased regulations. 
The tightening of regulations further strengthened the partnership between academia and 
industry. By the late 1950s and early 1960’s the partnerships had grown to the point that 
both academia and industry became leery of any “non-scientific” government influences for 
fear that they would begin to dictate what they could research, exerting control beyond 
regulations. “Academic physicians and the industry regarded the scientific weakness of the 
FDA as a very real threat to the integrity of pharmaceutical innovation and to clinical 
research, and thus to the public’s health.”14 The scientific weakness of the FDA, however, 
did not stop them from tightening their regulations on newly developed drugs. 
 The 1962 FDA regulations allowed the FDA to take greater authority over the 
testing, manufacturing, and marketing of drugs and served to solidify the relationship 
between academia-industry. The increased regulations by the U.S. government strengthened 
the relationship between and academic researchers and industry because industry officials 
needed to ensure that their products could pass FDA regulations. While the details of this 
arrangement lie beyond the scope of the argument, the nexus of relationships between 
government, academia, and industry create a story in which all three entities mutually relied 
on and influenced the others.  
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
14 Tobbell, Allied Against Reform, 888. 
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 The collaborations between the three players—industry, academia, and politics— 
though complex, have shaped the way in which research has developed. The U.S. was 
concerned with maintaining the collaborative research efforts that had made significant 
contributions to the public good during the war efforts. Academia, facing a renewed 
dedication to science and medical education, sought to collaborate with government and also 
industry officials regarding the scientific aspect of drug development. Industry saw these 
partnerships as opportunities to deepen the science behind their products, and also to 
increase its marketability though allying with physician-researchers to explain the validity of 
the product. This junction of collaborations, forecasted in Bush’s proposal, was solidified by 
the hefty investments in research made by the NIH. 
Funding Research 
 The NIH’s budget dramatically increased U.S. investment in health-related research 
between 1945-1970. In 1947, NIH funding for research was slightly over four million 
dollars. Within ten years, the total dollars invested would reach $100 million. In addition to 
investing in research, the government also saw the need to develop the research 
infrastructure of the NIH. Thus, the NIH saw its own budget—not just that portion used 
for grant awards—expand from $8 million in 1947 to more than $1 billion by 1966. 15 This 
significant public investment created jobs, and generated practical health benefits and 
products that could be invested in by private industry in the hopes of making a return on 
their investment. This period of research is often referred to as the “golden age” of research, 
where the resources being invested were rapidly yielding new knowledge and financial gains 
through grant-based initiatives.  !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
15 Victoria Harden, “A Short History of the National Health Institute,: NIH Medical Arts and Printing, 
http://history.nih.gov/exhibits/history/docs/page_06.html (accessed May 1, 2014). 
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The Golden Age of Research 
 The NIH grant awards were intended to support research projects and any additional 
costs incurred by the research institution itself.  Howard Schachman, a researcher, professor, 
and an influential figure in the development of grant review process, described the landscape 
of research in the 1950s as modest. He held a $7,000 grant from the National Science 
Foundation to help fund his research. Though he realized the possibility of other larger 
grants, he was content with the one that he had.16 The grant offered support for his research 
and provided minimal assistance for ancillary staff.  “Graduate students in the early 1950s 
were supported as teaching assistants or research assistants funded by small grants to faculty 
members or departmental funds. A typical laboratory would have one or two graduate 
students, a technician, and perhaps one postdoc, a far cry from the research group of 
today.”17 In a short time, the size of a research team, which is today composed of multiple 
graduate students, post-docs, and research assistants, the source of paying for those 
researchers evolved from a university-incurred expense to one absorbed frequently by grant 
awards.18  
 Grants were, and still are, awarded through a peer-review process that considers a 
wide-range of factors: research design, purpose, experience of researcher/s, budgets, and 
appropriate “fit” for the aims of the grants itself. Peer-review serves as the standard process 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
16 Howard Schachman, “From ‘Publish Or Perish’ to ‘Patent and Prosper.’” The Journal of Biological Chemistry 
281, no. 11 (2006), 6889; Nicole Kresge, Robert Simoni, and Robert Hill, “Innovations in Ultracentrifugation 
and an Analysis of Aspartate Transcarbamoylase: The Work of Howard K. Schachman,” The Journal of Biological 
Chemistry, 282, no. 21 (2007), e16. 
 
17 Schachman, “From ‘Publish Or Perish’ to ‘Patent and Prosper.’” 6891 
 
18 This represents an important distinction from today that will be described in a bit more detail below. The 
distinction is between “hard money,” i.e. built into the university’s budget, versus “soft money,”salaries that are 
only received through the procurement of grants.   
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for determining grant awards.19 At NIH, the review process is divided into two levels. The 
first review takes place with a team of “expert reviewers” who consider the scientific and 
technical value of the projects. This is an appointed review board of individuals who have 
expertise relevant to the proposed grant. The initial panel is responsible for scoring the 
application from one to five—one being the top score and five the lowest—and compiling 
comments from the grant reviewers. The grant and its score are passed on to the second 
level of review.   
 The second level of review takes place with both public representatives and scientific 
experts who are appointed to the NIH review council. They evaluate the project based on 
seven core values of NIH peer review: expert assessment, transparency, impartiality, fairness, 
confidentiality, integrity, and efficiency.20 While the 1-5 score is taken into account, the 
priorities of the NIH, special projects, potential overlaps, and the “general fit” of research 
needs are considered.  
 It is important to note that the research needs have been determined historically 
from within the scientific research community, though different types of researchers are 
represented—i.e. basic, epidemiologic, clinical, quantitative, and qualitative investigators—
their discipline is science. In this way, the focus of the research review process remains 
rooted in an epistemology that views science as an objective practice. Yet, with the !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
19 The process described here comes from NIH. Though NIH’s process functionally reflect the standard way in 
which peer review takes place. Laura Bonetta, “Enhancing NIH Grant Peer Review: A Broader Perspective,” 
Cell 135, no. 2 (2008), 201; Medical Research Council, “Our Mission,” Medical Research Council - United 
Kingdom, http://www.mrc.ac.uk/About/Missionstatement/index.htm (accessed October 23, 2014); Institut 
national de la santé et de la recherche médicale, “The Institute Mission,” Institut national de la santé et de la 
recherche médicale, http://english.inserm.fr/what-s-inserm/the-institute-missions (accessed October 23, 
2014).; Indian Council of Medical Research, “About ICMR,” Indian Council of Medical Research, 
http://icmr.nic.in/About_Us/About_ICMR.html (accessed October 23, 2014). 
 
20 National Institutes of Health, NIH Peer Review Process: Grants and Cooperative Agreements (Washington, D.C.: 
Department of Health and Human Services, 2013). 
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epistemological shift called for in the previous chapter, the transformative effects of research 
on historical reality have to be viewed more broadly than their scientific impact.  
 As seen below, the impact of research decisions on poor and vulnerable populations 
cannot be viewed as neutral. Therefore, the needs of the community in which the research is 
intended to benefit needs to play a part in setting priorities for awardees.21 While this process 
continues to be improved upon, it was not even on the radar of the award committee during 
the research’s “golden age.”  
 During the research boom, grant applications in the 1960s and into the 1970s 
enjoyed a near 60% success rate. This high success rate in grant awards allowed universities 
to use research dollars for needs beyond the scope of the research process itself. The influx 
of research dollars due to successful grant applications from university researchers led to the 
allocation of that money to cover a host of costs that the university attributed to research. 
These costs included construction costs for new buildings, administrative fees, graduate and 
post graduate fellowships, and eventually faculty salaries.  Research costs would eventually 
be used to justify two or three months worth of salary, but this gradually led to “establishing 
‘soft money’ faculty positions.”22  
Soft Money 
 Soft money positions signify that the faculty-researcher is responsible for raising a 
small to significant portion of one’s salary through grants. This is opposed to hard money 
positions, in which the faculty member is guaranteed and accounted for in the university’s 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
21 This review process can be contrasted with that of Comparative Effectiveness Research (CER) described in 
the next chapter. CER grant review intentionally focuses on the input of the community that the research 
intends to benefit.  
 
22 Schachman, “From ‘Publish Or Perish’ to ‘Patent and Prosper,’” 6894.  
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budget. Schachman notes that this has become common practice, particularly in medical 
schools. He recalls that one institution in California has been allocated state funds for 30 
full-time faculty salaries, and approximately 300 faculty members held those 30 slots. In the 
case of this institution, faculty members are required to raise around 90% of their salary 
from grant awards. With this type of system, universities were able to create much larger 
science departments than before, thereby justifying the construction of new buildings and 
research facilities to house their growing faculty. The researchers raising funds for their own 
salaries, coupled with the construction of new campus buildings, however, leads to 
discontent between university administrators and research faculty.  
 Given the amount of public funds used to support faculty time and construction of 
research buildings in the 1970s, complaints surfaced about too little of the grant money 
being used to support research. “Research scientists, faced with stringent budgets and with 
ratings on their grants below the funding level, argued strenuously that indirect costs 
amounting to billions of dollars annually, should be reduced markedly. In their view, the 
money saved could then be used to support more research.”23 As more questions arose 
about the university’s use of funds, so too did difficulties regarding the university’s ability to 
cover “indirect costs” with grant money. While successful applications from the mid 1960-
1970s were consistently near 60%, this figured dipped significantly in the 1980s and settled 
closer to 20%.24 This shift can be attributed, in large part, to changing priorities within the 
U.S. budget, which led universities to look for new sources for research funding.  
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
23 Schachman, “From ‘Publish Or Perish’ to ‘Patent and Prosper,’” 6895. 
 
24 Toby A. Appel, Shaping Biology the National Science Foundation and American Biological Research, 1945-1975, 
(Baltimore, MD: Johns Hopkins University Press, 2000).  
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 The economic benefit research afforded for universities increased throughout the 
1960s only to level off at the dawn of a new decade, forcing universities to explore 
alternative sources of funding for researchers.  Paula Stephan noted two factors in particular: 
the Vietnam War and the Mansfield Amendment. The 1969 Mansfield Amendment barred 
any research that was not directly targeted for the benefit of military function, and therefore 
restricted the use of government funds for university-based research.25 However the 
government had not been the only entity investing in research throughout this “golden age.” 
Universities’ own contributions “increased by 55 percent, and by contributions from all 
other sources, which included philanthropic organizations, that grew by 68 percent. 
Industry’s expenditures on academic research increased by almost 70 percent.”26 Thus, given 
the multiple investors and competition for research dollars, universities had to find a way to 
keep sources of revenue flowing in order to invest in new buildings, pay top researchers, and 
continue the philanthropic investment, all while NIH funds had stalled. Nevertheless, 
universities were determined to find ways to pay their researchers and generate some return 
for the intellectual property being developed at their institutions.27 While there was much 
debate about the patenting of research for industry purposes, universities themselves 
remained disinterested in patenting rights until the mid 1970s. 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
25 Paula Stephan, “The Endless Frontier: Reaping what Bush Sowed?” in The Changing Frontier: Rethinking Science 
and Innovation Policy, ed. Adam Jaffe and Benjamin Jones (Cambridge, MA: National Bureau of Economic 
Research, forthcoming), 2. 
 
26 Stephan, “The Endless Frontier: Reaping what Bush Sowed?” 18. 
 
27 Ibid. The number of institutions offering science PhDs almost tripled from 80 at the end of the war to 224 
by 1974. This made acquiring grants most difficult, particularly as NIH investments slowed. Thus, with 
hundreds of PhDs being produced each year, industry began to be able to pick off researchers and could also 
pay much better than academia. Here one can see the convergence of science, business, politics, and education 
affecting the way in which research is structured. While university researchers had to earn their soft-money 
salaries, industry PhDs were guaranteed theirs. 
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Patents and Current Research Funding 
 The slowing of NIH funds that emerged in the late 1970s and early 1980s, began to 
shift the position of universities with respect to patenting rights. As funding sources began 
to wane throughout the 1980s, universities sought other ways of maintaining the revenue 
flow to which they had grown accustomed. Concurrently, research itself became a more 
expensive undertaking, while pharmaceutical and newly emerging biotechnology companies 
tended to reap the financial benefits.  
 While no one would doubt the importance of ensuring the quality and safety of a 
drug, this comes at a cost. Significant resources, both financial and employee time, are 
devoted to clinical trials. 28 This has been particularly true as researching targeted the defeat 
of certain diseases, e.g. Nixon’s famous declaration of “war on cancer.”  Therefore, not only 
were universities engaged in basic science research, but medical campuses—institutions with 
both a university and a hospital—were now more heavily engaged in expensive and time-
consuming clinical trials. While technological breakthroughs and a spike in resources 
devoted to clinical trials led universities to seek alternative funding sources, it is was legal 
action that allowed universities to patent their intellectual property.  
Bayh-Dole and Diamond v. Chakrabarty 
 Two important events, the passage of the Bayh-Dole Act and the U.S. Supreme 
Court ruling Diamond v. Chakrabarty, both in 1980, solidified efforts to allow for the patenting 
of intellectual property derived from federal funds. The first of these developments, the 
passage of the Bayh-Dole Act, offered an opportunity for researchers, their university, and !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
28 Daniel Callahan, What Price Better Health?: Hazards of the Research Imperative (Berkeley and Los Angeles: 
Universitty of California Press, 2003), 218; Kaushik Sunder Rajan, Biocapital: The Constitution of Postgenomic Life 
(Durham: Duke University Press, 2006), 6.  
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private industry to more fully participate in the economic aspects of research.29 The act 
established a uniform patent policy in which universities and other non-profit research 
entities could “retain the title to inventions made under federally-funded research 
programs.”30 This was a reversal of years of policy that allowed the government to retain the 
intellectual property rights of developments that came from government funds. This 
legislation was reinforced by another development, the Supreme Court ruling in Diamond v. 
Chakrabarty.  
 The Diamond v. Chakrabarty ruling allowed for the patenting of a biologically 
engineered microorganism that was designed to be able to break down crude-oil spills.31 The 
consequences of this ruling were two-fold. Most importantly, it marked the first instance of 
patenting a product derived from federal funds. Secondly, the patent was for a biologically 
created organism. Thus, as biotechnology has become more sophisticated, the ability to 
create biologically engineered organisms has continued to grow and patents increase. 32 
While the Supreme Court ruling promoted a close 5-4 decision, it paved the way, along with 
Bayh-Dole, for patenting of new biotechnology and the potential for generating a substantial 
financial gain from those research endeavors.  !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
29 The act’s passage enabled greater collaboration with industry representatives and served as an instantaneous 
model for way in which research was conducted globally. The move to be open to the commercialization of 
publicly funded research was not exclusively a U.S. phenomenon. Similar legislation has been enacted in: Brazil, 
China, Denmark, Finland, Germany, Italy, Japan, Malaysia, Norway, Philippines, Russia, Singapore, South 
Africa, South Korea, and United Kingdom. 
 
30 Association of University Technology Managers, “Bayh Dole Act,” http://www.autm.net/home.htm 
(accessed December 15, 2014). 
 
31 Callahan, What Price Better Health?, 219; Rajan, Biocapital , 6. 
 
32 John Schwartz, “In Gene Patenting Case, Company Vows to Fight,” New York Times, 2009, 
http://thelede.blogs.nytimes.com/2009/05/13/in-gene-patent-case-company-vows-to-fight/ (accessed 
February 3, 2014); Douglas Robinson and Nina Medlock, “Diamond V. Chakrabarty: A Retrospective on 25 
Years of Biotech Patents.” Intellectual Property & Technology Law Journal 17, no. 10 (2005). 
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 Today, patenting practices at universities and non-profit organizations have become 
commonplace in the basic science research. The Association of University Technology 
Managers, the association of managers that oversees technology transfers at universities, 
serves as a gauge for the interaction between academia and industry. Since the passage of the 
Bayh-Dole Act, Callahan notes that as of the early 2000s, “American universities now own 
more patents than the twenty-five largest pharmaceutical and the biotechnology companies 
put together.”33 Patenting rights generally allow the intellectual property holder to maintain 
sole possession of the patent for 20 years from the time of application. This exclusive period 
of ownership, has allowed American universities to develop more than 4,000 companies and, 
according to AUTM survey data, has generated significant financial rewards, netting $36.8 
billion in 2012 alone.34 Patenting, while not problematic in and of itself, does complicate the 
motivations and values operating within research efforts, particularly as industry assumes 
more and more control over the research and development of new drugs. This shift, both 
within the university and industry engagement with research, has raised concerns within the 
research community about the purity of research efforts and the challenges of doing research 
in an environment with multiple interests and billions of dollars at play.35  !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
33 Callahan, What Price Better Health?: Hazards of the Research Imperative, 219. 
 
34  Association of University Technology Managers, “Bayh-Dole: It’s Working,” 
https://www.autm.net/AM/Template.cfm?Section=Bayh_Dole_Act&Template=/CM/ContentDisplay.cfm&
ContentID=11603, (accessed: May 25, 2015). The $36.8 billion in sales were generated by 70 academic 
institutions who had 15,741 full-time employees. 
 
35  Bhavan Sampat and Fredrick Lichtenberg, “What are the Respective Roles of the Public and Private Sectors 
in Pharmaceutical Innovation?” Health Affairs 30, no. 2 (2011), 332; Bhaven Sampat,  
Mission-Oriented Biomedical Research at the NIH,” Research Policy 41, no. 10 (12, 2012), 1729; Bhavan Sampat 
“Academic Patents and Access to Medicines in Developing Countries,” American Journal of Public Health 99, no. 
1 (2009), 9.; Howard Markel, “Patents, Profits, and the American People--the Bayh-Dole Act of 1980,” The 
New England Journal of Medicine 369, no. 9 (2013), 794; David C. Mowery, Ivory Tower and Industrial Innovation : 
University-Industry Technology Transfer before and After the Bayh-Dole Act in the United States (Stanford, Calif.: Stanford 
Business Books, 2004). 
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Conflicts of Interest 
 One approach to addressing emerging ethical questions between financial rewards, 
patents, and the goal of medical research centered on the issue of conflicts of interest. 
Conflicts of interest can arise for a variety of reasons, and when they do, they have been 
shown to affect decisions that researchers make. Josephine Johnston, a researcher at the 
Hastings Center, describes academic studies with financial ties to industry have tended to be 
favorable to the sponsor of the research and holding back negative publications.36 While 
financial conflicts can lead to disproportionately favorable outcomes in experiments, they 
have also been shown to improve the likelihood of a drug’s approval.37  
 In a recent study, exclusive industry partnerships with researchers who serve on 
regulatory boards, e.g. the FDA, tend to approve drugs at a 10% higher rate than those with 
no financial ties or multiple ties to the sponsor and a competitor.38 This is not to say that 
conflicts of interest cannot be balanced, however, it raises important questions regarding the 
motivation of research approval and consequences of patenting. Moreover, conflicts of 
interest raise questions regarding the validity of the approval process itself. In other words, 
are new drugs simply being approved because they offer an opportunity for financial gain or 
because of the health benefits they might bring?  Questions regarding conflicts of interest 
retain central importance and should continue to be investigated, as billions of dollars flood 
the global research market. !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
36 Josephine Johnston, “Conflict of Interest in Biomedical Research,”  in From Birth to Death and Bench to Clinic: 
The Hastings Center Bioethics Briefing Book for Journalists, Policymakers, and Campaigns, ed. Mary Crowley (Garrison, 
NY: The Hastings Center, 2008). 
 
37 Tobbell, Allied Against Reform, 894-897. 
 
38 Genevieve Pham-Kanter, “Revisiting Financial Conflicts of Interest in FDA Advisory Committees,” Milbank 
Quarterly 92, no. 3 (2014), 457-458. The average approval rate is about 50%, with exclusive financial ties to a 
sponsor it rises to a little over 60%.  
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Global Investments 
 Global investment in research and development, taking place through both public 
and private funding sources, reached over $1 trillion in 2014. Battelle, a company that tracks 
the business aspects of innovation across various industries, estimates that about half of that 
trillion is divided amongst basic science research and applied research throughout various 
public and private research institutions.39 The United Nations Education, Scientific, and 
Cultural Organization (UNESCO) derived close to the same figure as Battelle, with the U.S. 
leading the way in investments for health related research totaling over $475 billion, 
spending approximately 2.8% of its GDP on research.40 According to UNESCO, the 
funding sources for research come from one of several categories: business enterprise, 
government, higher education, private non-profit organizations, or “abroad.”41 Despite the 
breadth of funding sources, the majority of investments in research and development come 
from pharmaceutical and biotech industry re-investing their own money and utilizing their 
own scientists in an effort to keep costs down. 
 The estimated cost of bringing a drug to market can be upwards of $1.5 billion and 
take 15 years for approval. Most drugs, moreover, fail during the second and third phase 
trials, after which significant investments have already been made in research. In short, the 
ten leading pharmaceutical companies have spent over $58 billion on research and 
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39 Recalling from Chapter One (pp. 6-8), basic science research is research aimed at more deeply understanding 
the biological foundations of life; whereas applied medical research looks to take that information and translate 
it into treatments, pharmaceuticals, technologies, etc. to improve the health of persons. 
 
40  UNESCO Institute for Statistics, “Global Investments in R&D,” UNESCO, 
http://www.uis.unesco.org/FactSheets/Documents/sti-rd-investment-en.pdf (accessed January 6, 2015). The 
2.8% figure is based off of the latest data UNESCO had, which for the U.S. was the latest UNESCO estimates 
was 2.8%.  
 
41  Ibid. 
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development activities in 2009. However, as Valverde points out supporting Marcia Angell’s 
critique of the early 2000s, pharma companies exhaust “more time and resources on 
generation, collation, and dissemination of medical information than it does on production 
of medicine.”42 Thus, while R&D costs may be upwards of $1.5 billion there is debate about 
whether this is the actual cost of research itself, or ancillary marketing and dissemination that 
the companies deem necessary.  
 Marcia Angell, former editor of the New England Journal of Medicine, in addition to her 
critique of what “counts” as Research and Development (R&D), has been equally critical of  
industry’s proclivity to research primarily profitable drugs. She specifically highlights research 
practices focused on the development of “me too drugs.” “Me too” research centers on the 
development of new drugs to replace already serviceable pharmaceuticals in the market 
place. The hope is to develop an alternative drug with different chemical properties that will 
allow for the pharmaceutical company to hold a new patent on their product, regardless of 
whether or not it is more effective than the product already on the market.43  Here the lines 
between the health outcomes of research and the economics of research seem to switch 
places, with financial gain serving as researchers true goal. While medical research can be for-
profit, institutions of higher education and non-profit private investors, who account for 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
42  José Luis Valverde J.L., “The Pharmaceuticals Industry in Trouble,” Pharmaceuticals Policy and Law 15, no. 1-2 
(2013), 57.  
 
43 Marcia Angell, The Truth about the Drug Companies: How they Deceive Us and what to do about It (New York: 
Random House, 2004); Hille Haker, “The Institutional Corruption of Health Care Bodies,” Concilium 2014, no. 
5 (2014); Charles Ornstein and Ryann Grochowski Jones, “The Drugs that Companies Promote are Rarely 
Breakthroughs,” New York Times, January 7, 2015, http://www.nytimes.com/2015/01/08/upshot/the-drugs-
that-companies-promote-to-doctors-are-rarely-breakthroughs.html?rref=upshot&_r=0&abt=0002&abg=0, 
(accessed March 14, 2015). Me too drugs are those drugs that are developed to replace already serviceable 
pharmaceuticals in the market place. The hope here is to develop an alternative drug with different chemical 
property that will allow for the pharmaceutical company to hold a new patent on their product.  
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around 40% of the total investment in R&D, need to ensure that their research focuses on 
health outcomes over economic gain.44   
 Amongst the top ten research contributors, the United States, China, and Japan 
account for over 50% of investments made into research, a small portion of which flows 
through institutions of higher education.45 However, the question centers on what these 
institutions are doing with the funds. China, for example, invests no money for research in 
higher education, whereas the U.S. and Japan funnel a modest 10% through universities. 
Brazil, also in the top-ten of global investors, devotes the most, around 40% of their total 
research expenditures, India 4%, and the U.K. and France invest around 20% into 
universities.46 In other words, globally, university-based research still plays a role in shaping 
the landscape of, albeit not as significant as in the “golden age.” The question is how ought 
universities use those resources at their disposal?  
Established Priorities 
 If medical research is a practice, as proposed at the beginning of this chapter, and 
there are internal goods to the practice, then one of those goods has to be the actual 
improvement of people’s health. Yet, given the allocation of the NIH budget, it seems more 
investments are being made on the potential impact on people’s health than more immediate 
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44 UNESCO Institute for Statistics, Global Investments in R&D. 
http://www.uis.unesco.org/FactSheets/Documents/sti-rd-investment-en.pdf (accessed January 6, 2015). 
 
45 Ibid. This figure represents all forms of funding, both public and private. In the U.S., a little more than 60% 
of funding for R&D comes from business enterprises, 32% government, and approximately 8% divided 
between higher education and private non-profits. The U.K.’s business contributions are down to about 45% 
and government about 25%, with a larger portion left for funds coming from abroad, while only about 5% are 
higher education and private non-profit. India’s research is almost exclusively funded by their government, just 
shy of 70%, and business funding comprises about 30%.  China is increasingly a factor in research with 75% 
coming from business, 24% from government, and the remaining 1% coming from “abroad.” 
 
46 UNESCO Institute for Statistics, Global Investments in R&D. 
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needs. A look at the 2014 NIH “Estimates of Funding for Various Research, Condition, and 
Disease Categories (RCDC)” notes that over $16 billion went to research pertaining to 
Genetics ($7.3 billion), Biotechnologies ($5.7 billion), and Bioengineering ($3.3 billion). 
These three categories, while having the potential of generating future benefits, offer little 
immediate impact—particularly when considered in a global context. On the other hand, $14 
billion—not an insignificant amount—was devoted to research for Women’s Health ($3 
billion), Pediatric Research ($3 billion), HIV/AIDS ($2.9 billion), Cardiovascular ($1.9 
billion) Nutrition ($1.5 billion), Orphan Drugs ($809 million), Stroke ($300 million), 
Tuberculosis ($279 million), Infant mortality ($268 million), Malaria ($169 million), and 
Malaria Vaccine ($36 million).47 In other words, $2 billion more went to three research 
categories, as compared to the 11 categories that roughly correspond with priorities 
recognized by the WHO and the United Nations (UN) Millennium Development Goals as 
representing global health challenges. While genetic, biotechnologies, and bioengineering, no 
doubt, hold scientific promise of improving health, they also yield a high return on 
investment.48 Thus, it is unclear whether they are being prioritized for health or financial 
gain. Moreover, given that cutting-edge research is not likely to be realized for the majority 
of the world, ought high cost-high yield research be prioritized more than Women’s Health, 
Pediatric care, or HIV/AIDS?  
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47 National Institute of Health, “Estimates of Funding for various Research, Condition, and Disease Categories 
(RCDC),” U.S. Department of Health and Human Services, http://report.nih.gov/categorical_spending.aspx 
(accessed 2/8, 2015). 
 
48 Meg Tirrell, “Biotechnology Draws Record Profit as Research Money Slows,” Bloomberg, 
http://www.bloomberg.com/news/2013-04-23/biotechnology-draws-record-profit-as-research-money-
slows.html. (accessed 2/9, 2015). The recent Bloomberg report notes biotech companies increased their profits 
by 37% in 2012 and recorded $5.2 billion in earnings, which the article suggests is, at least in part, due to less 
spending on Research and Development. 
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Minding the Research Gap 
 When reflecting on the historical developments in medical research, the health 
improvements experienced globally tend to originate in the Western world and to offer 
greater benefit to persons from those countries. Although there are exceptions, such as the 
previously mentioned smallpox, applied research typically leads to the development of new 
medical treatments and interventions that center on the health of those who can afford these 
developments. David Resnik argues the economics of research creates disparities in research 
priorities. Disparities “exist because biomedical research on the health problems of the 
developing world is neither financially lucrative nor politically popular. Although some 
private foundations spend a great deal of money on the health problems of the developing 
world, their contributions are not enough to close the gap.”49 In short, the global medical 
research priorities, not just those of the U.S. described above, disproportionately improve 
the health of particular persons, i.e. those who those of high-income countries. This blind 
spot in establishing research priorities has resulted in a consistently unjust burden of disease 
that affects the majority of humanity.  
 The “10/90 gap” is a phrase coined by the Global Forum for Health Research that 
represents the disparities in medical research, in which 10% of the population benefit from 
90% of the research conducted. Conversely, this means that 90% of the world’s population 
receives only 10% of research’s benefit. These numbers were originally developed in the 
early 2000s by a WHO working group that calculated an “estimated 93% of the world’s 
burden of preventable mortality (measured as years of potential life lost) occurs in the !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
49 David Resnik, “The Distribution of Biomedical Research Resources and International Justice,” Developing 
World Bioethics 4, no. 1 (2004), 48. The Gates Foundation represents a key philanthropic group focused on 
closing the research gap.  
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developing world... [yet] only 5% [of research] was devoted specifically to health problems of 
developing countries…”50 While these figures have been challenged, and by most 
estimations decreased over the last two decades, the phrase stands as a symbolic point of 
reference for the continued disparity and underfunding for research that benefits the those 
bearing most of the global burden of diseases.51 Epidemiologic measurements of the global 
burden of disease demonstrate geographically which populations bear the heaviest burden of 
disease and serve as indicators of the need for improved medical care and treatment. 
Burden of Disease 
 Measuring the burden of disease provides important information about who is 
suffering from particular diseases, where they are located, and the estimated life lost There 
are two measures frequently used in public health to estimate the number of life years lost 
due to disease or premature death, QALY (quality adjusted life years) and DALY (disability 
adjusted life years). QALY estimates the number of quality life years lived and is more 
frequently used to establish a cost effectiveness strategy for investments in health. DALY, 
which is the measurement used by the WHO, is calculated by adding the number of years 
lived with a disability to the number of years lost due to premature death, based off of an  
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50 Research and Development to Meet Health Needs in Developing Countries: Strengthening Global Financing 
and Coordination Report of the Consultative Expert Working Group on Research and Development: 
Financing and Coordination, Research and Development to Meet Health Needs in Developing Countries: Strengthening 
Global Financing and Coordination (Geneva, Switzerland: World Health Organization, 2012), 32. 
 
51 While certain essays have been more dismissive of the continued use of the 10/90 gap for neglected diseases, 
there is a need to address the more prevalent chronic diseases that are now appearing in the low and middle 
income countires that cannot afford the same treatments that are being given to those in high income Western 
countries. For an argument against the usefulness of the 10/90 gap, see “Diseases of Poverty and the 10/90 
Gap” http://www.who.int/intellectualproperty/submissions/InternationalPolicyNetwork.pdf. 
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ideal standard, i.e. years of living without disease and/or disability.52   
 DALYs prove helpful when trying to trace the burden of disease on particular 
populations. The highest concentration of DALYs is located in Sub-Saharan Africa with 
Sierra Leone having the highest number of adjusted life years due to death or disability, over 
117,000 years. The lowest number of years lost is in Singapore (14,354 years), followed by 
Japan (15,700 years).53 A glance at the WHO numbers for morbidity and mortality indicate 
that there are vast disparities in the communities who bear the global disease burden. While 
research alone will not address the DALYs completely, they do serve as a focal point for 
what diseases are pertinent to these areas and to consider the role research could play.  
 According to the WHO, the top ten causes of morbidity and mortality cut across 
geographic and economic lines, but the number of deaths due to preventable diseases 
primarily plague low-income countries. 
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52 Annette Prüss-Üstün et al., Assessing the Environmental Burden of Disease at National and Local Levels (Geneva: 
World Health Organization, 2011), 27-38. This resource provides a helpful breakdown of the various 
calculations utilized to arrive at the DALY and QALY measurement.  
 
53 The U.S. number (22,775) is higher than all of Western Europe and Canada. 
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Figure 1. The 10 Leading Causes of Death in the World, 201254 
   
Figure 2. The Top 10 Causes of Death in Low Income Countries, 2012
 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
54 World Health Organization, “The Top 10 Causes of Death,” 
http://www.who.int/mediacentre/factsheets/fs310/en/index1.html (accessed December 20, 2014). 
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Table 3. The Top 10 Causes of Death in Lower-Middle Income Countries, 2012 
 
Table 4. The Top 10 Causes of Death in Upper-Middle Income Countries, 2012
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Table 5. The Top 10 Causes of Death in High Income Countries, 2012
 
As can be seen in Figure 1, the leading causes of death globally are comparable between 
those countries of varying economic status as seen in Figures 2-5. What proves significant 
about these deaths, however, is the combination of preventable causes of death that appear 
primarily in low-income countries and, to a lesser degree, in lower-middle income countries. 
However, these preventable health-related deaths—diarrheal diseases, birth complications 
(pre and post partum), and malnourishment—also appear alongside chronic diseases—TB, 
diabetes, heart disease, etc.  Preventable health complications presenting alongside increasing 
numbers of chronic diseases result in higher incidence of death. As a country’s income level 
increases the burden of disease related to public health causes and lack of access to health 
care correlatively dissipate.  
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“A Pathogenic Situation” 
 Paul Farmer notes—and the above statistics corroborate— these disparities 
demonstrate a propensity for preventable, or at the least treatable, diseases to 
disproportionately affect people living in low-income countries. He describes these 
disparities as epidemiological in nature.  
Most often, diseases themselves make a preferential option for the poor. Every 
careful survey, across boundaries of time and space, shows us that the poor are 
sicker than the non-poor. They’re at increased risk of dying prematurely, whether 
from increased exposure to pathogens (including pathogenic situations) or from 
decreased access to services—or as is most often the case, from both of these ‘risk 
factors’ working together.55  
 
What Farmer means by “pathogenic situations” is that the very conditions in which people 
live, not just the disease pathogens, make individuals more susceptible to contagion. Farmer 
highlights that, in this way, diseases tend to disproportionately affect persons who lack both 
socio-economic and health resources. Analysis of the global morbidity and mortality 
statistics for low and low-middle income countries demonstrates that they suffer unique 
health circumstances that do not create problems for higher income countries who have 
greater access to both economic and health resources. However, what also gains increased 
clarity is that health problems of higher income countries—cancers, cardiovascular disease, 
diabetes—are now beginning to afflict lower income countries. The introduction of chronic 
diseases compounds the already unique challenges presented by high incidence of child 
deaths from diarrhea, lower respiratory tract infections, and neonatal deaths in low-income 
regions.  
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55 Paul Farmer, Pathologies of Power: Health, Human Rights, and the New War on the Poor (Berkeley: University of 
California Press, 2003), 140. 
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 Two recent examples that reflect the challenges of combining disease, poor health 
infrastructures, and poverty are the continuing cholera epidemic in Haiti that began in 2010, 
and the recent, 2014, Ebola virus disease (EVD) spread in three West African countries, 
both of which exemplify Farmer’s analysis. These situations, while illustrating the 
importance of sound public health and health care delivery systems working together, also 
highlight the necessity of having adequate medical research develop from all areas: clinical, 
epidemiologic, and basic, to address emerging needs. Moreover, these case studies point to 
the continued complexities of under-researched diseases that exist primarily in low-income 
countries. 
Two Case Studies  
Cholera 
  In January of 2010, a massive earthquake struck Haiti, killing over 200,000 people 
and injuring another 300,000. Only ten months later, in October, an “unlikely” occurrence of 
cholera appeared that has led to the additional death of 8,000 people over the past four 
years.56 The source of the introduction of the disease, ironically, came from one of the UN 
workers from Southeast Asia sent to aid in the earthquake relief efforts.57 While the epidemic !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
56  Paul Farmer, et al., Haiti After the Earthquake, (New York: PublicAffairs, 2011), 383. Here Farmer notes a 
report from the CDC that cites the occurrence of cholera in Haiti was low: “While the current water, sanitation, 
and hygiene infrastructure in Haiti would certainly facilitate transmission of cholera (and many other illnesses), 
cholera is not circulating in Haiti, and the risk of cholera introduction to Haiti is low. Most current travelers to 
Haiti are relief workers from countries without endemic cholera, and they are likely to have access to adequate 
sanitation and hygiene facilities within Haiti, such that any cholera organisms they import would be safely 
contained.” Center for Disease Control, “Acute and Watery Diarrhea and Cholera: Haiti Pre-decision Brief for 
Public Health Action,” CDC, http://www.cdc.gov/cholera/haiti/pre-decision-brief.html, (accessed: February 
9, 2015). 
 
57 Rober Tauxe, “Cholera: Fourth Year of the Epidemic in Haiti; Sixth Decade of the Global Pandemic,” 
Pathogens and Global Health 108, no. 1 (2014), 1; Ezra Barzilay, et al., “Cholera Surveillance during the Haiti 
Epidemic--the First 2 Years.” The New England Journal of Medicine 368, no. 7 (2013), 599. “In 2008, an estimated 
63% of the 9.8 million persons in Haiti had access to an improved drinking water source (as defined by the 
World Health Organization [WHO]), with only 12% receiving piped, treated water; only 17% had access to 
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in Haiti is now in its fifth year, this particular strain is in its 53rd year and has affected 58 
countries. These countries where the disease has both endured and recurred are 
predominately lower income countries. Haiti is a country of limited economic resources, 
poor sanitation infrastructure, and minimal health care and public health resources. Thus, 
the challenge the country faces is a complex one. In order to address the challenge, a group 
of health care workers: physicians, nurses, public health experts, industry, and government 
officials gathered to begin strategizing to stop cholera’s spread.  
 Cholera, recalling from chapter one, is a bacterial-based disease that spreads through 
contaminated water, a common experience in Haiti. The disease can be controlled through 
sanitation efforts, effective rehydration, and, the use of vaccines. The debate around how to 
control cholera in Haiti, as Farmer describes it, ultimately has come down to a minimalist vs. 
maximalist approach.58 The minimalists argue that it would be “too difficult” to control the 
spread of the disease, and opposed vaccinations in favor of water protection. Farmer notes, 
“Safe, effective, and affordable oral vaccines exist, and yet remain unavailable in Haiti—as 
do, too often, timely diagnosis and care. When some suggested integrating vaccination into 
the response, public health officials were quick to note that vaccination was not cost-
effective (as if “cost” were fixed in stone and “effectiveness” well understood).”59 On the 
contrary, the maximalists argue that all possible ways to stop cholera be implemented or at 
least explored: improved sanitation, chlorine tables, effective and safe vaccines, rehydration !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
adequate sanitation.” 
 
58 Farmer, Haiti After the Earthquake, 199. 
 
59 Louis Ivers and Paul Farmer, “Cholera in Haiti: The Equity Agenda and the Future of Tropical Medicine,” 
American Journal of Tropical Medicine and Hygiene 86, no. 1 (2012), 7; WHO Publication, “Cholera Vaccines: WHO 
Position Paper-Recommendations,” Vaccine 28, no. 30 (2010), 4687. Many of the “minimalist” public health 
practioneers cited unproven trials; however, Farmer and Ivers point to several successful trials in India, 
Vietnam, Bangladesh, Mozambique, and elsewhere included in the WHO report on cholera vaccines.  
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therapies, and antibiotics. Farmer reports that conversations tended to default to the 
positions that academics and researchers had held for years and could not move beyond 
them to address the emergent situation at hand. The continued discord between experts 
resulted in a series of conference calls in the hope of developing a unified approach, the 
second of which was hosted by Harvard Medical School.  
 Harvard Medical School served as the host of the conference call focusing on health 
outcomes, and was not tied to a particular methodological or policy-based approach. The 
school and its officials—including Farmer as a professor of Global Health and Social 
Medicine—sought to mitigate the tensions between the two groups by assembling a team of 
cholera experts. The call included over 80 such representatives from Haiti, the U.S., Geneva, 
Korea, and beyond.60 The group was tasked with developing a consensus statement, 
generating the a clear focus for the group and, by hearing from people on the ground in 
Haiti, to appreciate the complexity of the situation at hand.  
 Haitian policies, lack of sanitation, lack of access to care, and a broken infrastructure, 
contributed to an already challenging recovery from the earthquake. While the government 
itself sought “a 10-year, $2.2 billion plan to eliminate cholera, including $1.6 billion to 
improve water and sanitation,” political corruption is a rampant problem, and therefore a 
major increase in aid was a tenuous solution at best.61 The university-mediated call resulted 
in a more unified group, aware of the problems and differing positions, but willing to 
approach treating the cholera epidemic interdisciplinarily and focused on those suffering 
from the disease  !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
60 Ivers and Farmer, “Cholera in Haiti,” 212. 
 
61 Sam Kean, “As Cholera Goes, so Goes Haiti: The West's Poorest Nation Confronts a New Disease,” Science 
345, no. 6202 (2014), 1268. 
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 The cholera epidemic is one example of a disease that, within the last 60 years, has 
primarily affected lower income countries with limited access to necessary treatments. 
Farmer and his colleague, Louise Ivers, sum up the challenge quite well: “One hundred fifty 
years after John Snow took the handle off the Broad Street pump, more than a century after 
his suspicions of bacterial origin were confirmed, 60 years after antibiotic therapy was 
discovered, and 30 years after a safe and effective oral vaccine was developed, cholera 
remains—among the world’s poorest—a leading infectious killer.”62 While this disease exists 
nowhere in high-income countries, except in instances of health relief workers bringing it 
back, its continued prevalence points to the inequity that exists with respect to disease 
burden. The fact that the disease persists, moreover, signals a lack of expectations that 
curative and/or preventive treatments, when available, will be provided for resource poor 
populations. This reality led Farmer and Ivers to put forward a rather simple explanation, 
namely, that the failure to cure tropical diseases results from lowered expectations to cure 
“diseases that disproportionately afflict poor people.”63 Despite the existence of proven 
treatments, including a vaccine and means of disease prevention, there is a dearth of medical 
care and a limited public health infrastructure, aside from any research limitations.  
 Cholera demonstrates the complexity of coordinating efforts between the public 
health, medical care, and available treatments. In this instance, the lack of medical research in 
and of itself was not a limitation. In fact, the research developed could serve as a supplement 
to prevention and rehydration. Therefore, the research has been done on cholera in the 
event of widespread outbreak, and vaccinations represented an option that could have been !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
62 Ivers and Farmer, “Cholera in Haiti,” 7-8. 
 
63 Ibid, 8. 
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utilized within a better health care infrastructure. In many ways, cholera represents a disease 
that has been prepared for adequately through medical research, but that needs a solid public 
health and health care delivery research structure to be successful. At the same time, cholera 
prevetion. However, this has not been the case with the recent Ebola epidemic, where 
neither the research, prevention, nor treatment options have been adequate.  
Ebola 
 There is no clearer example of the disproportionate response that the Ebola 
epidemic in West Africa received, compared to the frantic responses to isolated cases of the 
disease in the United States. In 2014, the Ebola virus disease (EVD) originated near the 
border of three West African countries, Guinea, Liberia, and Sierra Leone, and has caused 
the death of close to 9,000 people.64 Various practices have been implemented to attempt to 
contain the disease at its source. In Liberia, the government attempted an area-wide 
quarantine in its capital city, Monrovia. “60,000-120,000 people lived in deplorable, 
unsanitary, slum like conditions. Barbed wire and live bullets confide these desperate people; 
there was little or no health care available and highly infectious dead bodies lay in the streets 
for hours and sometimes days. After 10 days, the scheduled 21-day quarantine was halted.”65 
Large-scale quarantine, however, proves a fairly ineffective strategy for containing a disease 
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64 Michaeleen Docuclef, “No, Seriously, How Contagious is Ebola?” National Public Radio, (accessed, 
February 8, 2015), http://www.npr.org/blogs/health/2014/10/02/352983774/no-seriously-how-contagious-
is-ebola; Michael Rozier, S.J., “The Real Story About Ebola,” America Magazine, 211, no. 15 (2014), 27-29, 
http://www.americamagazine.org/real-story-about-ebola (accessed, November 3, 2014). 
Both articles, in basic terminology, emphasize that though Ebola is deadly it is not a highly contagious disease. 
The epidemiological term to describe the contagiousness of a disease is “r nough” a “Ro” number. This 
indicates a diseases basic reproduction rate. Thus, on average every one person with EVD will infect two other 
persons. The Ro for EVD is roughly 2. The Ro of EVD can be compared to influenza 2-3; HIV Ro 4; Polio 6; 
and the Ro for measles can be as high as 18. In short, vaccinations make a huge difference.  
 
65 Mark A. Rothstein, “The Moral Challenge of Ebola,” American Journal of Public Health 105, no. 1 (2015). 
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spread. Treatment options, however, are also limited given the disparate number of doctors 
available.  
 Even if both public health measures and medical delivery system were in place, no 
adequate treatment of the disease exists. While ensuring that medical care and public health 
structures are in place would exponentially increase survival rates, a lack of a vaccine 
provides an obstacle for preventing future outbreaks. Yet, the reason that the disease has 
received so much global attention is not because a vaccine does not exist, nor the deplorable 
conditions of Liberia’s quarantine, nor the deaths of thousands in West Africa. Rather, the 
national and international fervor was stirred by the death of one Liberian on U.S. soil. That 
one Liberian man’s name was Thomas Eric Duncan.  
 Mr. Duncan presented to a Dallas hospital emergency depart after exhibiting 
common symptoms associated with EVD: high fever, weakness, and abdominal pain. After 
being attended to, he was ultimately sent home, only to return two days later more 
contagious and highly symptomatic.66 When he returned, the disease had progressed 
dramatically, and he ultimately died. In the process of caring for the patient, two nurses 
became infected with EVD. Upon presenting with symptoms, both were treated and given 
immediate care and proper precautions—including the quarantining of one patient’s dog—
were put into place. The response was immediate. A systematic health care response was in 
place, public health precautions taken, and treatment was delivered quickly and effectively.   !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
66 The comparisons between the death have also stimulated discussion about the lingering racism that creates 
disparities in treating uninsured people of color in emergency rooms. Rebecca Hersher, “Liberians Wonder if 
Duncan’s Death was a Result of Racism.” National Public Radio, 
http://www.npr.org/blogs/goatsandsoda/2014/10/19/356986841/liberians-wonder-if-duncans-death-was-a-
result-of-racism (accessed February 2, 2015); Hanna Kozlowska, “Has Ebola Exposed a Strain of Racism?” The 
New York Times, http://op-talk.blogs.nytimes.com/2014/10/21/has-ebola-exposed-a-strain-of-racism/  
(accessed February 2, 2015); Judy Lubin, “Unequal Treatment? Race, Ebola, and the Tragic Death of Thomas 
Eric Duncan.” The Huffington Post, http://www.huffingtonpost.com/judy-lubin/unequal-treatment-race-
eb_b_5955786.html (accessed February 2, 2015).  
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 In contrast, the health care system in which the majority of people are contracting 
the disease is one in which a few dozen physicians care for the 4.2 million people of Liberia. 
Moreover, the lack of a public health infrastructure, where basic hygiene and removal of 
infectious and deceased bodies proves challenging, contributes to the spread of the 
epidemic.67 While challenges resulting from a lack of an efficient health care delivery and 
public health practices are known, these weaknesses are exacerbated by the comparatively 
little research that has been done on EVD. The lack of research has resulted in the reality 
that no vaccine or 100% curative treatment exists. Nevertheless, the epidemic did spur some 
international conversation towards investing in research to develop a vaccine.  
 The WHO convened an urgent meeting from September 29-30, 2014 to evaluate and 
discuss the production of a safe and effective EVD vaccine.68 70 scientists, public health 
officials, and representatives from industry, and regulatory bodies gathered to discuss two 
vaccines in particular: cAD3 from GlaxoSmithKline and U.S. National Institute of Allergy 
and Infections Disease (NIAID), and rVSV from NewLink Genetics and the Public Health 
Agency of Canada. Both vaccines have demonstrated 100% efficacy in nonhuman primates, 
and the action items resulting from the meeting stressed that phase one trials should be 
expedited and their results shared broadly to facilitate rapid progress in phase two. The 
continued neglect of research for EVD, despite outbreaks dating back to the 1970s, 
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67 Rothstein, “The Moral Challenge of Ebola.” Rothstein “in Liberia, the government imposed an area-wide 
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necessitated a fast-tracking process and the immediate institutions of new policies breaking 
with WHO research norms.69 
 While these developments come too late for Mr. Duncan and the thousands of 
others who have died, international conversations have begun that raise awareness about the 
need for research for under-researched diseases that affect vulnerable populations. Farmer 
argues that what is needed is: 
specific therapy, better and faster diagnosis, and effective vaccines. The vaccines and 
drugs required to treat so-called ‘emerging infections diseases’ do not exist because 
of what James Surowiecki has called ‘Ebolanomics’. When disease victims are both 
poor and not very numerous,’ he says,  ‘that’s a double whammy. On both scores, a 
drug for Ebola looks like a bad investment.70   
 
Again, the importance of prioritizing research based on health, not economics proves 
fundamental.  
 The cases of EVD and cholera confront medical researchers and health care workers 
with a clear option in making research and treatment decisions. Farmer, again, puts the 
choice into perspective by challenging “doctors and other health providers to make an 
option—a choice—for the poor, to work on their behalf. The insight is, in a sense, an 
epidemiological one: most often, diseases themselves make a preferential option for the 
poor.”71 Farmer’s epidemiological insight, also presents a similar epistemic option to that of 
Ellacuría’s in the previous chapter, and one that has historically not been one taken up in 
medical research agenda.  !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
69 This hurried approach to developing research to meet a pressing need points to the importance of having 
research ethics that is focused on protecting individual research subjects, and in particular those who are 
considered vulnerable subjects. Yet, it also points to the need for social bioethics to be attentive to under-
researched diseases in order to avoid the situation described above.  
 
70 Paul Farmer, “Ebola.”  
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Broadening the Scope of Research 
 Reflecting on the developments of the practice of medical research through the 
interactions of government, universities, industry, and burdens of disease demonstrates a 
nexus of priorities that research agendas can reflect. However, it seems economic returns 
receive more attention than improvements to the health of persons bearing a significant 
burden of disease. A 2012 Global Health Forum Report estimates, “for each year of 
potential life lost in the industrialized world, more than 200 times as much is spent on health 
research as is spent for each year lost in the developing world.”72 While access to health care 
and public health provide two strong pillars for a healthy society, access to and participation 
in the development of affordable treatments is essential.  
 From Vannevar Bush to present day discussions of research priorities, innovations in 
medical research focus consistently on its financial benefits. However, insofar as medical 
research functions as a practice, there are both intrinsic and extrinsic goods to that particular 
practice. Moreover, the epistemological reframing of the practice of medical research 
requires an examination of how research shapes historical reality. In the first few sections of 
this chapter, I have argued that governments, the pharmaceutical industry, and academia 
have gone a long way to shape research to prioritize returns on investment first and health 
second. While research, as seen in the case studies, serves as one piece of the puzzle, it 
proves an important dynamic in improving health. When establishing research priorities on 
both social and individual levels, medical research cannot be isolated from its constructive 
dynamic that contributes to the injustices present in the global burden of disease. Therefore, !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
72 Research and Development to Meet Health Needs in Developing Countries: Strengthening Global Financing 
and Coordination Report of the Consultative Expert Working Group on Research and Development: 
Financing and Coordination, Research and Development to Meet Health Needs in Developing Countries: Strengthening 
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it is necessary to reflect on the development of the relationships that make medical research 
possible, as has been done above, but also to reflect on the impact that these relationships 
have had.  
 Revisiting Responsible Conduct of Research 
 In Chapter Two, I discussed that responsible conduct of research focuses primarily 
on respecting the rights of research subjects and fulfilling an obligation to non-maleficence.  
However, when considering responsibility on a social and relational level as I have proposed, 
responsible research should take more seriously its obligation to engage in research that 
serves the vulnerable groups that research ethics aims to protect. When the economic gains 
of research become the focus over health, the health needs of those to whom Ellacuría 
referred to as the poor majority, become neglected and/or under-researched. 
Focus on the economics of research lends itself to prioritization of technological innovation 
that requires a significant financial investment and tends to yield profitable returns that fails 
to benefit a significant portion of humanity.  
 The emphasis placed on finances and being on the cutting edge of research tends to 
mask the health needs of the majority. Desires of individuals, predominately from high 
income, western countries, obfuscate true need of the global majority. In looking at the NIH 
funding priorities, it is not that funding does not exist to address concerns of the majority, 
but the allocation of those funds are disproportionate to health needs as indicated by the 
global burden of disease. Hille Haker argues that research choices are framed in a way that 
prioritizes individual choices, which reinforces the importance of technological innovation 
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that delivers health to some, while neglecting the needs of many.73 Lisa Sowle Cahill likewise 
posits that the accumulation of individualized choices made by a select few “affect society as 
a whole, changes expectation of health and normality, and reinforces economic and class 
stratification.”74 Thus, in the scenario Cahill describes, certain people will be expected to be 
healthy, while others are accepted to be at a higher risk of disease. This bears out in the 
reactions to Ebola, until it began to effect Western and high-income countries. However, if 
medical research considers its role in affecting the health for all, then interests have to move 
beyond a subjective and individualized understanding of health.  
 Haker proposes that a rights-based framework can more adequately take up the 
question of justice within scientific research ethics. She argues that linking human rights “to 
a general concept of well-being… needs to be spelled out under the conditions of modern 
medicine and needs to be negotiated in the process of ethical deliberation in general.”75 
However, who does the negotiations for rights? Who is obligated to ensure that these rights 
are met? How does the prioritization of medical research ensure that the voices of those 
most in need are heard?  
 Cahill, in some ways answers these questions, by arguing for a participatory model of 
justice frames needs, in this case health needs, as fundamental to any notion of the common 
good. Given the above discussion of the organizational players in the construction of 
medical research, the only ethical discussions that arose in research were worries over 
conflicts of interest and violation of individual rights. A participatory model of justice would !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
73 Hille Haker, “Viewpoint: Interests, Rights and Standards of Care in the Context of Globalized Medicine,” 
Journal of Internal Medicine 269, no. 4 (2011). 
 
74 Lisa Sowle Cahill, “Biotech and Justice: Catching Up with the Real World Order,” Hastings Center Report 33, 
no. 5 (2003), 36. 
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look first to the participants in the establishment of a medical research agenda, and also to 
those who stand to benefit. To begin to discuss the ethics of medical research beyond an 
economic and/or technological framework necessitates a consideration not just of interests, 
but of the health needs and rights from the perspective of those who have seemingly “no 
health” and “no rights.”  
 Cahill and Haker both begin with positive considerations, rights and the common 
good; however a liberationist ethics adopts a socio-historic perspective that begins from 
injustices. Though Haker, Cahill, and Ellacuría find common ground in their collective 
concern over the need to address global injustice, their starting points differ. Ellacuría starts 
with injustice through the biological fundament of ethics—i.e. to see what is unethical or 
unjust one only needs to turn to the places where people continually die prematurely. Haker, 
calls for an ethical analysis of the research beyond the individual focus demonstrated in a 
technology-based ethic, to one that focuses on rights through “the interpretation (articulation 
and analysis) of values and norms articulated in different and pluralistic settings, and to 
confront them with moral principles considered to be essential for human life and human 
flourishing.”76 While Cahill argues for a common good and participatory bioethics that 
considers “a more international, dialogical, multilayered, and multifocal approach …to 
handle the quandaries of globalization, including those posed by genetics-based 
biotechnology.”77 Each starting point has its own value, however, if the socio-ethical !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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framework of medical research is to be re-imagined in a way that considers the global burden 
of disease, then hearing from and understanding the experience of those suffering from 
these diseases proves fundamental.  
Shifting the Agenda 
 
 Publications generated from public and privately funded research initiatives tend to 
attest to a gap in research that does not benefit people living in lower income areas. In 2002, 
a study showed that out of 1393 new chemical entities (NCEs) marketed between 1975 and 
1999, only 16 targeted ‘‘tropical diseases’’ and tuberculosis.78 Within the world of research, 
publications are the best insight as to where the field is focusing its efforts and which 
projects are receiving funding. Given that publications trend away from addressing the needs 
of the majority, awareness must be raised within the scientific community, not only about 
their needs, but also about the potential of the scientific community to address those needs.  
 The WHO and United Nations have implemented international mechanisms and 
standards that raise awareness of disparities in access to health care, public health 
infrastructures, and medications. The most discussed of these awareness-raising platforms 
are the Millennium Development Goals (MDG). The MDGs devise an action plan aimed at 
alleviating poverty and focus on those people suffering from hunger, malnutrition, and 
disproportionately infected by disease.79 Of the eight goals, four come to bear directly on 
health: reducing childhood mortality (MDG 4); improving maternal health (MDG 5); 
combat HIV/AIDS, malaria, and other diseases (MDG 6); and establishing global !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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http://www.un.org/millenniumgoals/reports.shtml (accessed May 25, 2014).  
!!
183!
partnership for development (MDG 8). To meet each of these goals would require a highly 
strategic approach to the way in which medical research can contribute to improving 
maternal and child health, but also improving upon distribution of its fruits can participate in 
decreasing the gap of those who bear the burden of HIV/AIDS, malaria, TB and other 
diseases that disproportionately affect low-income countries. MDG 8 specifically focuses on 
the necessary development of global partnerships for addressing health inequalities.  
 The MDGs propose a different way of addressing and prioritizing a research agenda. 
Instead of a financially driven model, their model is rooted in the health needs of the poor 
majority. However, in order to move towards these realities, other institutions have to 
commit to the priorities that the MDGs highlight. In this way, a radical shift is necessary in 
setting research priorities that explore the underlying values and injustices endemic to the 
practice of medical research. It is here that bioethics and Catholic universities can play a 
crucial role.  
Social Bioethics 
 Though arguments within the last decade have emerged in the bioethics literature 
about research inequalities, described at the conclusion of Chapter Two, the focus has 
primarily centered on research practices within low-income countries and only limitedly 
focused on priorities setting. Norman Daniels argues that this focus has resulted in “a 
myopic view that misses the institutional context in which clinical relationships operate and 
can overlook factors that affect health more broadly than do exotic technologies.”80 Haker 
has likewise called attention to the necessary broadening of bioethics to consider the 
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contexts in which research is implemented.81 Although bioethicists have been attentive to 
promoting responsible conduct of research that protects vulnerable persons, it has overall 
neglected the applicative dimension that disproportionately burdens the same people. 
 Henk ten Have argues that the traditional framing of vulnerability has been 
understood as an individual deficiency, rather than the result of a social situation. “Being 
vulnerable is often the result of a range of social, economic and political conditions, and 
therefore beyond the power and control of individuals.” 82  Therefore, bioethics cannot be 
content to consider issues only within the medical realm, but must take up broader socio-
political factors that affect health statuses and medical realities. While bioethicists are not 
responsible for developing policies addressing health inequalities, they (we) have a 
responsibility of calling attention to issues within medical research that perpetuate the 
vulnerability of a given population. In this case, as Farmer noted, the poor majority 
consistently represent the sick majority, for whom diseases make their own preferential 
option.  Thus, in order to establish more equitable research practices, and distribution of the 
developments from that research, broader participation is needed in the shaping of the 
research agenda. 
 Thomas Pogge argues for a broadening of research priorities in an effort to move 
beyond the disequilibrium present in current research efforts. Pogge roots his critique in one 
of the four key principles of bioethics, as articulated by Beauchamp and Childress, non-
maleficence. He argues that if non-maleficence hinges on “doing no harm,” then it is !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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fundamental for bioethics to take up and offer a corrective to the current system that does 
harm to the majority of human beings.83 He wants to broaden the approach academics take 
in their addressing injustices within the distribution of drugs, treatments, healthcare, while at 
the same time incorporating industry in this task through the development of the Human 
Impact Fund (HIF).  
 The HIF would financially incentivize innovators and industry to participate in a 
system that would more reliably insure the development of “high-impact” medicines for 
disease that disproportionately burden poor and vulnerable populations.84 This is the type of 
structural and innovative change necessary to reshape the research agenda from its current 
construct; this approach will be explored in more detail in the next chapter.  Yet, any 
restructuring of a research agenda must include necessarily the perspective of those often 
excluded. 
Advocacy and Research 
 Another type of approach aimed at reshaping the research agenda developed through 
the efforts of HIV/AIDS research advocates who brought attention to the harm being done 
to them by current research practices. The participatory action of HIV/AIDS research 
advocates gradually allowed for more equitable access to medications and clinical trials. 
While advocacy efforts can have potential drawbacks, the advances made by HIV/AIDS 
research advocates identify the influence that they can have on reshaping the process, 
funding, and distribution within medical research. Most importantly, HIV/AIDS research 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
83 Thomas Pogge, “Real World Justice,” The Journal of Ethics 9, no. 1-2 (2005), 33-36. 
 
84 Thomas Pogge, “The Health Impact Fund and its Justification by Appeal to Human Rights.” Journal of Social 
Philosophy 40, no. 4 (2009). 
!!
186!
advocates were able to tell humanizing stories of those suffering from the effects of a 
relatively unknown disease.85  
HIV/AIDS Research Advocates 
 The discovery of HIV and the subsequent onset of AIDS became a central focus of 
health researchers in the 1990s due, in part, to the efforts of HIV/AIDS research advocates.  
These advocates lobbied, protested, wore red ribbons, educated themselves to become a part 
of the research community itself, and educated the research community about who the 
people were suffering from this new and unknown disease. In the early 1980s, as 
information was emerging about the disease, it increasingly became thought of as a “life style 
disease,” a disease of drug users and gay men. This understanding has been proven to be 
patently untrue.  Nevertheless, by framing HIV/AIDS as a disease associated with personal 
behaviors, society was able to distance itself from “those” people who had AIDS. Epstein 
notes that to have AIDS at that time “is bound up with the cultural understandings of what 
such groups are like, while the very identity of the groups is shaped by the perception of 
them as ‘the sort of people who get this illness.’”86 In part, the early efforts of research 
advocates was about reclaiming the identity of the affected individuals as human beings and 
persons with stories and struggles that challenged the popular narrative. As the stories 
emerged, it became clearer “who these people were.” They were able to tell their story and 
the story of others who also suffered from the disease.87  !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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 AIDS research advocates were uniquely positioned in the U.S. because of the 
community organizing that had already taken place in the gay community. Thus, a unique 
strength of AIDS research advocates was that they were already organized within the 
communities and could easily “mobilize to meet a new threat…”88 Advocacy was nothing 
new to this community, and they quickly developed effective strategies that raised awareness 
of their health needs. AIDS research advocates utilized “creative approaches rather than 
following established rules of lobbying, [created] drug buyers’ clubs…red ribbons…and 
telephone ‘zaps,’ wherein the telephone switchboard of a specific company was jammed by a 
coordinated barrage of incoming calls.”89 These were not only influential awareness raising 
practices at the time, but they greatly shaped the way in which other disease-based research 
advocacy groups would develop.  
 Collective efforts through “buyers’ clubs,”—made more famous by the Academy 
Award winning “Dallas Buyers’ Club,”—placed pressure on the FDA to grant quicker and 
larger volume access for patients to experimental drugs through clinical trials, as opposed to 
importing and distributing unproven treatments.90 Due to advocacy efforts, the wait time for 
an application approving a new drug dropped from 34.1 months in 1986 to 12.6 by 1999. 
Yet, just as important, HIV/AIDS activists did not just raise awareness of their plight, they 
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absence of stories fo people of color suffering from disease. Her ethnographic approach integrates the stories 
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underservered and underrepresented populations proves to be extremely important when advocating for 
research, as seen below.  
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educated themselves on the science and began to actively participate in discussions about the 
ongoing research.91  
 HIV/AIDS research advocates became credible sources of the language of medical 
science and research, in addition to bringing their own cultural perspective and stories about 
the realities of suffering from the disease. After their gradual success with the FDA, the 
community recognized, however, that while they had increased access to experimental 
medicines there were few treatments in development. These advocates shifted their efforts 
beyond the FDA and towards the NIH’s “AIDS Clinical Trials Group of the National 
Institute of Allergy and Infectious Diseases.”92 This shift prompted an increased emphasis 
on the ability to speak the language of research in order to be informed about the ongoing 
experiments, trials, and for advocates to keep researchers informed about the needs of the 
community. As they increased their knowledge of medical research and the science behind it, 
they were able to present “themselves as credible within the arena of credentialed expertise. 
At the same time, these activists succeeded in changing the rules of the game, transforming 
the very definition of what counts as credibility in scientific research such that their particular 
assets would prove efficacious.”93 Not only were the activists able to speak the language of 
research, they were able to share with them the effects of research on the community, 
identify those within the community who needed access, note the side-effects of 
medications, and personalize the stories of those living with the disease. Thus, advocacy 
efforts were able to allow researchers to think beyond the mechanisms of the disease in 
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order to consider their research in the context of helping another human being suffering 
from a disease.  
 Their contributions, moreover, effectively reshaped how NIH clinical trials were 
conducted. Within ten years, due to pressure from activists, there were three ways in which 
AIDS research was conducted: standard clinical trial protocols through the AIDS Clinical 
Trials Group, community-based programs, and the Division of AIDS Treatment Research 
Initiative. The latter of the three was important for advocates because their “hallmark is 
speed in conducting ‘clinical trials and related research that evaluate new therapies and novel 
treatment approaches for those with HIV disease.’”94 Yet, their work did not stop there. 
Advocacy efforts played a key role in increasing access to trials for women and people of 
color through parallel clinical trials and increased community-participation in research.95 In 
the 1990s, their efforts increased access and participation in research within the U.S. New 
research advocates emerged, particularly from NGOs, who broadened the efforts to address 
the global problem of access and treatment for those unable to afford treatments particularly 
in Sub-Saharan Africa.  
 While the U.S. advocates were successful in shifting the research agenda to devote 
more resources to the development of treatments, those treatments, due to the high cost of 
development and patenting, were rarely affordable outside of high-income countries. Larger 
organizations, such as Oxfam and Doctors without Borders, began advocating for 
distribution of necessary medications to low-income countries. This debate was a much 
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harder fight against the claim of the pharmaceutical industry that lower costs in low-income 
countries could ultimately lower revenues in high-income countries, thereby diminishing the 
profit margin and the amount available to be spent on research and development.96  
 These changes became all the more important when South Africa implemented a 
requirement that all pharmaceuticals be made available in their generic forms. This led to 
vociferous objections from pharmaceutical companies. However, despite their objections, 
advocacy efforts ultimately resulted in a 2001 amendment of a framework for intellectual 
property called the “Trade Related Aspects for Intellectual Property Rights Agreement” 
(TRIPS). TRIPS, up until this point, had given patent-holding pharmaceutical companies a 
virtual monopoly on necessary drugs.97 After this agreement, however, access to these drugs 
was seen as a right, but what remained unclear was whose responsibility it was to carry out 
this right, that of sovereign nations or pharmaceutical companies.  
 This lack of clarity came to a head in a lawsuit brought by the drug industry against 
South Africa, who had modified its laws to ensure an affordable price of generic medications 
for its citizens. After a long legal battle and public advocacy campaign for HIV/AIDS 
patients by Oxfam, one of the major players in drug development and patenting, 
GlaxoSmithKline, eventually declared it would not enforce its patent on its HIV/AIDS 
drug, Zerit, and granted a license for the production of a generic version in South Africa.98 
Ultimately, the pharmaceutical industry withdrew their suit, enabling negotiations between !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
96 Lissett Ferreira, “Access to Affordable HIV/AIDS Drugs: The Human Rights Obligations of Multinational 
Pharmaceutical Corporations.” Fordham Law Review / Edited by Fordham Law Students 71, no. 3 (2002), 1141-
1142. 
 
97 Rachel Kiddell-Monroe, “Access to Medicines and Distributive Justice: Breaching Doha's Ethical 
Threshold,” Developing World Bioethics 14, no. 2 (2014), 59-60. 
 
98 Ferreira, “Access to Affordable HIV/AIDS Drugs,”: 1154; Cahill, “Biotech and Justice,” 40-42. 
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particular countries and the development of lower-cost effective treatments for 
HIV/AIDS.99  
 Despite these successes, however, lower costs for treatment did not always result in 
increased access. Though this is not necessarily a problem medical research itself can solve, 
attention to the necessarily collaboration with public health organizations and local 
organizations working in low-income countries is essential. In other words, advocating for 
drug access or development without participation from the targeted community will 
inevitably result in a less than ideal outcome, as could be seen in the early stages of 
HIV/AIDS research advocates in the U.S. This example shows the importance of those 
institutions who participate in the process of medical research, including universities, and the 
distribution of benefits can play in ensuring that products reach those most in need. 
However, over time these advocates were able to demonstrate the important contribution 
that advocates can make in altering the research agenda.  
The Good and the Bad 
 As can be seen from the example above, advocacy for research can positively 
influence, not only where research dollars flow, but also put a human face to the disease. 
This is an area in which all universities can contribute, and Catholic universities ought to be 
uniquely obligated. Their efforts were able to first put a human face to the disease through 
stories, struggles, and hopes expressed by advocates, dissociating the research from the 
immediate financial burdens and potential economic gains in order to situate the disease and 
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99 João Guilherme Biehl, “Pharmaceuticalization: AIDS Treatment and Global Health Politics,” Anthropological 
Quarterly 80, no. 4 (2007), 1083. Brazil became the first country to provide free access to Antiretroviral drugs 
(ARVs) and did so through a combination of activists, policy makers, and corporate actors within the 
pharmaceutical industry. 
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the research in the context of a person in need. 100 However, given that the economy is so 
closely tied to research, funding decisions often become just another policy decision.  
Nevertheless, these representatives are accountable to their public and to government 
agencies. By hearing from those suffering from the disease and their representatives, 
advocates raise awareness for those suffering from disease and announce their role as 
members of the public to whom the policy makers are accountable. Advocacy breaks the 
exclusive business or political focus that the patent and profit model of the intellectual 
property system encourages. In the case of HIV/AIDS, delinking access to medications and 
participation in research from intellectual property rights and linking them with human rights 
was a crucial step.  
 A second positive outcome of advocacy efforts increases the fluidity of information 
exchange between researchers, patients, and industry representatives. This open flow of 
information is something that HIV/AIDS advocates made possible, and that the WHO 
working group on research and development believe to be essential in order to generate 
better and more cost effective treatments for drugs globally. The CEWG on research and 
development argues that to facilitate this open flow of information, it is necessary to create a 
database in which open source content of various investigations could be held.  
 Creating a Global Observatory on Health for R&D could play a crucial role in 
priority setting.101 Much like the advocates for HIV/AIDS research were able to increase the 
flow of information and access to information for patients, an information database would !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
100 Research and Development to Meet Health Needs in Developing Countries: Strengthening Global 
Financing and Coordination Report of the Consultative Expert Working Group on Research and 
Development: Financing and Coordination, Research and Development to Meet Health Needs in Developing Countries: 
Strengthening Global Financing and Coordination, 37. 
 
101 This is a possibility that Catholic universities should consider as will be described in the next chapter.   
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enable all users to: analyze data on financing for global health R&D; produce analysis to 
inform national R&D portfolios management; guide R&D priority-setting at different 
levels; establish benchmark activities with other users; and monitor and evaluate trends 
against national, regional and global strategies.102 Thus, rather than duplicating efforts and 
guarding secrets, sharing information between the key players—universities, private industry, 
non-profit organizations, government, etc.—would be encouraged.  
 In essence, HIV/AIDS research advocates were able to reimagine the way in which 
patients participated in research for their diseases. Through their efforts, advocates were able 
to increase the flow of information between researchers, patients, and industry. They 
demonstrated the value of community-based research in developing more targeted and 
widely accessible clinical trials. Perhaps most impressively, they were able to alter the 
research agenda by increasing the allocation of resources—both financial and human—for a 
marginalized population, both locally and globally. Although the benefits continue to be 
unevenly distributed, advocates took positive steps to make the benefits of research more 
accessible to marginalized populations. Yet, advocacy participation, despite the many 
successes, presents challenges too. 
  Rebecca Dresser, overall, offers praise for advocacy work in her seminal text, When 
Science offers Salvation. As can be deduced from the title, Dresser is concerned with the amount 
of faith that is placed in the scientific and research community and the concerns it presents 
for research ethics. There are two concerns that prove relevant to the discussion at hand. 
First, Dresser cautions that advocates tend to stress the positive dimension of research. !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
102 Research and Development to Meet Health Needs in Developing Countries: Strengthening Global 
Financing and Coordination Report of the Consultative Expert Working Group on Research and 
Development: Financing and Coordination, Research and Development to Meet Health Needs in Developing Countries: 
Strengthening Global Financing and Coordination, 37. 
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Namely, that the studies they are participating in are understood as “new treatments” and 
“life-saving research.” The reality is, however, that in certain instances the trials may not 
actually benefit them, and the “life-saving research” may save someone else’s life not their 
own. 103 She notes that when HIV/AIDS activists campaigned and received more resources 
for studying, they did not like what they saw. There was discontent with the randomized 
controlled clinical trials, the “gold standard” of research, because it was unknown whether 
one would benefit or not from the research. When research participants and patients, 
moreover, were asked to discontinue other medicines, they often withdrew from the trial if 
there was any chance they could receive a placebo, “a standard thereby they deemed 
unsatisfactory.”104 While their advocacy efforts pushed forward  more just distribution of 
resources—something definitely needed—they also presented other challenges with respect 
to conducting an effective clinical trial.  
 A second concern Dresser raises concentrates on increasingly political dimension of 
advocacy work that offers only those with a seat at the table—or the ability to pay for one 
through lobbyists—the opportunity to shift the research agenda. In this way, advocacy 
efforts could result in increased funding for a particular disease simply because they have a 
seat at the table, and thereby exacerbate social inequalities. Given that research funding 
allocation functions as a political process, it would be detrimental to the just distribution 
efforts highlighted in the global work of HIV/AIDS research advocates if advocacy began to 
take up the more partisan lobbying efforts.  !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
103 Rebecca Dresser, When Science Offers Salvation Patient Advocacy and Research Ethics, (New York, NY: Oxford 
University Press, 2001).This is referred to as the therapeutic misconception, and is widely prevalent when 
people enroll in research. Often, when patients see that a treatment is not working the electively withdraw from 
the trial, limiting the effectiveness of the trial. Thus, when seeking informed consent ensuring that patients 
understand that they are not enrolling in new treatment, but rather participating as a research subject.  
 
104 Dresser, When Science Offers Salvation, 24. 
!!
195!
 In coupling her first concern, therapeutic misconception, with her second concern, 
politically advocating for a cure, Dresser expresses a final concern that advocates can 
become so involved, alongside their scientist collaborators, that the possibility of not finding 
a cure becomes unimaginable. Both scientific researchers and advocates must necessarily 
maintain a perspective, that is not without hope, but that is inclusive of a wide range of 
available research options and alternatives. These alternatives and options, however, cannot 
happen without mutual communication between the researchers, those suffering from 
disease and their advocates, private industry, and public funding sources.  
 Communication concerning research priorities often lacks the multiple perspectives 
necessary to create a socially responsible research agenda. The advocates for HIV/AIDS 
research demonstrate the complexity of factors—political, economic, personal—that play a 
part in establishing a research agenda. Most importantly, however, these factors put a human 
face and social condition to those suffering with the disease. Yet, for the vast majority of the 
world, those suffering the global burden of disease have no one to speak for them. They 
have no advocates and, as Dresser rightly cautioned, only those with a voice receive funding.  
 It is worth noting that even those who received and participated in the shaping of 
the HIV/AIDS research agenda—and perhaps a cause of their success—were predominately 
white males who were the primary participants in research in the 1980s and those who were 
deciding what agenda items ought to be pursued.105 Thus, the critical question for research 
advocates with a horizon for the poor majority is, who are their advocates? What ought 
these advocates advocate for? How can one ensure—insofar as possible— its successful 
implementation? !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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Conclusion: Towards Responsible Advocacy 
 In a 1987 essay, Jürgen Habermas focuses on the discursive dynamic that takes place 
within the learning process at the university. It is through this discourse in which 
“specialized internal public spheres coalesce and branch apart again in the university’s 
programs.”106 This learning process, however, is not idealized within the university, but 
rather creates space for discourse. Habermas argues that even though a researcher “appears 
to work alone in the library, at his writing desk or the laboratory, his learning processes are 
inextricably interwoven with a public ‘community of investigators.’”107 For medical research, 
patients in need of new drugs, physicians working with these patients, and public health 
officials aiming at disease prevention form a part of this essential community. Thus, to 
engage in responsible medical research one needs to broaden the horizon of investigation. 
This role is not exclusively the responsibility of a scientific researcher, but must engage the 
entire community.  
 For Catholic universities, this discourse takes on an important facet when confronted 
with injustices around complex structures in which they participate. The structure of medical 
research is one such challenge that Catholic universities should reflect on in light of the 
concern for justice. In the globalized context of research, however, the conversation about 
how to prioritize justly particular contexts, populations, and needs with the allotted research 
dollars is ongoing.  
 Drawing from the previous chapter, the insights of Ellacuría and liberation theology 
emphasize the importance of the place or the context from which one begins the necessary !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
106 Jurgen Habermas and John R. Blazek, “The Idea of the University: Learning Processes,” New German 
Critique Spring/Summer, no. 41 (1987), 3. 
 
107 Habermas and Blazek, “The Idea of the University,” 21.  
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dialogue. If the place of the poor, or option for the poor and vulnerable groups, is to have 
an epistemological impact, then it is necessary to begin reflecting on a research agenda from 
their perspective. Beginning from this perspective does not necessarily mean physical 
location. This consideration can take the form of an intellectual stance that prioritizes 
experiences of injustice and suffering that can be omitted often in establishing research 
priorities. Starting from the intellectual place of the poor shifts the conversation to concerns 
about equity, distribution, and need. These concerns come into focus by reexamining the 
morbidity and mortality statistics above or looking at the World Health Organization 
DALYs—just as John Snow looked at London’s Weekly Returns to target his 
investigations—and in so doing, recognizing those who have historically been marginalized.   
 The task of the Catholic university, however, is not just to know who these people 
are, but also to engage in practices and dialogue that aim to reshape participation in 
academy-industry relationships, targeting diseases that ought to be researched, and 
participating in global advocacy networks These challenges necessarily take the university 
beyond intercampus dialogues and create conversations within the larger Catholic Church, 
businesses and non-profit organizations, and the communities who are in need. While 
research cannot cure everything, it has historically provided a necessary piece of the 
puzzle—alongside a solid public health infrastructure and access to medical care. Catholic 
universities are in a unique position to be leaders in this type of research effort because of 
their established global network which better enables these institutions to serve as advocates 
for and with others and to ensure a more just distribution of the benefits of medical 
research.  
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 Ellacuría describes the function of the university as inherently political, and thus one 
of its tasks is to confront structures that perpetuate injustice. The structure of medical 
research is one that, at least benignly, neglects the majority of the world in its efforts. 
Advocacy efforts at the university level, and particularly engaging academic scientists, can 
take place through targeting publications to highlight under researched diseases, grant efforts 
that seek to benefit the majority of humanity, and focused hiring practices that demonstrate 
the universities’ commitment to bringing in the best researchers who share both a deep 
commitment to excellence in research, but also a shared concern for justice. The goal, then, 
is to engage others more broadly to participate in the “community of investigators”, as 
Habermas describes it. By implementing an advocacy-based institutional model of research, 
the goals would be to: raise awareness around the distortion of the distribution and priorities 
of medical research; restore health as the most important intrinsic good of the practice of 
medical research; and to participate with partner organizations in establishing a more just 
framework to distribute the benefits of the research undertaken. While this will not, 
unfortunately, eradicate diseases or eliminate disparities entirely, it hopefully will position 
Catholic universities as institutions engaged in a practice of medical research that prioritizes 
justice and solidarity through targeted research efforts and serve as an example for others to 
follow.!
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CHAPTER FIVE 
SOCIALLY RESPONSIBLE MEDICAL RESEARCH 
Introduction 
 A socially responsible medical research agenda needs to reflect on the research 
structures that allow the health needs of the majority to go under researched. As seen in the 
previous chapters, the development of medical research has occurred alongside the 
production of technologies and drugs that have consistently promoted health benefits tied to 
potential economic gains, over those with greater health benefits for more people. An 
analysis of the empirical data on morbidity and mortality statistics, reviewed in Chapter Four, 
reflects these disparities in research and burden of disease.  
 The unjust burden of disease that afflicts the poor majority, however, emerged over 
time through political, economic, and university-based decisions. The tension in creating a 
medical research agenda exists between research that benefits individual persons and 
research poised to benefit larger groups within the population. This unjust distribution of 
research, which came to prioritize particular individuals, e.g. soldiers, and diseases from high-
income countries, can be seen through the historical development of medical research 
described in Chapter One.   
 Chapter One maintains an intentional focus on research that targeted improvements 
to the health of the general public.  Yet, even this research was not without its injustices. 
While John Snow’s cholera research focused on his immediate neighborhood and the 
development of international public health practice, distortions about what type of research
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 truly benefited the public became the contentious.  The tension between the priorities of 
public health over the future health of particular individuals, peaked with the unethical 
research practices associated with eugenics. The practice of negative eugenics, a popular 
method in the U.S., UK, and in Nazi Germany, served as the watershed event that prompted 
a more concerted effort to focus on the ethical conduct of research and protecting the rights 
of research subjects.  
 Despite the complex socio-historic origins of research ethics, in practice the focus 
centered on protecting the individual rights of research subjects by relying on the physician’s 
obligation to do no harm. This individualistic approach, however, ignored why unjust 
research practices continually affected particular groups of persons, e.g. racial minorities and 
those of lower socio-economic status. While consideration was given to the protection of 
individuals from vulnerable populations, little ethical reflection concerned itself with the 
vulnerability of these particular groups. It was, and to a large extent still is, problematic that 
the application of research ethics virtually ignores the socio-historic context in which 
research takes place. Particular groups continue to be excluded from the benefits of the 
social practice of medical research. The historical analysis from Chapter Two, coupled with 
the disparities in research described in Chapter Four, demonstrates the lacunae of a socio-
ethical analysis of research that considers the injustices within the priorities and distribution 
of medical research.  
 The injustices associated with the priorities of medical research, I hypothesized, were 
not due to lack of good science, but rather, an epistemological problem that allowed for 
science to be interpreted as morally neutral and objective practice. The turn to the work of 
Xavier Zubiri and Ignacio Ellacuría in Chapter Three provided a needed epistemological 
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shift for scientific research. Ellacuría and Zubiri both acknowledged scientific research as 
fundamental not only for understanding, but also for shaping the way in which historical 
reality is experienced. This experienced reality, however, is one in which the majority of 
persons disproportionately experience poor health and economic poverty. While science is 
often thought of as a neutral and objective practice, I follow Ellacuría and Zubiri’s argument 
that the practice of scientific and medical research itself has in fact participated in shaping 
the injustices within historical reality.  
 An epistemology of historical reality emphasizes that human actions in history 
contribute to the way in which reality is constructed and that no practice should be 
considered morally neutral. Given the current global health disparities, certain persons and 
institutions have continually received priority, while the health needs of the economically and 
socially poor have been neglected, creating both a moral an ethical dilemma. In order to right 
this historical wrong, I argue that a liberationist, social, and Catholics ethic must begin from 
and with the perspective of the poor majority, a majority whose health needs go largely 
ignored resulting in premature death and disability of millions of individuals.  
 Reflecting on the social ethics of medical research begins with an analysis from, if 
not physically, then at least intellectually, the places where lives are consistently lost before 
their time. In this way, the health research needs of the poor majority that become the 
starting point for establishing an ethical research agenda. While anyone can take up research 
that focuses on the health needs of the poor majority, this approach proves constitutive for 
Catholic universities that emphasize the moral importance of social justice.  
 This final chapter argues: Catholic universities have a moral responsibility to 
prioritize medical research for health that demonstrates the effectiveness of its commitment 
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to social justice, perhaps most clearly articulated after the Second Vatican Council. At the 
Second Vatican Council increased attention was turned to the places in which the Catholic 
Church lived and worked. The context of many Liberation Theologians was one of poverty 
and oppression, and many argued for the Catholic Church to actively address the political 
and social structures that permitted the oppression to continue. In El Salvador the Catholic 
university, the UCA, came to play a prominent role in shedding light on present injustices. 
Ellacuría, among others, emphasized that the functions of the university: teaching, research, 
and service, should socially project the injustices present and challenge them. It is taking up 
the preferential option for the poor that allows the injustices to be seen most clearly.  
The option for the poor functions as more than a rhetorical move to emphasize those that 
often bear the weight of injustice, and instead should result in institutional practices and 
policies that socially project the needs of the poor in the daily work of the university.  
  Research that focuses on the experience and health needs of the poor that signifies 
the epistemological shift that needs to take place within medical research. Making an option 
of the poor serves as the standard by which justice ought to be measured. 1 The 
epistemological function of the option for the poor contains a political task to confront the 
socio-historic structures that perpetuate poverty, vulnerability, and marginalization of the 
majority of humanity through the social practices in which one is engaged, which in this 
instance is medical research.2  
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1!Ignacio Ellacuría, “The Challenge of the Poor Majority,” in Towards a Society that Serves its People: The Intellectual 
Contribution of El Salvador's Murdered Jesuits, ed. John J. Hassett and Hugh Lacey (Washington, D.C.: Georgetown 
University Press, 1991), 208. Also see p. 19 Chapter 3, n. 33. In this chapter, I maintain the use of Ellacuría’s 
definition of the poor, “the vast bulk of humanity whose standard of living is such that they can scarcely satisfy 
their most basic needs; this majority whose standard does not permit them sufficient human development…” 
 
2 Ellacuría, “The Challenge of the Poor Majority,” 208.  
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 While Catholic university-based medical research ultimately makes up a small 
minority of the overall medical research conducted in the U.S., these institutions participate 
in national and international networks of research. When working collaboratively, these 
networks can focus their research efforts to confront the health problems that face the poor 
majority. The first section of this chapter explores the context in which Catholic universities 
take up their task of medical research. The second section argues that normative values 
presented in liberationist thought should influence the social practice of medical research by 
considering the option for the poor, the importance of “place”, and a notion of justice that 
begins from the experience of injustice. The final section concludes in a similar way to which 
the dissertation began, by offering paradigmatic examples—not specific proposals—of 
research efforts that make it feasible to take up the option for the poor in establishing 
research initiatives and/or cultivating partnerships aimed at benefiting those on the margins 
of society.  
Catholic Universities and the Context of Medical Research 
 It is estimated that over 200 times as many dollars are spent on a life lost in a high-
income country compared to that one life lost in a low-income nation. Catholic universities 
cooperate in the unjust practices of medical research insofar as they do not offer an 
alternative approach to research that takes up the health needs of the poor. The option for 
the poor, rooted in the Catholic Church’s social teaching, has become a key source of 
identity for their universities. However, when it comes to medical research on a global scale, 
it often fails to be put into practice because of its contradiction to the way in which research 
is typically funded. If research continually avoids addressing issues that face the majority of 
humanity, then the practice of research results in a social practice that perpetuates systemic 
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injustices by ignoring the legitimate health needs of the majority of the world. While this 
injustice is a question for all involved in medical research, it poses a unique challenge to 
research at Catholic universities as institutions situated in a globalized world and amidst the 
tension between the local and universal church.  
Between the Local and the Global 
 John Paul II’s Ex Corde Ecclesiae describes the Catholic university as an institution 
that exists in relationship to the church as both local and universal. The document describes 
the relationship of the university most strongly in its unity with the local church; however, as 
an academic institution, he also notes that it participates in the international academic 
community, whereby “each institution participates in and contributes to the life and the 
mission of the universal Church…”.3 While the exact nature of the relationship of the local 
churches and the universal church has been the content of much theological discourse, there 
is little debate from the document that the university itself in fact participates in some ways 
in both dynamics. 4  Thus, the context of research for Catholic universities ought to consider 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
3  John Paul II, Ex Corde Ecclesiae (1990), no. 27. “As such, it participates most directly in the life of the local 
Church in which it is situated; at the same time, because it is an academic institution and therefore a part of the 
international community of scholarship and inquiry, each institution participates in and contributes to the life 
and the mission of the universal Church, assuming consequently a special bond with the Holy See by reason of 
the service to unity which it is called to render to the whole Church.”  The quote above is a partial quote of 
John Paul II’s more theologically charged point that pertains to the relationship between the local and universal 
church. This is relationship is important because of the general understanding of academic freedom at the 
university and, in particular, the function of theology within academia. These points have been well elaborated 
on elsewhere, and lie beyond the scope of this dissertation, but bear noting. Despite the disputations around 
the exact nature of the Catholic university’s relationship to the universal church, it participation in the universal 
church and, as John Paul II noted, the international context in which is fundamental.   
 
4  Kilian McDonnell, “The Ratzinger/Kasper Debate: The Universal Church And Local Churches,” Theological 
Studies 63, no. 2 (2002). Kasper essentially understood that the church universal exists in and develop from local 
churches. Conversely, Ratzinger argued that the universal church existed ontologically prior to all local 
churches, and that the only de facto remnants of the universal “The pope and the curia remain as the only 
elements in the presentation [of the universal Church].” 
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local needs, but also the way in which those needs relate to the globalized world in which it 
is immersed.   
 The work of the university operates in a globalized world characterized by rapid 
technological developments, increased interdependence across borders, and a widening 
economic and health gap between the rich and the poor. Globalization is not a new topic, 
yet it continues to defy a singular definition. David Hollenbach, for example, borrows from 
Keohane and Nye to describe globalization “as the increase in networks of interdependence 
among people at multicontinental distances.”5  Thomas Massaro settles on the broadest 
definition possible by describing globalization simply as “everything and its opposite,” and in 
so doing, “calls attention to rival construals, countervailing forces, and ethical dilemmas 
unleashed when national borders seem suddenly irrelevant.”6 Sumner Twiss argues that 
globalization is “the multidimensional and interactive processes of economic, political, and 
cultural change across the world resulting in increased social interconnectedness as well as 
opportunities for social confrontation among peoples.”7 Finally, Rebecca Todd Peters 
characterizes it as “economic, social, political, and cultural processes that serve to break 
down traditional barriers that have separated peoples, nations, and cultures from one 
another.”8 These definitions share a common focus on globalization’s ability to transcend 
boundaries, but also this ostensible absence of boundaries result in new global challenges. In 
a globalized world, “local” concerns can no longer be considered as confined to a particular !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
5  David Hollenbach, The Common Good and Christian Ethics (Cambridge, UK; New York: Cambridge University 
Press, 2002), 213.  
 
6  Thomas Massaro, “Introduction,” Journal for Peace and Justice Studies 14, no. 1 (2004). 
 
7  Sumner B. Twiss, “History, Human Rights, and Globalization,” Journal of Religious Ethics 32, no. 1 (2004), 40. 
 
8  Rebecca Todd Peters, Solidarity Ethics: Transformation in a Globalized World, 2014), 3. 
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geographic area. Instead, local actions partake in an interdependent global community that, 
for good or for ill, is here to stay.  
 Scientific inquiry, moreover, is not absolved from the effects of globalization. Yet, 
medical research traditionally remains focused on particular projects of individual researchers 
that mostly reflect specifically local and national priorities. However, the prioritization of 
local research, which for high-income countries projects potential future needs, can overlook 
more pressing health needs that could benefit directly from immediate medical research. 
Catholic medical research, given the global presence within a Church committed to justice, 
should presume a fundamental orientation towards research that not just expands a reservoir 
of knowledge or targets national priorities for which it can receive funding, but engages in 
medical research that stands to benefit the health of all human beings.9  
Catholic Research 
 Out of the 225 Catholic colleges and universities in the U.S., only about 10% of 
them engage in medical research. 10  For the last five years, these universities have averaged 
around 400 NIH grants per year, most of which are generated from six awardees: 
Georgetown University, Saint Louis University, Loyola University Chicago, University of 
Notre Dame, Boston College, and Creighton University.11 Within this group, Georgetown 
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9  Michael J. Buckley, The Catholic University as Promise and Project : Reflections in a Jesuit Idiom (Washington, D.C.: 
Georgetown University Press, 1998), see chapter two. 
 
10 Catholic Data, Catholic Research, Catholic Statistics, “Frequently Cited Research,” 
http://cara.georgetown.edu/CARAServices/requestedchurchstats.html (accessed March 22, 2015); Association 
of Catholic Colleges and Universities, “Frequently Asked Questions,” 
http://www.accunet.org/i4a/pages/index.cfm?pageid=3797#WorldPercentage (accessed March 22, 2015). 
Globally there are over 1800 colleges and universities in operation. 
 
11 All data pulled from National Institute of Health, “NIH Awards Database,” 
http://www.report.nih.gov/award/index.cfm?ot=&fy=2014&state=&ic=&fm=&orgid=2869001&distr=&rfa
=&om=y&pid=&view=state (accessed March 22, 2015) 
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receives the most NIH funding, with a five-year high in 2010 of $69.4 million from 162 
grants and low in 2014 of $47.5 million from 104 grants. Their grants consistently double 
that of the next two Catholic university recipients, which is some variant of Loyola 
University Chicago, the University of Notre Dame, and/or Saint Louis University.  
 The grants achieved by the universities are wide-ranging, and in many respects 
mirror NIH funding priorities. The received grants focus on research in biotechnology, 
clinical trials, genetics, and also HIV/AIDS, health disparities, preventive medicines, heart 
disease, etc. In other words, Catholic universities do not distinguish themselves in choosing 
research priorities from their non-Catholic counterparts. Thus, Catholic university medical 
research reflects NIH funding, and likewise engages in medical research irrespective of the 
global inequalities in health. This presents a moral challenge for Catholic universities, and 
one that liberation theology argues that the Catholic university ought embrace.  
Research and a Liberationist Social Ethic 
 If status quo medical research produces inequity and injustice, then Catholic medical 
research ought to prioritize preferentially the needs of those that suffer from the inequity 
and injustice, i.e. the poor. Liberation theologians have been the most vocal and consistent at 
grounding socio-ethical concerns in the needs of the poor. Ignacio Ellacuría’s normative 
insights for establishing a research committed to solidarity and situated intellectually in the 
place of the poor, challenges structures that allow for unjust practices. Liberationists take up 
the concept of justice from the experience of injustice that denies an opportunity for 
participation in the co-construction of historical reality. In Chapter Three, I noted that the 
participation in shaping reality proves a fundamental criterion for justice. This concept of 
justice begins from contextual experiences of injustice, while at the same time creating 
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counter social and political systems that can more easily realize opportunities for 
participation and equity.  
Solidarity 
 Solidarity values the interconnectedness of human beings by prioritizing critical 
reflection that considers the actions of individuals and groups from the perspective of 
mutually conditioned social relationships. Liberationists theologize the notion of solidarity 
by locating its foundation in the incarnation of Jesus, through which God enters into a 
mutual relationship with human history. Liberationists point to the partiality of Jesus’ actions 
on behalf of those groups that were socially marginalized, in particular: women, the poor, 
and those who were disabled either from birth or illness. However, solidarity is not exclusive 
to liberation theology, but has a tradition rooted social theorists who likewise explore this 
concept as an important social and political value is incorporated into the theological insights 
of liberation theology.  
 Émile Durkheim describes solidarity as both a chosen and given interconnectedness 
within society that shapes the social order. Durkheim distinguishes between two types of 
solidarity, mechanical and organic. Mechanical solidarity exists sui generis through shared 
social bonds, rules, values, and beliefs that bind individuals and provide an unmediated sense 
of solidarity within the collective.12 While mechanical solidarity links the individual to society 
without an intermediary, organic solidarity develops in more complex and cosmopolitan 
contexts within “divisions of labor” in which each individual is called upon to play a specific  
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
12 Émlie Durkheim, The Division of Labor in Society, trans. WD Hall, (New York: Free Press, 1984), 60-61. Peters, 
Solidarity Ethics, 20-21.   
!!
209 
role in society.13 The success of society rests, then, on the capability of individuals fulfilling 
their role. As industrial societies shifted away from mechanical forms of solidarity, Durkheim 
expressed concern that the individuation within modern society would make it more difficult 
to maintain a sense of organic solidarity, which he saw as fundamental for social stability.14 
While Durkheim was concerned about social stability, Weber and Marx focused on the 
political implications of solidarity.  
 Politically, Max Weber and Karl Marx build on the sense of solidarity as a connection 
amongst social groups that translates into political practices. For Weber, it was the formation 
of meaningful relationships that would yield democratic principles of fairness and equity.15 
Marx, however, was less concerned about this sense of solidarity amongst all individuals, 
emphasizing the importance of solidarity within one’s social class. In a certain sense, Marx’s 
solidarity operates as an exclusive form of class solidarity that functions differently than the 
concept as proposed by Weber or Durkheim. While the approaches of Marx and Weber 
differ from that of Durkheim, their insights lend themselves to the socio-political vision 
incorporated into solidarity from the perspective of liberation theology. However, liberation 
theology views solidarity from the unique perspective of the incarnation, which calls 
individuals and communities to a shared commitment around solidarity.  
 For liberation theology, solidarity emphasizes both the importance of social and 
political stability as prioritized in social theory, but does so through an individual and 
collective call to conversion. Gustavo Gutiérrez focuses on conversion as fundamental in 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
13 Durkheim, The Division of Labor in Society, 83-85. 
 
14 Peters, Solidarity Ethics, 21. 
 
15 Ibid. 
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order to break with the old way and to re-orientate individuals and institutions toward the 
way things ought to be. Conversion, he notes, calls for a recognition of the presence of sin 
and suffering both in the world and in one’s own life and the desire to turn away from it. 
This metanoia is not just for one’s own sake, but in recognition of one’s participation as a part 
of the collective. “It becomes necessary for us to examine our own responsibility for the 
existence of unjust ‘social mechanisms.’ In addition to calling for personal 
transformation…[t]he conversion required will have to be radical enough to bring us into a 
different world, the world of the poor.”16 Here one can observe the influence of social 
theory on liberation theology insofar as it the critical analysis of social structures that allow 
one (or many) to recognize the need to change course in order for society to thrive. This 
conversion focuses on a new way of acting that allows for the development the whole of 
society, an important departure from Marx. In this regard, conversion calls one to act for 
and with those who remain most frequently left out of participating in the building up of 
society.17  
 Therefore, conversion does not evoke the generic promotion or defense of human 
rights, but one that confronts particular divisions within society. Drawing from Ellacuría, the 
only way to fully encounter this reality, “means engaging, remembering, and ultimately 
undoing its terrible negativity. In a word, it demands conversion, a conversion of the human 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
16 Gustavo Gutiérrez, “Conversion,” in Michael Griffin and Jennie Weiss Block, eds. In the Company of the Poor: 
Conversations between Dr. Paul Farmer and Fr. Gustavo Gutierrez, Maryknoll: Orbis, 2013, 75.  
 
17 Hille Haker in a recent essay in Concilium has emphasized Johann Baptist Metz’s “insight that there is no 
meaningful theology unless it attends to the suffering, and laments the neglected responsibility and refused 
solidarity.” See Haker, “Solidarity and Justice Reconsidered,” Concilium no.1, 2014; also see: Johann Baptist 
Metz, “Theology as Theodicy” in A Passion for God: A Mystical-Political Dimension of Christianity, trans. J. Matthew 
Ashley, (New York: Paulist Press, 1998), 54-71.  
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heart and a conversion in historical reality.”18 Therefore, while solidarity may require an 
individual conversion, solidarity is always situated in the political and requires social action 
that promotes inclusion of those most frequently excluded. 19 For liberation theologians, 
conversion begins with the recognition of injustices that burden the majority of the world 
and moves towards a praxis of solidarity that turns to the places where suffering exists and 
human flourishing is limited.  
The Importance of Place and Story 
 In Chapter One, I cited that India’s Council on Medical Research (ICMR) does not 
prioritize economics as a goal of medical research, but instead describes it as research 
focusing on disease prevention and developing treatments for those suffering from chronic 
and/or acute disease. Unlike the descriptions of high-income countries—France (Inserm), 
U.K. (MRC), and U.S. (NIH)—that explicitly identify economic profit as a goal of medical 
research, the ICMR omits economics as a goal of the practice itself. Instead, the ICMR 
policy articulates the importance of balancing research priorities based on the public health 
needs of the country with those of individuals. In the description offered by the three 
western, high-income nations, no mention of public health or reducing disease burden 
appears as an explicit focus of research. The context from which India articulates its research 
priorities, however, is undoubtedly shaped by more widespread cases of urgent health need !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
18 Burke, The Ground Beneath the Cross: The Theology of Ignacio Ellacuri ́a, 106.!
 
19 Barbara Prainsack and Alena Buyx, “Solidarity: Reflections on an Emerging Concept in Bioethics,” Nuffield 
Institute for Bioethics, 2011, (accessed: April 9, 2015), http://nuffieldbioethics.org/wp-
content/uploads/2014/07/Solidarity_report_FINAL.pdf Solidarity, while a tenant of CST and liberation 
theologies, has more recently gained traction in secular bioethics.  A 2011 report from the Nuffield Council on 
Bioethics emphasizes both the individual and social dimension of solidarity as an emerging—though largely 
considered a European value—in bioethics literature. Primarily the concept has pertained to public health, 
equity in health care systems, and global health. There has been no reference to institutional practices of 
solidarity with respect to medical research, a crucial piece to working for a solution to a global health problem 
like Ebola. 
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that in many ways reflect global health needs. Low-income and lower-middle income 
countries, like India, who make-up what Jon Sobrino refers to as the “world of the poor,” 
should shape values and social practices that draw our attention to acute social problems.  
 The “world of the poor” draws our attention to the importance of an 
epistemological shift that begins by “realizing” the fact that the basic needs of many are not 
being met. Prioritizing medical research from the place of the poor necessitates addressing 
the disparities in global research that contribute directly to unjust burdens of disease 
“shouldered” by the poor majority. Following Ellacuría, human beings through the 
structures that shape these injustices have an option of “taking charge” of the concerns for 
and with the majority or ignoring them.  
 Ellacuría’s three-fold method of realizing, shouldering, and taking charge of the 
weight of reality is done so from the perspective of the poor, which requires challenging the 
injustices endemic to the experience of poverty. If this is the place from which medical 
research becomes reconsidered, then the narrative of research that focuses on cures, 
breakthroughs, and improved quality of life, must be reimagined. It was the telling of the 
story of those suffering from HIV/AIDS and humanizing their needs that contributed to 
changes in policies surrounding medical research practices. Thus, the place and the stories 
from these places prove fundamental to the re-imagining and evaluation of the medical 
research agenda.   
 Distinguished anthropologist and physician, Arthur Kleinmann, describes that 
sharing experiences of suffering transforms the relationship between the hearer of the 
narrative and the context from which the experience is being told. Ultimately, “the semiotic 
iteration of the suffering of lay men and women into the taxonomies of healing professionals 
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is then shown to distort the moral world of patient and community.”20 While some may be 
reluctant to characterize medical researchers as “healing professionals,” it does not diminish 
the impact that the personalization of the stories of suffering can contribute to a reframing 
of the objective of one’s engagement in the social practice of medical research. One possible 
explanation is that ethnographic work, like that of Kleinmann, allows individuals or groups 
to “interrogate themselves as much as they seek to learn from the people with whom a study 
is undertaken.”21 Here the option of place emerges. Does one opt to remain removed from 
the stories of suffering and injustice—as happened for many in the U.S. following the 
current Ebola outbreak—or does one opt to see oneself as involved in the continuation of 
these unjust experiences?22  
 In essence, liberation theology rejects abstract theories that fail to recognize the lived 
experiences of those communities suffering particular injustices. As sentient-intellectual 
persons, human beings have the capacity to move beyond these contexts and place oneself 
in the position of the other and, thus, to be better poised to develop policies that allow for 
institutional change. Liberation theology and philosophy argue that it is the option for the 
context and experience of the poor majority that offers the most authentic place from which 
to critique the unjust construction of reality. “The moment of option, which seeks that 
place-that offers-truth and does truth, should not be blind but enlightened. It is first 
enlightened by its ethical assessment of justice and freedom, or better, of ‘no justice’ and ‘no !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
20 Arthur Kleinmann, Writing at the Margin: Discourse Between Anthropology and Medicine, (Los Angeles, CA: 
University of California Press, 1997), 96. 
 
21 Christian Schare, and Aana Marie Vigen, Ethnography As Christian Theology and Ethics, (London: Continuum, 
2011), 16.  
 
22 Jessica Firger, “Ebola Death Toll Rises in West Africa While Americans’ Interest Wanes,” 
http://www.cbsnews.com/news/ebola-death-toll-rises-in-west-africa-while-us-interest-wanes/, January 8, 
2015, (accessed: March 26, 2015). 
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freedom’…”23 Rather than an abstract theory of justice, liberation theology argues that 
justice must be conceived from the place of those who have no justice.24 
Justice and Structural Injustices 
 For Ellacuría, the concept of justice develops from places and experiences of 
injustice that function on both personal and structural levels, evoking a critical response 
through a dialectic between utopia and prophetism.25 In Chapter Three, I referenced one of 
Ellacuría’s final essays, “Utopia and Prophetism.” Utopia, derived from the Christian 
understanding of God’s Kingdom historicized through the actions of Jesus, exists in tension 
with prophetism—a critical and historical response that calls for social change. “Utopia and 
prophetism, if presented separately, tend to lose their historical effectiveness and become an 
idealistic escapism; and so, instead of becoming forces for renewal and for liberation, they 
are at best reduced to functioning as a subjective solace for individual persons or for whole !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
23 Michael Lee, ed. Ignacio Ellacuría, 114. 
 
24 Ivan Petrella, Beyond Liberation Theology: a Polemic, (London: SCM Press, 2008), 12, fn.25. Also see Enrique 
Dussel, Ethics of Liberation in the Age of Globalization and Exclusion., trans. Alejandro A. Vallega, (Durham: Duke 
University Press), 2013. John Rawls, A Theory of Justice, (Cambridge, MA: Harvard University Press, 1999). 
Sheldon S. Wolin, Politics and Vision, (Princeton, NJ: Princeton University Press, 2004), 532-533. Iris Marion 
Young, Responsibility for Justice, (Oxford, U.K.: Oxford University Press, 2012), 64-72. Thus, while liberation 
theology would certainly be sympathetic to a robust theory of justice like Rawls’s and readily take up his 
difference principle, it would be critical of his a-historical starting point. The original position would be seen as 
abstracted, and questions would have to be raised about how one comes to understand and experience 
injustice. While conversations behind the “veil of ignorance” may have full knowledge of circumstances, the 
interlocutors would remain unaware of the particulars of race, gender, and economics, which historically 
contribute to unjust disparities. Aside from an historical starting place, the second point of departure would be 
the focus on macro political organization. Although liberation theologians and philosophers emphasize 
structural and political change, this change begins from the micro level in hopes of unmasking unjust structures 
and enacting practical and historical change.  
 
25 Note here, that the starting place is the concrete experience of injustice that is challenged by the historical 
teachings and actions of Jesus about God’s Kingdom. While there are resonances of Aquinas’s natural law 
approach to the common good—especially in the utopic vision— at work in the efforts of liberation theology, 
their starting places differ. For Aquinas, it is a metaphysical orientation of the will towards justice as a “good,” 
whereas for liberation theology it is the witnessing to the experiences of injustices and suffering that are 
endemic to the human condition that serve as the inciting incident. Thus, it is not an abstract concept of justice 
as a “good” that is the starting point, but rather it is the historical experiences of injustice that demands a 
response or, as Gutiérrez noted above, a call to conversion and institutional change.  
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people’s.”26 In other words, separating the two can contribute to an understanding of utopia 
as describing something that ought to be patiently waited for in the future while enduring 
present sufferings.  
 For liberation theologians, like Ellacuría, Gutierrez, and Sobrino, present injustices 
have to be actively worked against in light of an already begun utopia, God’s kingdom, in 
which suffering ought not exist. The act of seeking justice from the place of injustice 
requires persons or people who do not directly experience injustice to transcend their own 
situation in order to contemplate the reality and injustice of the condition of another and to 
work for and with them to transform it. Therefore, utopia does not represent an escape 
from, but rather a realization of that which is possible yet unfulfilled within the current 
social, political, and economic models critiqued by prophetism.  
 Prophetism makes utopia present in reality through critiques of current unjust 
structures that call for social change and a new way of life.27 Prophetism functions as a 
critical “interpretation of the surrounding social world—and of ourselves—that uncovers a 
reality in which certain possibilities are realizable while others are not.”28 Thus, it is not an 
idealized notion but, instead, a notion grounded in an historical realism that draws attention 
to the places and contexts in which injustice is experienced as a way of life. From the 
perspective of injustices, alternatives are sought as a means by which to establish a more just 
social order. Yet, this social order cannot be understood apart from historical experiences !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
26 Ignacio Ellacuría, “Utopia and Prophetism in Latin America: A Concrete Essay in Historical Soteriology,” in 
A Grammar of Justice: The Legacy of Ignacio Ellacuría, trans. Kevin Burke and J. Matthew Ashley.  
 
27 Kevin Burke and J. Matthew Ashley, A Grammar of Justice: The Legacy of Ignacio Ellacuría, (New York: Orbis 
Books, 2014), 7. 
 
28 José Manuel Romero Cuevas, “Humanism, History, and Criticism in Ignacio Ellacuría,” The Xaveri Zubiri 
Review 10, no. 1 (2008), 11. 
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and accounts of injustice. 
  Justice conceived within the context of liberation hopes for the already begun 
utopia, which develops through a critical stance towards unjust social structures that create 
victims and disparities between race, class, and gender.  
“[J]ustice, giving to each what is due to each, not only makes freedom possible but 
also what is moral and just. Liberation from every form of oppression, whatever it is, 
is a real process of ‘just-ification.’ This justification is the real means of promoting 
freedom and the conditions that make it possible. In this sense, liberation is a 
process of ‘ad-just-ment’ with oneself, in that it seeks to break one’s internal and 
external chains. It is a “just” process in that it tries to overcome manifest injustice; 
and it is a “justifying” process in that it seeks to create adequate conditions for the 
full development of all and for an equitable use of the conditions.”29  
   
Justice, therefore, is understood as a process that begins from and seeks to rectify inequitable 
distribution of “what is due, ” while working towards conditions that allow for greater and 
more equitable participation in the process of creating a just society. Ensuring the possibility 
for justice, however, requires both a personal and a social process of “ad-just-ment” by 
identifying and challenging those structures that deny human beings the fullness of freedom 
entitled to them. Once unjust social structures become revealed, alternative policies and 
practices must be established that counter the structural injustices. In discussing the unjust 
distribution of medical research, Catholic universities, must serve as one of the institutions 
of social change by “ad-just-ing” and “just-ifying” their institutional commitment to just-
research that prioritizes the health needs of the 90% over those of the 10%.  
 Catholic universities committed to justice, therefore, have a social responsibility to !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
29 Ignacio Ellacuría, "Utopía y Profetismo Desde América Latina: Un Ensayo Concreto De Soteriología 
Histórica," Revista Latinoamericana De Teologia 17, Mayo/Agosto (1989), 163. [J]usticia sobre la libertad, pues no se 
puede ser libre injutamente, minetras que la justicia, al dar a cada uno lo que le es debido, no solo posibilita la liberad, sino que la 
moraliza y justifica. La liberación de toda forma de opresión, cualquiera que ésta sea, es como proceso real justi-ficación, el medio 
real de potenciar la libertad y las condiciones que la hacen posible.  En este sentido la liberación es un proceso de ‘ajuste’ consigo 
mismo, en caunto busca desembarazarse de las cadenas interiors y exteriors; es un proceso ‘justo,’ en cuanto trata de supercar una 
injusticia manifiesta; y es un proceso ‘justificador’ en cuanto busca crear condiciones adecaudas para el desarrollo pleno de todos y 
para un equitativo uso de ellas. 
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engage in the practice of medical research from the place of the poor and in solidarity with 
those individuals and communities whose health needs remain under-researched. From the 
perspective of liberation theology and the function of the Catholic university, narrative and 
place converge in an act of solidarity that allows for the recognition of victims of injustice 
and serves as a catalyst to pursue alternative just and inclusive policies. Given the funding for 
medical research, as reflected on in the previous chapter, it is difficult to argue that current 
research practices reflect the socio-ethical norms of a liberationist approach to research. 
 Liberation theology offers a sustained critique that challenges Catholic universities to 
take up their particular responsibility to ensure that they do not participate within a structure 
of medical research that allows for injustice. Alternatively, these institutions should strive 
establish counter structures that promote justice and target research that benefits the health 
of those most in need. In opposition to socially unjust structures, Catholic medical research 
socially projects that explicitly prioritizes the needs of the poor and vulnerable in their 
research agenda.  
Developing a Socially Responsible Agenda 
 Constructing a socially responsible research agenda that maintains a preferential 
option for the poor requires a creative approach requires targeting existing funding 
structures, cultivating new research partners, and imagining alternative structures that enable 
research for the poor majority. For some areas of research, funding structures are already in 
place; however, new ways for structuring research, building capacity in underserved areas, 
and distributing the fruits of research still need to be explored. This final section, like the 
opening chapter, offers paradigmatic examples of medical research that reflect research 
priorities that come from and develop in solidarity with the poor majority. These examples 
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represent potential dialogue partners and offer alternative approaches for Catholic 
universities to consider in addressing injustices within the practice of medical research itself. 
Existing Structures for Medical Research 
 Some Catholic universities will be hesitant to take up a justice-oriented research 
agenda outside of currently established funding sources. While other examples in this section 
examine potential ways of engaging in research outside of current funding sources, this first 
example explores research that more closely aligns within socio-ethical norms described 
above. Comparative Effectiveness Research (CER), recently instituted in the U.S. as the 
Perspective on Patient-Centered Outcomes Research Institute (PCORI), funds research that 
focuses on evaluating and improving the quality of health care outcomes pertaining to 
preventive, diagnostic, and treatment options in order to better inform and support all 
involved in the research process. While the current concentration of CER initiatives operates 
out of high-income countries, such as the U.S., France, U.K., Germany, and Australia, 
efforts have already been made to extend this type of research beyond national borders. 
Given the global presence of Catholic universities and the Catholic Church, these 
institutions—assuming they are willing to collaborate—have the opportunity to participate in 
research that can more easily work with low and lower-middle income countries to build up 
their research capacity and assist in the development of programs to improve upon health 
care outcomes. 
Comparat ive Effec t iveness Research   
 In 2009, and Institute of Medicine (IOM) report detailed ten characteristics of a 
CER. The first priority, and perhaps the most significant for the broad applicability of this 
type of research, emphasizes that the “prioritization of CER topics should be a sustained 
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and continuous process, recognizing the dynamic state of disease, interventions, and public 
concern.”30 The process for establishing a CER agenda, therefore, requires continued 
evaluation of current research needs, including a willingness to forego projects that do not 
represent current public health needs. The continued evaluation of necessary research from 
the perspective of the public is something that does not appear—or at the least is not 
reflected—in the current NIH research agenda, for example.  
 The criteria for prioritization of CER research focuses on health, disease prevalence, 
mortality, and morbidity, which will certainly reshape the priorities in need of study.31 Here 
CER already takes important steps in developing a globally translatable research program 
because of its focus on methods that address local health problems and engage in evaluating 
the resources needed to improve health outcomes. In order to meet these health concerns, 
however, the IOM report states that CER requires broad participation of key research 
stakeholders and frequent updates. These updates require wide distribution if they intend to 
address the most urgent health needs and identify best practices. For CER programs in 
Europe, this has translated into focusing on the effectiveness of newly developed drugs, 
pricing, and general availability of those drugs.   
 The U.K.’s National Institute for Health and Care Excellence (NICE), originally 
established in 1999 as the National Institute for Clinical Excellence, operates collaboratively 
with the National Health Service (NHS) to ensure the quality of care and the availability of 
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30 Institute of Medicine (U.S.), Committee on Comparative Effectiveness Research Prioritization, “Initial 
National Priorities for Comparative Effectiveness Research,” Institute of Medicine of the National Academies, 
Washington, DC: National Academies Press, 2009. 
 
31 Jordan VanLare, Patrick Conway, Harold Sox, "Five Next Steps for a New National Program for 
Comparative-Effectiveness Research." The New England Journal of Medicine 362, no. 11 (2010), 972. 
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needed treatments throughout the country. 32 One of the successful means of ensuring 
treatment availability is through the evaluation of new drug developments. The 
recommendations of NICE serve as the measure by which a new drug is included in the 
comprehensive coverage offered through the NHS. Considered in this review process is the 
cost-effectiveness, which “is particularly important for drugs that have new indications, are 
expensive, are expected to be widely used, or whose benefits differ by indication or patient 
subgroup.”33 Thus, NICE’s role naturally led to CER’s interface with industry through 
recommendations regarding the effectiveness of a drug by studying its effects on morbidity 
and mortality of a given population.  
 Therefore, the role of CER does not focus on approval or rejection of a drug, 
instead, once approved, it reviews the efficaciousness of the drug in patient care. In the 
instances that a “particular health technology is found to have inconclusive or insufficient 
evidence of a comparative effectiveness analysis, NICE will often make the recommendation 
that the examined therapy be used only in research.”34 In this way, the recommendations 
from NICE have a bearing on drug coverage through the NHS, but also provide the 
pharmaceutical industry with a link to continually evaluate their product through further 
research and hopefully present the efforts of companies to develop “me-too drugs,” 
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32 NICE, “Who we are,” National Institute for Health and Care Excellence, https://www.nice.org.uk/about/who-
we-are, (2014), accessed: April 11, 2015.  
 
33 Corinna Sorenson, “Use of Comparative Effectiveness Research in Drug Coverage and Pricing Decision: A 
Six-Country Comparison,” The Commonwealth Fund, Vol. 91, (July 2010) 
 
34 Elias Dayoub, “Lessons from Abroad and at Home: How PCORI can Improve Quality of Care (and Prove 
it) by 2019,” Health Affairs Blog, (May 2, 2014) accessed: April 11, 2015.  
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knowing that they will not be brought to market.35 In addition to interfacing with both drug 
industry and political institutions, CER engages in research that can evaluate clinical 
effectiveness across under-researched populations, e.g. underserved communities, racial and 
ethnic minorities, and/or gender differences.36  
 In the U.S., PCORI, a development from the 2010 Affordable Care Act, focuses on 
research efforts that more intentionally engage patients in research that supports preventive, 
diagnostic, and treatment-based options for larger patient populations.37 The focus of 
PCORI’s efforts center on improving the overall quality of health care, which takes place by 
targeting research that more effectively addresses the concerns facing patients within a 
particular sector of the population. One of PCORI’s initiatives strives to foster engagement 
with primarily underserved patient populations, in order to develop a collaborative and 
trusting relationship in which the research comes from and aims to benefit that same 
community. In this regard, PCORI funding demonstrates a key principle of just-research by 
working in solidarity with a community that stands to benefit from the research taking place. 
Developing policies for research that focus on community involvement and benefits in 
research, coupled with evaluating broadly the effectiveness of existing treatment options, 
demonstrates some of the possible avenues for implementing CER in a variety of settings. 
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35 Marcia Angell, The Truth about the Drug Companies: How they Deceive Us and what to do about It (New York: 
Random House, 2004), 74-93. “Me-too drugs” have a different molecular make-up, but do not significantly 
alter the effectiveness of already existing drugs, and prod the drug companies to produces products that . 
 
36 Underserved patient populations are those populations with limited access to healthcare resources due to a 
variety of factors, but can typically be broken down by race, ethnicity, and/or gender. Socio-economic status 
certainly comes to bear on this classification as well.  
 
37  Methodology Committee of The Patient-Centered Outcomes Research Institute (PCORI), “Methodological 
Standards and Patient-Centeredness in Comparative Effectiveness Research: The PCORI Perspective,” Journal 
of the American Medical Association 307, no. 15 (2012), 1636. 
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 The methods of CER offer a diversity of approaches, ranging from targeting large-
scale systemic challenges in health care, to studying the effects of technology to maximize 
health needs, to simply identifying basic necessary resources required to treat acute medical 
needs. Unlike the previously described research typically associated with NIH or NSF, the 
focus of CER research centers around health outcomes, not projected benefits, with the aim 
of improving upon or validating best practices. The focus CER places on outcomes and 
clinical effectiveness lends itself to broad adaptability for research in low-income countries 
because it is rooted in already existing needs and evaluating the current options for 
addressing those specific concerns.  
 Lower-middle and upper-middle income countries, like India and China, have relied 
on the U.K.’s NICE program to enhance and focus their own research efforts around 
addressing local health challenges.38 India, for examples, has worked with NICE to develop 
clinical guidelines to assess local and national health concerns through retrospective analysis 
of case studies in an effort to standardize and adapt clinical care to best meet urgent health 
needs. China has similarly taken up efforts to address its health concerns through 
partnership with NICE to study its healthcare infrastructure through assessing the impact of 
technologies on health care outcomes. While both India and China are assessing capacity 
retrospectively, their approaches have varied. India has concentrated on evaluating the 
effectiveness of health care systems and concerns through focusing on outcomes more 
broadly, while China is specifically interested in improving outcomes through the use of 
technology. While in their infancy stages, the collaborations between NICE, India, and 
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38 Rajesh Balkrishnan, et al., “Global Comparative Healthcare Effectiveness Research: Evaluating Sustainable 
Programs in Low & Middle Resource Settings,” The Indian Journal of Medical Research 137, no. 3 (2013). 
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China serves as an important model for the possibilities for developing partnerships beyond 
local borders.39  
 Positively, CER offers a model of research with prospects for current funding that 
simultaneously aligns with the social values of Catholic institutions. CER can adopt research 
practices that target persons typically omitted from medical research with the direct aim of 
improving health care outcomes of the immediate population. With the focus clearly on 
health benefits, CER does not ask the question of pharmaceutical trials, i.e. “does it work?” 
Rather, the question of CER is “which works better?”40 This research, then, shifts the focus 
from economics and technology to an evaluation of the effects/influences of economics and 
technology on the health of a person or population.  
 A limitation of CER research, however, arises from its need for large and potentially 
complex data sets to evaluate health care outcomes and the personnel to conduct the 
evaluations. Moreover, within these complex data sets, specific questions need to be asked to 
yield results that can translate into reformed practices.41 A second point of concern is the 
limited methodological approaches that can yield outcomes that would be helpful for a given !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
39 One of the challenges to effective health care delivery is the disparity between access clinical care and the 
necessary resources to provide that care. The U.S., for example, wastes an estimated thirty-cents on every dollar 
spent for health care, but arguably has access to the greatest technology necessary to yield quality health care 
outcomes. However, the latest technology does not equal effective outcomes. CER can enable cross analysis of 
the type and/or quality of technology needed to work within countries with limited resources. Just as NICE is 
partnering with other countries to develop CER techniques to assess their health care needs. Catholic 
universities could similarly take up these CER endeavors on both a local and global scale. This is research, 
according to the IOM report, that the U.S. is interested in developing and the mission of sustainability and 
justice as equity that can be pursued through CER is worth fostering. See Institute of Medicine (U.S.)., 
Committee on the Learning Healthcare System in America, Best Care at Lower Cost: The Path to Continuously 
Learning Health Care in America (Washington, D.C.: Institute of Medicine, (U.S.), Committee on the Learning 
Healthcare System in America, 2013). 
 
40 Lisa Parker and Howard Brody, “Comparative Effectiveness Research: a Threat to Patient Autonomy?” 
Health Progress, 92, no. 5, (2011), 64-71. 
 
41 David Rubin, “On the Limitations of Comparative Effectiveness Research,” Statistics in Medicine. Vol. 29, 
no. 19 (2010), 1991-1995. 
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population.42 Even within these limitations, there is room for research that focuses on 
developing new methodologies as an area of research. In order to develop areas for research, 
however, collaborative partners need to be established.  
 In pursuing collaborators and collaborations, Catholic universities should reflect on 
their role as institutions at the intersection of the global and local research needs. 
Developing collaborative partners proves fundamental to promote a broad research agenda 
that not only does research for communities in need, but also aims to develop research 
capacity within those areas. While establishing partnerships can be challenging, it reflects the 
institutional commitment to socially projected research, i.e. research that reflects the needs 
of the community in its research, which can be enhanced by establishing institutional policies 
that set the transform of societal needs as an explicit goal. One potential partner that has 
demonstrated a capacity for engaging in social projected health care has been Partner’s in 
Health (PIH).  In this next section, I will introduce a key consideration in developing 
partnerships, which emphasizes the crucial step of identifying collaborators that challenge 
existing unjust structures and policies and aim to transform them.  
Cultivating New Relationships 
 Research alone will not result in a substantial change for the global health needs of 
the majority. Therefore, targeting organizations that have deeply established roots in local 
communities aimed at providing health care delivery and developing public health 
infrastructures serve as important collaborators for intended research efforts. PIH serves as 
one example of a locally embedded collaborative partner that focuses on increasing health 
care delivery and developing more robust public health infrastructure, but relies on !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
42 Robert Temple, “A Regulator's View of Comparative Effectiveness Research,” Clinical Trials, Vol. 9, no. 1 
(2010), 56-65. 
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collaborative partners for research. Collaborating on research projects and building capacity 
for research is something that Catholic universities can offer an organization like PIH. 
However, addressing gaps in research and building capacity for research does not ensure 
necessarily that the benefits of research reaches communities in need, there are also 
structural and policy challenges that disincentivize medical research on major global health 
challenges.   
 Another example of structural reform, focusing on gaps in the research delivery 
pipeline, appears in the proposal of Thomas Pogge’s Health Impact Fund (HIF). The 
significance of Pogge’s much criticized efforts, stemming from the complexity surrounding 
the programs implementation process, posits an alternative patenting structure to address 
the economic challenges that contribute to the lack of incentive for research focused on the 
health needs of the poor majority. Rather than a particular form of research, the HIF offers 
an opportunity for academic researchers to serve as advocates in an effort to ensure that 
their own research projects have the intended impact, especially for projects that stand to 
improve access to treatment for low-income communities.  While Pogge’s model is not 
perfect, and in reality has gained little political traction, it serves as a unique example of an 
approach that tackles the structural and policy issues perpetuated by a patent system that 
does not reward research on drugs needed to address global health challenges. Both the HIF 
and PIH offer an example of social institutions that challenge structures that limit health care 
delivery and access to essential medicines for large segments of the global poor.  
Partners  in Health (PIH) 
 PIH is a non-profit organization, founded by Jim Kim, Paul Farmer, Ophelia Dahl, 
Todd McCormack, and Thomas White, that has developed a growing number of global 
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partnerships with communities in low-income countries to strengthen public health 
infrastructures and access to health care services. PIH unapologetically grounds its model of 
health care in a preferential option for the poor:  
Our mission is to provide a preferential option for the poor in health care. By establishing 
long-term relationships with sister organizations based in settings of poverty, Partners In 
Health strives to achieve two overarching goals: to bring the benefits of modern medical 
science to those most in need of them and to serve as an antidote to despair. We draw on 
the resources of the world’s leading medical and academic institutions and on the lived 
experience of the world’s poorest and sickest communities. At its root, our mission is 
both medical and moral. It is based on solidarity, rather than charity alone. 43 
 
In a sense PIH’s mission statement aligns with what ought to be the goals of medical 
research writ large, but certainly with goals of medical research at a Catholic university. Their 
commitment to the option for the poor, cultivating local partnerships, utilizing the latest 
technological and medical advances to benefit those most often excluded, and focus on 
solidarity—both intellectual and practical—demonstrates the epistemological effects of an 
organization that begins with the horizon of the poor majority.  
 PIH has cultivated local/global relationships in Haiti, Rwanda, Lesotho, Malawi, 
Mexico, Russia, Peru, Navajo Nation, and Boston that focus healthcare delivery and public 
health education, with an eye towards developing a capacity for research, while also ensuring 
its distribution in these areas. PIH’s research priorities do not reflect the breadth of NIH 
research priorities, but rather a narrower agenda with more immediate effects. They cite their 
health priorities as: Cancer & Chronic Diseases; Child Health; Cholera; Community Health 
Workers; Ebola; HIV/AIDS; Mental Health; Nursing; Surgery; Tuberculosis; and Women’s 
Health. These research priorities reflect the health needs of the people with whom they 
work.  !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
43 Partners in Health, “Our Mission,” http://www.pih.org/pages/our-mission (accessed March 7, 2015). 
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 Collaboration with research partners like PIH, demonstrates a commitment to 
developing a socially projected research agenda that reflect the needs of a particular 
community. PIH serves as an exemplar in its focus on local health needs and its cultivation 
of academic and philanthropic partnerships committed to the same common goal. Through 
PIH’s alliance with Harvard University and the Brigham and Women’s Hospital in Boston, 
they have cultivated partnerships that research by exploring “the impact of global health 
initiatives on national health systems with commissions from the World Health Organization 
and UNAIDS.”44 The system for collaboration is in place. Universities educate students 
about the impact and importance of global health and focus on research that addresses 
health needs raised by locally embedded partners, global and local. PIH, the partner 
organization, ensures the delivery of health care, establishes preventive health measures, and 
implements improvements that come about through research. While PIH, and other similar 
organizations, demonstrates a commitment to ensuring health care delivery and disease 
prevention through public health strategies, further work has to develop research capacity 
within these vulnerable places.  
 Developing research capacity requires a commitment to working with partner 
organizations to identify areas of research need and also challenge existing research 
structures. In order to be leaders in global health research, collaborative relationships must 
be mutually beneficial. While PIH might not prove capable of taking on widespread clinical 
trials, they can engage in research similar to CER, as discussed in the first section. In this 
way, efforts could be made to study the effects and possibilities of improving the quality of 
care in a given area. On the other hand, if a university wanted to conduct a large scale trial !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
44 Global Health Delivery Project at Harvard University, “Our Work,” Global Health Delivery Project, 
http://www.globalhealthdelivery.org/our-work/, (accessed, May 2, 2015).  
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for an under-researched drug or with a vulnerable population, measures have to be put into 
place so as to ensure that benefits resulting from that research extend to the research 
population, which is already built into CER.  
 The example of PIH highlights the importance of international partnerships, 
however, the geographic location should not dictate the partnership. Instead, the needs of 
the community and collaborations with organizations that may have limited access to the 
fruits of research efforts most aptly define the parameters of the partnership. The important 
factor in determining a collaborative partner for research is the ability to translate the 
benefits of research into effective health care. Even with effective health care delivery 
systems and public health infrastructure, systemic change to the way in which research flows 
will still be needed. Thus, partnering with PIH represents one way to include multiple 
vulnerable populations in the process of research. However, developing partnerships alone 
will not resolve the structural challenges involved in medical research. Advocacy efforts 
prove essential in an effort to ensure that research developments benefit their targeted 
population.  
  Catholic universities have the obligation to advocate for systemic changes that 
allows for more just distribution of knowledge garnered through medical research to those 
communities most in need. While establishing partnerships with organizations committed to 
delivering health care and engaging in research that can affect the health of the poor 
majority, exploring systemic changes to the unjust distribution of research also needs to be 
explored. Advocacy efforts around policy change can be significantly enhanced by academic-
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researchers who recognize the social enterprise of their research efforts and see the need to 
address the breakdowns in the drug development pipeline.45 
Health Impact  Fund (HIF) 
 The HIF proposes to address the challenge posed by economic forces that generate 
little incentive for medical research to target neglected diseases and/or disease that 
predominately affect low- and middle-income countries. 46 While, in reality, university 
researchers have little to do with the market forces and intellectual property rights restricting 
essential medicines, they have also done little by way of acknowledging or attempting to 
reform the injustices of the system in which they participate. Systemic change proves 
necessary to the consideration of medical research as a discipline that impacts society. The 
example of the HIF, while not serving as an endorsement of the system, represents an 
important model for rethinking the complexities associated with medical research.47 
 The HIF aims to alter both the politics and economics that govern research by 
deemphasizing return on investments that do not positively affect the health needs of the 
majority.  A large portion of these efforts would require government financing to establish a 
“pay-for-performance mechanism that would offer innovators the option—no obligation—
to register any new medicine or, under certain conditions, also a traditional medicine or anew 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
45 Paul Farmer, et al, Reimagining Global Health an Introduction (Los Angeles: University of California Press, 2013). 
 
46  Thomas Pogge, “The Health Impact Fund and its Justification by Appeal to Human Rights,” Journal of Social 
Philosophy 40, no. 4 (2009), 166. 
 
47 Jorn Sonderholm, “A Reform Proposal in Need of Reform: A Critique of Thomas Pogge’s Proposal for how 
to Incentivize Research and Development of Essential Drugs.” Public Health Ethics 3, no. 2 (2010). Jorn 
Sonderholm, “A Critique of an Argument Against Patent Rights for Essential Medicines,” Ethics and Global 
Politics 7, no. 3 (2014). In these two essays Sonderholm acknowledges the need for patent reform, or the 
potential argument that patents for essential medicines be omitted as unjust in low-income countries. While he 
does not agree with Pogge’s arguments, he recognizes the injustices of the current system.  
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use of an existing medicine.”48 The funding would be established by and paid for through 
high-income governments that opt-in. However, there exists no obligation for industry or 
governments to buy-in. These two entities, nevertheless, must participate in order for the 
HIF to function, i.e. the greater the number of governments and industries that opt-in, the 
more financial incentives would exist to research diseases that cause the greatest health 
challenges for the majority.49 And, while the registration process would function similarly to 
current patenting practices, the caveat would be that the return on investment takes place 
based off of actual health impact measured by Quality Adjusted Life Years.50  
 During the first 10 years on market —half of the typical duration of patent—a drug 
would be made available in the areas most in need for no more than the lowest possible cost 
of production and distribution. After 10 years, generic production and distribution of the 
product would then be allowed. With financial incentives, “HIF would foster the 
development of new high-impact medicines—also against diseases concentrated among 
poor, such as tuberculosis, malaria, and other tropical diseases, which are now neglected 
because innovators cannot recover their R&D costs from sales to the poor.”51 Pogge’s 
model represents an alternative, structural way of re-thinking the drug pipeline that, 
unaltered, continues to exclude those most in need of treatment options.  
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
48Thomas Pogge, “The Health Impact Fund: Enduring Innovation Incentives for Cost-effective Health Gains,” 
Social Europe,  http://www.socialeurope.eu/2011/01/the-health-impact-fund-enduring-innovation-incentives-
for-cost-effective-health-gains/ (accessed March 9, 2015).  
 
49 Ibid. 
 
50 The Health Impact Fund, “Summary,” http://healthimpactfund.org/the-health-impact-fund-a-summary-
overview/, (accessed May 2, 2015). 
 
51  Pogge, The Health Impact Fund and its Justification by Appeal to Human Rights, 546 
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 The description of Pogge’s HIF is not an endorsement of it, nor something that 
Catholic universities should necessarily adopt. However, reconsidering the structure of 
medical research is something that the university should undertake in establishing its 
research priorities. Pogge rightly calls on university academics to partner with him in support 
of creating the HIF and demonstrates the complex task that would benefit greatly from the 
expertise of academic medical researchers. While this may not be the model universities want 
to endorse, medical researchers offer unique insights into the drug development process at 
the most basic level. Their perspective is enhanced further by the technical nuance to 
advocate for systemic change from within the structure of medical research itself.  
 Medical researches, implicitly or explicitly, are already contributing to the debate 
through their research. Advocates prove necessary to shift this agenda and priorities, and 
“…academic silence can reasonably be interpreted as academic acceptance that the main 
view represented in the public debate are credible and consistent with the available 
evidence.”52 This cannot come from the ivory tower but, rather, the voices of those 
marginalized by and excluded from medical research benefits need to be heard. In this way, 
research advocates need to both speak broadly to the research community through 
publications and presentations and to alter the structures that limit the just-distribution of 
the produced innovations.  
  HIF and PIH both offer systemic changes to the way in which medical research is 
delivered to low- and middle-income countries. HIF takes a political approach rooted in a 
complex overhaul of the drug pipeline in an effort to treat those with medications for 
diseases that are often under-research. The approach of PIH, perhaps most consistent with a !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
52  Thomas Pogge and Luis Cabrera, “Outreach, Impact, Collaboration: Why Academics should join to Stand 
Against Poverty,” Ethics and International Affairs 26, no. 2 (2012), 168. 
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liberationist approach, is rooted in a process of community engagement and locally delivery 
of effective health care. If PIH represents the grassroots approach to assessing health care 
and medical research needs, then Pogge’s system—even if flawed—represents a type of 
socio-political overhaul that attempts to interrupt the current injustice within the distribution 
of medical research.  
 Catholic universities have an obligation to take up the responsibility beyond simple 
engagement in just-research, and to advocate additionally for reforms to structures that 
contribute to its inequitable distribution. Yet, the present reality suggests that the current 
structures may simply prove impermeable to suggested reform. In this case, alternative 
approaches to collaboration and advocacy for social justice based on health priorities may 
need to be considered. This change could necessitate a complete rethinking of the approach 
to research and the adoption of alternative structures for approaching the health needs of 
the poor majority.  
Exploring Alternative Visions 
 The final two examples focus on challenging the current inequalities that exist by 
developing parallel structures that strive for more targeted funding and better sharing of 
information developed in the research process. The first option takes up the idea of a co-
operative university, while the latter considers—following the WHO suggestion—the 
development of an open source database that lists research being conducted on urgent 
health needs. While these types of structures represent departures from the way in which the 
process of medical research takes place, they also draw on a type of ethical imagination 
needed to think through global challenges. 
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Mondragón   
 Mondragón is co-operative business and educational institution developed in the 
Basque region of Spain, which has grown into a sustainable Spanish business with 
multinational locations. The model was developed by Father Jose Maria Arizmendi as a way 
to institute, what he believed to be, a sustainable business model. The business developed 
from the local community built and relying on principles of Catholic Social Teaching to 
inform its mission.  
 Mondragón has developed into an international, multi-million dollar for-profit co-
operative business. It consists of 150 co-operatives, three research and development centers, 
a university, its own bank, and health care system.53 While the focus at Mondragón is not on 
medical research, it does generate patents, currently holding 716, which seems crucial to the 
practice of research—as presently conceived. These patents have made them one of Spain’s 
leaders in alternative energy sources of wind power, fuel cells, and solar panels.54 They 
emphasize these sustainable projects, not at the expense of economic returns, but also not 
subservient to the economic demands. The Mondragón co-operative has created a parallel 
business model and one that pharmaceutical business executives could emulate by 
incorporating more social equity into the internal structures and priority setting for neglected 
diseases. One of the key features of Mondragón, aside from the co-operative organizational 
structure, was the creation of its own research pipeline through its university.  !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
53  David Herrera, “Mondragon: A for-Profit Organization that Embodies Catholic Social Thought,” Review of 
Business. 25 (2004), 56. “The Mondragón Cooperatives have created businesses in four key areas: finance, 
industry, retail, and knowledge. They have four university campuses, a culinary arts school in San Sebastian, the 
largest research and development center in all of Europe (with fourteen separate entities), the Caja Laboral 
Bank with 380 branches in Spain, and an incubation center for creating new products and services.” 
 
54  Georgia Kelly, “The Mondragon Cooperatives: An Inspiring Economic Hybrid,” Tikkun 28, no. 2 (2013), 
25. 
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 Mondragón University understands that integrating the three main activities of a 
university—education, research, and service—is the most effective way of increasing quality 
and fulfilling its social mission. It does so, however, with a targeted and collaborative 
approach throughout the co-op. Research is conducted through a collaborative model 
“based on research alignment, from oriented basic research to innovation, with the 
participation of three key actors: universities, technology centers, and businesses through 
R&D departments.”55 They decide that in order for their research to be cost-effective, but 
still to meet the socio-ethical principles held by the company, research has to align with the 
cooperatives interests.  The goal, then, is to incorporate researchers in order to “produce 
top-quality research and bring the university closer to businesses as the key to innovative 
dynamics and to the training of would-be researchers for businesses and technology 
centers.”56 A key distinction between current models of university research and Mondragón’s 
lies in the fact that university researchers do not set the agenda, Mondragón does. 
Mondragón University considers chooses research in line with its strategies to create wealth 
in the community. They hire researchers that prove capable of enacting the institutional 
standards for research—as opposed to letting researchers themselves set the agenda.  
 To apply Mondragón’s model for medical research presents several obstacles, not the 
least of which requires a significant financial investment on the part of individuals who see a 
value in the mission focus and potential success of a co-operative model for business and 
education. However, it demonstrates a targeted and collaborative approach to research that 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
55 Mondragon, “Research Model,” http://www.mondragon.edu/en/research/research-model, (accessed May 1, 
2015). 
 
56 Ibid. 
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would more directly be able to address some of the gaps in medical research. Finances aside, 
Mondragón could serve as an intriguing dialogue partner because of their commitment to 
Catholic social values, equity within their institution, and their focus on education that yields 
practical results. A focus on the practical results of health impact, however, will require 
information sharing. Thus, while a business model and current research practices tend to 
guard new and innovative information, a model for research that intends to generate the 
highest health impact will need to openly share its resources in order to demonstrate 
progress and not duplicate research efforts.  
Internat ional  Federat ion o f  Cathol i c  Univers i t i es  (IFCU) 
 Participation in an open source database and priority setting, as proposed by the 
WHO’s Consultative Expert Working Group for health research, could prove a successful 
undertaking of the International Federation of Catholic Universities (IFCU). An open source 
database and working group on medical research would represent an important step in 
raising awareness for diseases in need of research. An open source database and 
collaborations with the IFCU would demonstrate the leading role that Catholic universities 
ought to play in addressing the global need in medical research.  
 The IFCU, as part of its mission, aims to develop a collaborative environment for 
Catholic higher education. It recognizes the importance of research in this social project and 
holds within its current structure a Center for the Coordination of Research (CCR). “Aware 
of the concerns, interests and expectations of Catholic universities and their respective fields 
of action, the CCR offers a platform for encounter, debate, production and circulation of 
knowledge, in order to permanently question the main challenges posed today to human, 
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scientific, social and ecclesial development.”57 There is no specific mention of collaboration 
on medical research. While a working group on medical research that affects the most 
vulnerable would be a start and an open source database would be even better. Here, the 
IFCU could provide a place for intentional dialogue to develop a research agenda that speaks 
to the socially projected needs from a diverse community of representatives.  
 Developing a Catholic and international collaborative focused on medical research 
around diseases that disproportionately affect the poor and marginalized allows for the 
pooling of resources and streamlining of efforts to address global health needs. Those 
already engaged in medical research targeting poor and vulnerable populations is currently a 
small subset of researchers. The hope, as with other initiatives in the IFCU, would be to 
bring together the leaders in research on global health needs to raise awareness and capacity 
of Catholic universities to engage in collaborative research. Establishing a network of 
knowledge would foster, hopefully, effective support and creativity between its members, 
create space to share information, and save expense by releasing new information more 
quickly, consequently limiting the duplication of work.  
 Collaborative research, which has been at the heart of most of these projects, can 
prove to be a time-consuming and challenging effort. However, when reflecting on the 
original paradigmatic examples in Chapter One, the most effective forms of research 
addressing global health needs were collaborative. The above examples are emblematic of 
the types of approaches, though not necessarily an exact blueprint, that can offer correctives 
to structural injustices within the research process. Each of the examples challenges the !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
57 International Federation of Catholic Universities, “About IFCU,”  
http://fiuc.org/en/docs/about_ifcu/ex_corde_ecclesiae_foundation. (accessed, May 1, 2015).  
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existing economic or technological epistemology at work in research and offers the global 
health of the poor as a guiding framework. Targeted research efforts, developing 
partnerships, and exploring creative alternatives to enhance the health options of the poor 
majority is fundamental for Catholic university research. And while these examples of 
signaled potential dialogue partners, universities themselves have to restructure their own 
institutional approach to medical research. By way of conclusion, the final section sketches 
some fundamental steps that need to be taken for Catholic university medical research to 
project an option for the poor onto their research agenda.  
Conclusion: Is a Different Kind of Research Agenda Possible? 
 The most fundamental shift for the university has to come from instituting structural 
and policy changes that ground the norms for medical research through explicitly 
prioritization of the health needs of the poor majority. Ellacuría clearly articulated the 
importance of social projection as the way for conducting research at the UCA. The UCA 
research, however, was not about the task of research per se. Research, rather, served the task 
of the university’s mission to engage in education, research, and service in order to 
understand and transform the injustices within the community. Medical research must 
likewise be reimagined in through a similar multifaceted approach. Therefore, relying on the 
efforts of individual researchers to set up the research agenda of the institution will continue 
to produce disparate results that fail to achieve desired health outcomes.  
 When attempting to transform a culture, challenges emerge when change is forced 
from the top. Thus, while hiring for mission proves important, that mission must include the 
ability to collaborate and focus on a unified goal. While Catholic universities may speak 
about the option for the poor, it rarely appears as the subject of research practices or in the 
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education of students on how to conduct research. Students who engage in research are 
taught the importance of conducting research that respects research subjects, but more need 
to be taught about the social reality of those who benefit and those who do not from the 
research conducted. Conducting research as a social practice and educating for just-research, 
or socially-projected research, can transform and refocus the intrinsic good of medical 
research from the knowledge produced to the knowledge produced for the health and care of 
individuals most in need.  
 While developing strategic priorities for health research may be possible, financing 
for this plan proves limited. Thus, given the challenge of finding grants for these particular 
areas of research, more institutional and hard money commitments prove necessary. Many 
researchers finance portions of their own salaries through grant projects they have earned. 
This creates practical challenges when targeting a small sub-sector of grants that one may or 
may not receive. Increasing the hard money commitment for researchers frees researchers to 
pursue more competitive grants as long as they maintain a focus for neglected and under-
researched diseases. Moreover, reconsidering tenure requirements might also be necessary in 
order to reward researchers for their commitment to engaging in medical research befitting 
the institutional mission. With this type of institutional reform, Catholic universities might 
be able to recruit well-published and higher profile researchers that focus on global health 
and neglected diseases to working at the university, which reinforces the institutional 
commitment to engage in a distinct kind of research—one that is socially projected.  
 The final step, and perhaps the simplest implementation for Catholic universities, is 
the development of and participation in advocacy networks through publishing. In the 
research community, publications represent priority. In other words, if something is 
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considered important, someone is researching and publishing on the topic. What is seldom 
referenced, except when crises emerge—e.g. Cholera and Ebola—are efforts to bring 
awareness to neglected diseases more broadly and more consistently. While it is an 
expectation that researchers engage in retrospective analysis detailing their research efforts, 
attempting to establish broader areas for funding and research that benefit the poor majority 
more prospective and collaborative publishing proves necessary in order to bring attention 
to under-researched areas.58 This prospective approach will necessitate collaborations 
interdepartmentally in order to provide ethnographic, sociological, and even theological 
importance for why certain projects ought to be pursued over others. The strength of the 
social science efforts, moreover, will be reinforced by the scientific approach that can point 
to potential practical solutions in development in the lab or clinical trials. Yet, all of this is 
for naught if the epistemology of research remains the same.  
 This dissertation began with a focus on paradigmatic accounts of the development of 
medical research that sought to both improve the health of communities and particular 
individuals. Gradually, the focus of researching for health was seen along side the possibility 
of economic gain. Currently, the most economic gain stems from genetic and biotechnology 
based research. Not only does it hold economic possibilities, it also represents the newest 
scientific knowledge being discovered as it relates to medical research. However, the 
epistemic foundation of this research begins from a perspective of new knowledge and 
economic gain with little mention of health. However, if health became the hermeutic 
through which medical research was understood, then medical research agenda would have 
to shift.  !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
58 These publications likewise need to be included in one’s academic portfolio for tenure, perhaps a break from 
institutional standards. 
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 When making the epistemological move to reflect on research from the perspective 
of health, one’s attention has to turn to places in which a lack of “health” exists. As noted in 
Chapter Four, DALYs serve as tangible markers of the structural injustices endemic to the 
practice of medical research itself. These injustices develop through a false epistemology for 
medical research that prioritizes financial gain and future promise for the minority over 
present and dire health needs for the majority. Thus, research for the common good, a 
fundamental tenant of Catholic Social Teaching, proves impossible as long as current 
structures prevail. In a certain sense, medical research is left with the task of avoiding the 
common harm.  
 Catholic universities, in solidarity with those most vulnerable, must make a 
preferential option for the poor apparent in the practice of medical research. While this final 
chapter has proposed dialogue partners in this endeavor, individual institutions and 
collaborative networks should take this occasion to reevaluate their own research priorities 
and policies to see how they participate in the current injustices in medical research.  This is 
not an easy task, and the ways forward proposed here most certainly need nuance. However, 
this is not intended to be the end of the conversation but the beginning. These pages have 
focused on the importance of collaborative dialogue and health-oriented research that seeks 
to transform the ways in which Catholic universities engage in the social practice of medical 
research. Catholic universities committed to engaging in medical research have the obligation 
to implement institutional changes that promote and prioritize the health needs of the poor 
majority in pursuit of justice from places of injustice.  
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